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“The	scientific	man	does	not	aim	at	an	immediate	result.	He	does	not	expect	that	his	
advanced	ideas	will	be	readily	taken	up.	His	work	is	like	that	of	the	planter	—	for	the	future.	
His	duty	is	to	lay	the	foundation	for	those	who	are	to	come,	and	point	the	way.	He	lives	and	
labors	and	hopes.”	
Nikola	Tesla  
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Transcription	factors,	cytokines,	and	chemokines	
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TGF	 	 –	 Transforming	growth	factor	
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ABSTRACT	
 
Heart	transplantation	 is	often	the	 last	resort	for	end-stage	heart	disease.	Despite	 increasing	
success	in	this	medical	field,	transplant	recipients	remain	at	significant	risk	for	both	early	and	
late	allograft	failure.	The	cascade	of	events	leading	to	heart	transplant	rejection	are	initiated	
by	donor	brain	death,	progress	throughout	ex	vivo	preservation	of	the	organ,	are	exacerbated	
during	reperfusion,	and	culminate	in	cardiac	allograft	vasculopathy	(CAV).	The	aim	of	this	thesis	
was	to	evaluate	the	efficiency	of	adeno-associated	virus	(AAV)	as	a	vector	for	gene	therapy	of	
the	heart	transplant,	elaborate	on	the	role	of	vascular	endothelial	growth	factor	B	(VEGF-B)	in	
heart	transplant	ischemia-reperfusion	injury	(TX-IRI)	and	hypoxia-inducible	factor	(HIF)	in	the	
inflammatory	properties	of	allograft-infiltrating	myeloid-derived	cells.	
	
The	long-term	kinetics	and	safety	of	AAV	serotypes	2,	8,	and	9	were	evaluated	by	perfusing	the	
coronary	tree	of	 rat	heart	 transplants	with	each	serotype	and	comparing	the	reporter	gene	
expression	at	set	 time-points	and	 inflammatory	response	at	 the	end-point	of	 the	study.	We	
studied	the	role	of	VEGF-B	in	ischemia-reperfusion	injury	of	cardiac	allografts	by	transgene-	and	
AAV-mediated	overexpression	of	VEGF-B	in	rat	cardiac	allografts.	The	significance	of	HIF	as	an	
immunoregulatory	switch	 in	myeloid-derived	cells	was	determined	by	using	transgenic	mice	
with	myeloid	cell-targeted	activation	or	knock-out	(KO)	of	HIF-1α	and	-2α	as	heart	transplant	
recipients.		
	
We	found	that	AAV2	was	most	effective	in	transducing	heart	transplants	after	intracoronary	
injection,	whereas	 AAV9	was	most	 effective	when	 injected	 systemically	 into	 the	 transplant	
donor.	 Adeno-associated	 virus	 serotype	 9	 caused	 a	mild	 inflammatory	 response	 in	 cardiac	
allografts,	whereas	AAV2	and	8	did	not.	Chronic,	but	not	short-term,	VEGF-B	overexpression	in	
rat	 cardiac	 transplants	 resulted	 in	 cardiomyocyte	hypertrophy	 and	higher	 energy	demands,	
with	 subsequent	 higher	 susceptibility	 towards	 TX-IRI.	HIF-1α	 and	 -2α	 activation	 in	 recipient	
myeloid	cells	established	an	immunoregulatory	phenotype	that	significantly	suppressed	both	
TX-IRI	and	acute	rejection	and	prolonged	allograft	survival.	 
	
Our	results	highlight	the	 importance	of	the	route	of	administration	on	heart	transplant	AAV	
gene	therapy	and	suggest	AAV2	as	the	preferred	vector	for	intracoronary	perfusion	and	AAV9	
for	systemic	delivery	in	experimental	rat	heart	transplant	models.	Vascular	endothelial	growth	
factor	B	may	regulate	heart	energy	demand	and	thus	might	play	an	important	role	in	transplant	
ischemic	 tolerance.	 Hypoxia-inducible	 factor-1α	 and	 -2α	 act	 as	 important	 switches	 for	 the	
immunoregulatory	phenotype	of	myeloid	cells,	and	may	offer	a	viable	 therapeutic	 target	 to	
alleviate	allograft	rejection.	
	 	
	 10	
INTRODUCTION	
 
In	the	early	days,	transplanted	organs	were	plagued	by	failure	and	patient	death.	It	was	soon	
discovered	 that	 the	 one	 overwhelming	 obstacle	 towards	 long-term	 survival	 of	 organ	
transplants	was	the	immune	response	of	the	recipient.	Accumulated	evidence	from	research,	
however,	has	broadened	our	knowledge	of	the	underlying	problem	to	not	only	immunologic	
factors,	 but	 also	 non-immunologic	 insults	 to	 the	 transplanted	 tissue	 during	 brain	 death,	
procurement,	preservation,	and	reperfusion	of	the	organs.1,2	We	have	now	come	to	understand	
that	 the	 earliest	 insults	 to	 the	 transplant	 stimulate	 the	 recipient	 innate	 immune	 system	 to	
identify	 the	 foreign	 allogeneic	 tissue	 and	 to	mount	 an	 effective	 delayed	 adaptive	 response	
against	it.	
	
The	medical	community	is	lacking	reliable	and	valid	markers	for	transplant	rejection.	Still	today,	
heart	 transplant	 recipients	 are	 screened	with	 endomyocardial	 biopsies	 and	 coronary	 artery	
angiograms.	These	highly	 invasive	diagnostic	modalities	burden	the	patients	with	potentially	
serious	 complications.	 Patients	 require	 life-long	multidrug	 immunosuppressive	 regimens	 to	
prevent	 the	 rejection	 of	 their	 transplant,	 exposing	 them	 to	 harmful	 side-effects	 and	
opportunistic	 infections	that	may	give	rise	to	compliancy	concerns.	These	 issues	necessitate	
new	both	diagnostic	and	therapeutic	modalities.	One	prominent	method	is	gene	therapy.	The	
method	uses	viral	 vectors	 to	 introduce	exogenous	genetic	material	 into	specific	 tissues	and	
cells.	It	could	potentially	eliminate	the	need	for	invasive	diagnostic	methods	and	harmful	drug	
side-effects	by	using	suitable	promoters	that	activate	vector-carried	reporter-	or	therapeutic	
genes	 in	 a	 tissue-specific	 manner.	 Adeno-associated	 viruses	 (AAV)	 are	 among	 the	 most	
researched	viral	vectors	due	to	their	low	pathogenicity	and	high	transductivity.3		
	
After	brain	death,	one	of	the	earliest	 insults	to	the	transplant	 is	 ischemia	during	the	ex	vivo	
preservation	and	 subsequent	 reperfusion	after	 implantation	 into	 the	 recipient.	 The	hypoxic	
environment	and	the	ensuing	inflammation	activate	several	innate	molecular	pathways.	Among	
the	best	characterized	ones	are	hypoxia-inducible	factors	(HIF)	and	vascular	endothelial	growth	
factors	 (VEGF).	 Hypoxia-inducible	 factors	 are	 transcriptional	 regulators	 that	 allow	 cell	
adaptation	to	hypoxic	environments	by	regulating	a	wide	set	of	metabolic-,	angiogenic-,	and	
inflammatory	 genes.4	 The	 VEGF	 family	 comprises	 VEGF-A,	 -B,	 -C,	 –D,	 and	 -E	 with	 their	
corresponding	 receptors	 VEGFR1,	 -2,	 -3,	 and	 NRP1	 and	 -2.5	 They	 play	 a	 significant	 role	 in	
angiogenesis,	lymphangiogenesis,	and	inflammation.5	
	
This	thesis	investigates	the	efficiency	and	safety	of	AAV	serotypes	2,	8,	and	9	as	gene	vectors	in	
heart	 transplantation,	 utilizing	 viral	 vectors	 and	 genetically	 modified	 research	 animals	 to	
determine	the	role	of	VEGF-B	in	TX-IRI	and	HIF-1α	and	-2α	in	mediating	myeloid	cell	properties.	
The	study	aims	to	advance	our	knowledge	of	VEGFs	and	HIF	in	organ	transplantation,	and	to	
identify	new	potential	therapeutic	targets	for	treating	acute	and	chronic	transplant	rejection.	
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REVIEW	OF	THE	LITERATURE	
	
1. Clinical	heart	transplantation	
 
1.1	 History	of	heart	transplantation	
	
Doctors	Norman	Shumway	and	Richard	Lower	from	Stanford	University	laid	the	foundation	for	
clinical	heart	transplantation	in	the	1950s	and	1960s.	The	subsequent	development	of	the	first	
heart-lung	machine	by	Dr.	John	Gibbon	in	1952	enabled	the	first	adult	heart	transplantation	
performed	by	Dr.	Christiaan	Barnard	in	Cape	Town	December	3rd	1967	and	the	subsequent	first	
pediatric	heart	transplantation	by	Dr.	Adrian	Kantrowitz	three	days	later	 in	New	York.6-8	The	
first	heart	transplant	was	obtained	from	a	donor	after	cardiac	death.	The	notion	of	donor	brain	
death,	however,	was	first	defined	in	Harvard	in	1969.9	Dr.	Michael	DeBakey	implanted	the	first	
left	ventricular	assist	device	in	1966,	and	the	first	successful	long-term	device	implantation	was	
performed	 by	 Dr.	 William	 Bernhard	 in	 Boston	 Children’s	 Hospital.10,11	 The	 first	
immunosuppressant,	 azathioprine,	 was	 introduced	 in	 1962.	 It	 was	 not	 until	 the	 advent	 of	
cyclosporine	in	1976,	however,	that	acute	rejections	of	non-renal	organ	transplants	became	
universally	manageable.12	
	
1.2	 Transplant	volumes	
	
The	 number	 of	 heart	 transplantations	 have	 increased	 steadily	 throughout	 the	 years,	 with	
current	rates	of	close	to	4,500	procedures	annually.13	The	development	of	cardiac	inotropes	
and	mechanical	 assist	 devices	have	allowed	medical	 teams	 to	bridge	 their	 patients	 to	 their	
transplantation,	prolonging	patient	 lives	and	subsequently	also	 transplant	waiting	 list	 times.	
Consequently,	many	transplantation	programs	have	adapted	donor	extended	criteria,	such	as	
prolonged	>4-hour	 ischemia	 times,	 age	>55	 years,	 abnormal	 ECG,	diabetes,	 chronic	 alcohol	
consumption,	 and	 recently	 also	 ABO-incompatibility	 and	 cardiac	 death	 to	 counter	 the	
increasing	demand	for	organs.14-16	
	
1.3	 Immunosuppression	
	
The	immunosuppressive	drug	regimen	for	heart	transplant	recipients	consists	of	induction	and	
maintenance	 therapy.	 Induction	 therapy	 is	 used	 in	 ca.	 50%	 of	 cases,	 and	most	 commonly	
consists	 of	 rabbit	 antithymocyte	 immunoglobulin	 or	 IL-2	 receptor	 antagonist	 basiliximab.	
Maintenance	therapy	is	chosen	on	an	individual	basis,	and	usually	combines	a	triple	therapy	of	
calcineurin	inhibitor,	corticosteroid,	and	a	cell	cycle	inhibitor.	Tacrolimus	is	the	most	preferred	
calcineurin	 inhibitor,	 whereas	 mofetil/mycophenolic	 acid	 is	 the	 preferred	 cell	 cycle	
inhibitor.13,17	
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1.4	 Indications	and	outcomes	of	heart	transplantation	
	
Cardiomyopathy	remains	the	most	common	indication	for	heart	transplantation	among	both	
adult	(ca.	49%)	and	pediatric	patients	(ca.	45%).13,18	The	median	age	at	heart	transplantation	is	
54	years	among	adult	patients.13	
	
The	1-year	and	5-year	survival	of	patients	receiving	heart	transplants	between	1992-2011	is	
81%	and	69%,	respectively.19	Forty-eight	percent	of	adult	heart	transplant	recipients	develop	
CAV	within	10	years	of	 their	procedure,	and	68%	develop	renal	dysfunction.13	Primary	graft	
failure	accounts	for	41%	of	early	<30-day	post-operative	deaths	and	CAV	for	17%	of	>5-10-year	
post-operative	deaths	among	adult	heart	transplant	recipients.13	
	
2. Stages	of	heart	transplantation	
 
From	both	a	macro-	and	microenvironmental	point	of	view,	transplantation	may	be	divided	into	
6	often	overlapping	stages,	each	with	their	own	distinct	roles	in	the	development	of	transplant	
rejection:	donor	brain	death,	ex	vivo	cold	preservation	of	the	heart	transplant,	warm	ischemia	
during	 surgery,	 reperfusion,	 the	 recipient	 innate	 immune	 response,	 and	 activation	 of	 the	
adaptive	immunity	(Figure	1).		
Each	of	these	stages	are	first	described	separately	and	then	together	to	depict	the	collective	
cascade	of	events	leading	to	development	of	CAV	and	rejection	of	the	heart	transplant.	
	
2.1	 Donor	brain	death	
	
Currently,	the	main	criteria	for	a	heart	transplant	donor	is	brain	death.20	Although	logical	and	
necessary	 from	 an	 ethical	 point	 of	 view,	 it	 poses	 a	 significant	 problem	 from	 a	 scientific	
perspective	due	to	the	damaging	effect	it	has	on	the	heart	transplant.	The	negative	impact	of	
brain	death	on	outcomes	of	heart	transplantation	have	been	established	with	animal	models.21	
Figure	1	–	Stages	of	heart	transplantation:	1)	brain	death	2)	cold	ischemia	during	ex	vivo	preservation	3)	warm	ischemia	during	
transplant	implantation	into	the	recipient	4)	reperfusion	of	the	transplant	5)	innate	immune	response	and	6)	allorecognition	
and	activation	of	the	adaptive	immune	response.	
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Brain	death	 initiates	a	deleterious	 systemic	cascade	 that	may	be	 roughly	divided	 into	 three	
often	overlapping	events:	
	
Catecholamine	storm	–	cortical	damage	and	increased	intracranial	pressure	induce	the	release	
of	 norepinephrine	 and	 neuropeptide	 y	 from	 the	 adrenal	 medulla,	 but	 also	 locally	 in	 the	
myocardium	 via	 sympathetic	 innervation.22,23	 Experimental	 models	 refuting	 correlation	
between	cardiac	troponin	I	and	systemic	catecholamine	levels	after	cardiac	sympathectomy	in	
baboons	 suggest	 a	 more	 critical	 role	 of	 the	 local	 release	 of	 catecholamines	 in	 mediating	
myocardial	 damage.24	 The	 effect	 is	 profound	 systemic	 hypertension,	 increased	 vascular	
resistance,	intense	coronary	vasospasm,	and	arrhythmias,	causing	myocardial	ischemia,	release	
of	reactive	oxygen	species	(ROS),	irreversible	contraction	band	stretching,	and	cell	death.24,25	
The	 reduced	 activity	 of	 calcium	 adenosine	 triphosphatase	 leads	 to	 cardiomyocyte	 (CMC)	
calcium	overload,	which	induces	a	prolonged	state	of	high-affinity	actin-myosin	interaction,	and	
eventually	irreversible	myocardial	contractions	and	necrosis.26,27	
	
Endocrine	dysfunction	–	within	hours	after	brain	death	a	decrease	 in	 circulating	pancreatic,	
thyroid,	adrenocortical,	and	pituitary	hormones	leads	to	severe	fluid,	electrolyte,	and	glucose	
abnormalities.28	The	resulting	dysfunctions	of	thermal	regulation	and	mitochondrial	processes	
leads	 to	 enhanced	anaerobic	metabolism,	metabolic	 acidosis,	 and	 tissue	hypothermia,	with	
their	corresponding	negative	myocardial	repercussions.29	
	
Inflammatory	 reaction	 –	 Ischemia	 and	hemodynamic	 alterations	 lead	 to	 enhanced	 cytokine	
release	from	the	brain,	intestines,	and	activated	vascular	endothelial	cells	(VEC).	Upregulated	
cytokines	 include	TNF-α,	 IFN-g,	 IL-1α	and	–β,	 IL-2,	 IL-2Rb,	CCL2,	and,	most	 importantly,	 IL-6.	
Activation	of	the	VEC	leads	to	upregulation	of	ICAM-1,	VCAM-1,	P-,	and	E-selectin.30	Also,	brain	
death	 upregulates	 the	 expression	 of	 major	 histocompatibility	 complex	 II	 antigens.21	 This	
systemic	 and	 local	 pro-inflammatory	 state	 increases	 the	 immunogenicity	 of	 the	 heart	
transplant	 and	 leads	 to	 enhanced	 rejection	 episodes	 and	 higher	 incidence	 of	 primary	 graft	
dysfunction	after	transplantation.21	 
	
2.2	 Cold	and	warm	ischemia	
	
After	procurement,	the	heart	transplant	is	preserved	in	cold	solution	during	transportation	to	
the	recipient,	with	mean	ischemia	times	of	approximately	3.3	hours	internationally.19	The	lack	
of	blood	circulation	and	nutrients	stimulates	anaerobic	metabolism,	exacerbating	local	acidosis	
and	accumulation	of	metabolic	waste	products.	At	first,	the	ischemic	cardiac	tissue	strives	to	
adapt	to	the	oxygen-poor	milieu	by	entering	a	hibernating	state,	characterized	by	a	metabolic	
switch	 from	 the	 normal	 highly	 oxygen-consuming	 fatty-acid	 oxidation	 towards	 anaerobic	
glycolysis.31,32	The	demand	for	adenosine	triphosphate	(ATP),	however,	eventually	overwhelms	
the	adaptive	mechanisms,	causing	a	critical	decrease	in	ATP	levels	and	subsequent	failure	of	
ATP-dependent	membrane	transporters.	Sodium	and	calcium	accumulate	within	cells,	opening	
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the	mitochondrial	permeability	transition	pore	(MPTP),	which	exacerbates	the	decline	in	ATP	
production	 and	 leads	 to	 cellular	 swelling,	 membrane	 rupture,	 and	 cell	 death	 via	 necrosis,	
apoptosis,	necroptosis,	and	autophagy.33,34	This	results	in	release	of	intracellular	immunogenic	
damage-associated	molecules	(DAMPs),	which	later	prove	detrimental	in	activating	the	innate	
immune	response.	During	warm	 ischemia	when	 the	heart	 transplant	 is	anastomosed	 to	 the	
recipient	these	aforementioned	metabolic	changes	and	damaging	processes	are	potentiated	
by	the	lack	of	cold	preservation	solution.	
	
2.3	 Reperfusion	
	
Paradoxically,	 restoration	of	blood	 flow	 to	 the	heart	 transplant	exacerbates	 the	deleterious	
events	initiated	by	prior	ischemia.	It	is	characterized	by	several	pathologic	processes:	
	
No-reflow	phenomenon	–	despite	reperfusion	of	the	heart	transplant	the	myocardial	tissue	may	
experience	prolonged	impaired	tissue	perfusion.	The	reason	is	microvascular	obstruction	due	
to	microthrombi,	VEC	and	CMC	swelling,	myocyte	and	pericyte	contracture,	and	neutrophilic	
plugging	 of	 the	 vasculature.35-37	 Tissue	 edema	 and	 inflammation	 also	 play	 a	 role	 in	 this	
phenomenon.38,39	
		
Oxygen	paradox	–	sudden	reoxygenation	of	the	heart	transplant	causes	an	abrupt	increase	in	
oxygen	 tension	 and	 saturation	 of	 the	 cellular	 antioxidant	 pathways.	 Enzymes	 such	 as	
endothelial	cell	(EC)	xanthine	oxidase	and	neutrophilic	NADPH	mediate	the	formation	of	ROS.40	
These	may	deplete	the	myocardium	and	VEC	from	protective	nitric	oxide	(NO),	which	leaves	
the	tissue	vulnerable	to	neutrophilic	influx,	superoxide	accumulation,	vasoconstriction,	and	EC	
damage.41-43	Furthermore,	ROS	induce	opening	of	the	MPTP,	membrane	peroxidation,	damage	
to	the	sarcoplasmic	reticulum,	neutrophil	chemotaxis,	DNA	damage,	and	enzyme	denaturation.	
	
Calcium	 paradox	 –	 damage	 to	 the	 sarcolemma	 and	 ROS-mediated	 dysfunction	 of	 the	
sarcoplasmic	reticulum	exacerbates	the	already	present	intracellular	calcium	overload.44	This	
intracellular	hypercalcemia	acts	in	concert	with	ROS	and	an	acidic	pH	to	induce	further	MPTP	
opening,	and	thus	uncoupling	of	oxidative	phosphorylation,	mitochondrial	swelling,	and	CMC	
death.	
	
pH	paradox	–	the	rapid	washout	of	intragraft	lactic	acid,	along	with	the	activities	of	Na+-H+	and	
Na+-HCO3	 pumps	 results	 in	 an	 abrupt	 correction	 of	 intracellular	 pH	 and	 subsequent	MPTP	
opening	and	CMC	hypercontracture.44,45	
	
Microvascular	 dysfunction	 and	 inflammation	 –	 reperfusion	 injury	 results	 in	 microvascular	
leakage	through	destabilization	of	the	vascular	wall	and	formation	of	EC-EC	gaps.46-48	One	of	
the	 main	 mechanisms	 behind	 reperfusion-mediated	 microvascular	 dysfunction	 is	 oxidant-
induced	 early	 leukocyte-EC	 interactions.40,49,50	 These	 include	 ROS-mediated	 release	 of	
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proinflammatory	 cytokines	 and	 chemokines	 by	 the	 EC	 (such	 as	 IL-1	 and	 TNF-α),	 local	
parenchymal	cells,	and	infiltrating	leukocytes;	expression	of	adhesion	molecules	on	activated	
EC	and	leukocytes	(CD11/CD18	integrins,	ICAM-1,	and	P-selectin);	and	depletion	of	endothelial	
nitric	 oxide	 (NO).51-55	 This	 combined	with	 the	 ischemia-induced	 decline	 in	 EC	 NO	 synthase	
(iNOS)	 activity	 and	 oxidation	 of	 soluble	 guanylyl	 cyclase	 (sGC)	 serves	 to	 amplify	 the	
inflammatory	response.	Host	leukocytes,	mostly	neutrophils,	form	adhesive	interactions	with	
the	activated	EC	in	postcapillary	venules,	migrate	into	the	tissue,	and	start	releasing	oxidants	
and	 hydrolytic	 enzymes	 that	 damage	 the	 parenchymal	 tissue	 and	mediate	 EC	 and	 pericyte	
dysfunction.	 The	 damage	 on	 both	 intra-	 and	 intercellular	 cytoskeletal	 components	 and	
contraction	 of	 EC	 disrupt	 tight-	 and	 adherens	 junctions	 of	 the	 vascular	 wall,	 leading	 to	 EC	
blebbing	and	the	formation	of	EC-EC	gaps,	vascular	leakage,	and	influx	of	host	leukocytes.46-48	
	
Ischemia-reperfusion	 injury	 activates	 both	 the	 vascular-	 and	 the	 lymphatic	 endothelium	
(LEC).56,57	The	former	mediates	leukocyte	entry	after	reperfusion,	and	the	latter	leukocyte	exit	
early	 after	 transplantation.	 Also,	 the	 hypoxic	 environment	 has	 been	 shown	 to	 affect	 the	
phenotype	 of	 the	 passenger	 leukocytes,	 so	 that	 dendritic	 cells	 increase	 their	 expression	 of	
vascular	endothelial	growth	factor	receptor	3	(VEGFR3).56	
	
2.4	 Innate	immune	response	
	
The	 innate	 immune	 response	 is	 the	 body’s	 first	 line	 of	 surveillance	 and	 defense	 against	
imminent	threats.	The	cellular	arm	comprises	neutrophils,	monocytes,	macrophages,	dendritic	
cells	 (DC),	 natural	 killer	 cells	 (NK	 cells)	 (Figure	 2),	 and	 relatively	 recently	 discovered	 innate	
lymphoid	cells	(ILC);	whereas	the	humoral	arm	consists	mainly	of	the	complement	system	and	
natural	antibodies.	Additional	innate	immune	cells	are	eosinophils,	basophils,	and	mast	cells,	
but	are	excluded	due	to	their	disconnection	to	transplant	 immunology.	These	factions	work	
together	to	form	an	antigen-independent	sentinel	system.	
	
	
	
The	cellular	arm	of	 the	 innate	 immune	system	 is	equipped	with	 special	pattern	 recognition	
receptors	 (PRR),	 of	 which	 toll-like	 receptors	 (TLR),	 particularly	 TLR-4	 in	 the	 setting	 of	
Figure	2	–	Cells	of	the	immune	system	relevant	to	transplantation.	APC,	antigen	presenting	cells.	
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transplantation,	 are	 the	 hallmark.58,59	 These	 receptors	 provide	 immune	 cells	 the	means	 to	
identify	 non-self	 pathogen-associated	 molecular	 patterns	 (PAMPs).	 It	 was	 not	 until	 1994,	
however,	that	Dr.	Polly	Matzinger	introduced	the	Danger	model,	which	proposed	that	immune	
cells	not	only	recognized	pathogens,	but	were	also	activated	by	DAMPs	from	injured,	stressed,	
or	dying	cells.60	These	signals	are	again	 recognized	by	a	specialized	set	of	PRRs	on	not	only	
innate	immune	cells,	but	also	on	adaptive	immune	cells	and	VECs	(Table	1).	Ligation	of	PRRs	
causes	 downstream	 activation	 of	 the	 inflammasome	 and	 proinflammatory	 transcription	
factors,	most	notably	NF-κB,	causing	cytokine	and	chemokine	production,	as	well	as	enhanced	
antigen	presentation	and	upregulation	of	costimulatory	signals	from	antigen	presenting	cells	
(APC).61,62	
	 	
	 Table	1	–	Pattern	recognition	receptors 
	
	
	
	
	
	
	
	
	
	
	
PRR,	pattern	recognition	receptor;	CD,	cluster	of	differentiation;	RIG,	retinoic	acid-inducible	gene;		
DC,	dendritic	cell;	ICAM,	intercellular	adhesion	molecule.	
	
Land	et	al.	studied	the	danger	model	in	renal	transplantation	and	found	that	blocking	of	DAMPs,	
especially	 free	 radicals,	 significantly	 prolonged	 renal	 allograft	 survival.63	 These	 findings	
underscore	 the	 importance	 of	 the	myocardial	 insults	 during	 all	 the	 steps	 leading	 to	 organ	
reperfusion	in	activating	the	host	immune	response	against	the	heart	allograft.			
	
All	cells	of	the	innate	immune	system	are	derived	from	myeloid	stem	cells	(Figure	3),	except	NK	
and	 innate	 lymphoid	cells,	which	stem	from	a	 lymphoid	progenitor.	Each	of	 the	cells	of	 the	
innate	immune	system	have	their	own	unique	functions	in	the	body’s	defense	system,	which	is	
why	they	warrant	separate	consideration.	
	
PRR	type	 Receptor	family	
Cell	surface	receptors	
Toll-like	receptors	
C-type	lectin	receptor	
CD14	
Receptor	of	advanced	glycation	end	products	
Intracellular	receptors	
Nucleotide-binding	oligomerization	domain-like	receptors	
Retinoic	acid-inducible	gene-I-like	receptors	
Nod-like	receptors	
RIG-like	helicases	
Inflammasomes	
Secreted	receptors	 Mannose	binding	lectin	receptor	
Phagocytosing	receptors	
Mannose	receptor	
DC-specific	ICAM3-grabbing	non-integrin	receptor	
Macrophage	receptor	with	collagenous	structure	
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Neutrophils	
	
Neutrophils	 are	 short-lived	 cells	 of	 ca.	 6-8	 hours	 of	 life,	
originate	from	the	bone	marrow,	and	present	in	abundant	
quantities	in	the	blood	circulation.	They	usually	pool	at	the	
margins	of	the	vascular	wall	and	are	mobilized	and	migrate	
into	the	area	of	tissue	injury,	where	they	are	captured	by	
the	activated	VECs.	During	periods	of	greater	demand,	they	
proliferate	 and	 are	 mobilized	 from	 the	 bone	marrow	 in	
response	 to	 growth	 factors	 and	 chemokines,	 such	 as	
granulocyte	colony-stimulating	factor	(G-CSF).		
	 	
Table	2	–	Neutrophil-derived	soluble	molecules.64		
CXCL,	 chemokine	 (C-X-C	 motif)	 ligand;	 CCL,	 chemokine	 (C-C	 motif)	 ligand;	 IL,	 interleukin;	 IFN,	 interferon;	 MIF,	 migration	
inhibitory	factor;	G-CSF,	granulocyte	colony-stimulating	factor;	GM-CSF,	granulocyte-macrophage	colony-stimulating	factor;	
SCF,	 stem	 cell	 factor;	 RANKL,	 receptor	 activator	 of	 nuclear	 factor	 kappa-B	 ligand;	 TNF,	 tumor	 necrosis	 factor;	 APRIL,	 a	
proliferation-inducing	ligand;	BAFF,	B	cell	activating	factor;	CD,	cluster	of	differentiation;	TRAIL,	TNF-related	apoptosis-inducing	
ligand;	VEGF,	vascular	endothelial	growth	factor;	HGF,	hepatocyte	growth	factor;	HB-EGF,	heparin-binding	epidermal	growth	
factor-like	growth	factor;	FGF,	fibroblast	growth	factor;	NGF,	nerve	growth	factor;	NT,	neurotrophin;	TGF,	transforming	growth	
factor.	
	
Neutrophils	are	activated	by	PRR	ligation,	G-CSF,	GM-CSF,	TNF-α,	and	type	1	and	2	IFNs,	and	
undergo	degranulation	to	release	cytotoxic	proteins	and	generate	ROS	to	clear	damaged	or	
pathogen-infected	cells.	The	inflammatory	chemokines	they	secrete	function	to	attract	more	
neutrophils,	 monocytes,	 and	 adaptive	 immune	 cells	 to	 the	 inflammatory	 site,	 facilitate	
migration	into	the	tissue,	and	to	activate	them	once	there	(Table	2).	Neutrophils	also	activate	
NK	cells	to	produce	IFN-g,	and	indirectly	stimulate	maturation	of	lymphocytes,	particularly	of	
the	Th1	type,	via	DC-SIGN-,	MAC-1-,	and	CEACAM1-dependent	activation	of	monocyte-derived	
DCs.65-68	They	also	contribute	to	the	humoral	arm	of	the	innate	response	by	secreting	soluble	
PRRs,	 such	 as	 ficolins	 and	 pentraxins	 that	 activate	 the	 complement	 system	 and	 enhance	
phagocytosis.69,70	 Although	 generally	 not	 recognized	 as	 APCs,	 recent	 studies	 have	
demonstrated	the	capacity	of	neutrophils	to	deliver	and	present	antigens	to	 lymphocytes	 in	
lymph	nodes	during	microbial	infections.71,72	
	
	
	
	
	
Secretory	type	 Molecule	
Chemokines	
CXCL1,	2,	3,	4,	5,	6,	8,	9,	10,	11	
CCL2,	3,	4,	17,	18,	19,	20,	22	
Inflammatory	
IL-1α,	1β,	3,	6,	7,	9,	12,	16,	17A,	17F,	18,	23	
IFN-g,	IFN-α,	G-CSF,	GM-CSF,	SCF,	RANKL,	TNF,	APRIL,	BAFF,	CD30L,	CD95L,	TRAIL,	
VEGF,	HGF,	HB-EGF,	FGF2,	NGF,	NT4	
Anti-inflammatory	 IL-1RA,	4,	10,	MIF,	TGF-β1,	and	β2	
Figure	3	–	Myeloid-derived	cells.	
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Monocytes	and	macrophages	
	
Macrophages	are	present	in	both	the	circulation	as	monocytes	and	periphery	in	the	form	of	
tissue-specific	 phagocytes,	 such	 as	 Kupffer	 cells,	 osteoclasts,	 and	 alveolar	 macrophages.	
Circulating	monocytes	have	an	estimated	half-life	of	70h.	Accumulating	evidence	has	revealed	
the	 diverse	 functions	 of	 tissue-resident	 macrophages.	 In	 the	 heart,	 cardiac	 resident	
macrophages	participate	in	the	electric	conductance	system	and	in	both	the	inflammatory	and	
regenerative	phase	of	myocardial	infarction.73,74		
	
Table	3	–	Macrophage-derived	soluble	molecules.	
CCL,	 chemokine	 (C-C	 motif)	 ligand;	 CXCL,	 chemokine	 (C-X-C	 motif)	 ligand;	 MIP,	 macrophage	 inflammatory	 protein;	 MIG,	
monocyte	induced	by	interferon	gamma;	IP,	interferon-gamma-inducible	protein;	IL,	interleukin;	TNF,	tumor-necrosis	factor;	
TGF,	 transforming	 growth	 factor;	 IGF,	 insulin-like	 growth	 factor;	 PDGF,	 platelet-derived	 growth	 factor;	 MMP,	 matrix	
metalloproteinase;	G-CSF,	granulocyte	colony-stimulating	factor;	VEGF,	vascular	endothelial	growth	factor;	Arg,	arginase;	NO,	
nitric	oxide.	
	
Tissue-resident	 macrophages	 and	 the	 first	 monocytes	 to	 reach	 the	 site	 of	 injury	 are	 not	
sufficient	to	mount	a	full	immune	response.	Instead,	they	secrete	chemokines	and	proliferation	
signals,	such	as	G-CSF,	CCL2,	and	CCL5	to	mobilize	additional	monocytes	and	macrophages	from	
the	 bone	 marrow	 and	 spleen	 to	 the	 site	 of	 inflammation	 (Table	 3).	 Macrophages	 act	 as	
patrolling	 cells	 of	 the	 tissues.	 They	 are	 activated	 by	 PRR	 ligation	 or	 IFN-g;	 phagocytose	
pathogens,	foreign	material,	and	necrotic	cells;	and	belong	to	the	APC	family	of	leukocytes.75	
Antigen	 presenting	 cells	 present	 phagocytosed	 material	 on	 their	 major	 histocompatibility	
complex	(MHC)	at	their	cellular	surface	to	the	cells	of	the	adaptive	immune	system	to	enable	
the	activation	of	an	antigen-specific	immune	response	(see	later).	
	
Dendritic	cells	(DC)	
	
Like	macrophages,	DCs	are	present	 in	 the	periphery	as	sentinels,	 in	 the	blood	as	circulating	
monocytes	and	pre-DCs,	and	stored	in	lymphoid	tissue.	What	makes	DCs	special,	however,	is	
their	robust	antigen	presenting	function;	one	DC	can	provide	all	three	stimulatory	signals	(MHC	
I/II	+	B7	+	cytokines)	required	to	initiate	an	effective	adaptive	immune	response.	As	such,	they	
are	the	most	important	bridge	between	the	innate	and	adaptive	immunity.76	
	
Dendritic	cells	have	several	subtypes	at	different	stages	of	maturation.	At	the	first	level,	they	
are	 divided	 into	 classical	 and	 nonclassical	 (pre-dendritic	 cell)	 DC.	 Classical	 DCs	 comprise	
CD8α+/CD103α+	 and	 CD11b+	 DCs,	 and	 nonclassical	 ones	 include	 monocyte-derived	 and	
plasmacytoid	DCs.	CD8α+/CD103α+	DCs	 are	only	 found	 in	mice.77	 They	are	 activated	by	TLR	
ligation,	secrete	 IL-12p70,	and	mainly	specialize	 in	presenting	pathogen-derived	antigens	on	
Secretory	type	 Molecule	
Chemokines	 CCL2,	5	(RANTES),	MIP-2α (CXCL1/CXCL2),	MIG	(CXCL9),	IP-9	(CXCL11),	IP-10	(CXCL10)	
Inflammatory	 IL-1,	6,	8,	12,	18,	23,	27,	TNF-α,	TGF-β,	IGF-1,	PDGF,	MMP,	G-CSF,	VEGF	
Anti-inflammatory	 Arg1,	CCL17,	CCL22	YM1,	FIZZ1,	NO		
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MHC	I	molecules	to	CD8+	T	cells,	especially	spleen-derived	ones.78	CD8α+	DCs	can	also	sense	
circulating	 DAMPs	 and	 pathogens	 from	 spleen	 fenestrae,	 with	 subsequent	 CD8+	 T	 cell	
activation,	and	present	glycolipid	antigens	to	NK	cells	in	a	CD1d	context,	promoting	subsequent	
Th1	and	Th2	responses.79	CD11b+	DCs,	on	the	other	hand,	are	the	most	abundant	type	of	DCs	in	
lymphoid	organs,	and	present	antigens	on	MHC	II	to	CD4+	T	cells.	They	produce	cytokines	IL-6	
and	IL-23	upon	activation,	as	well	as	chemokines	CCL3,	-4,	and	-5	after	TLR	ligation.80-82	
	
Like	macrophages,	DCs	may	migrate	via	both	 the	blood	and	 lymphatic	 system,	 the	 latter	of	
which	has	been	suggested	as	an	important	route	for	exiting	the	heart	and	tracheal	transplants	
after	 antigen	processing.56,57,83	 Chemokines	CCL19	and	 -21,	 S1P1/S1P3	 signalling,	 as	well	 as	
VEGF-C	direct	the	migration	of	DCs	towards	the	lymphatics.56,57,83		
	
Natural	killer	cells	
	
According	to	the	“missing-self”	model,	NK	cells	are	equipped	with	MHC	I-specific	receptors	that	
discriminate	between	self	and	nonself;	if	MHC	I	is	missing	on	the	target	cell,	it	is	recognized	as	
foreign	 and	 eliminated.84,85	 In	 addition	 to	 foreign	 non-self	 cells,	MHC	 I	 dissipates	 from	 the	
surface	of	unhealthy	and	dying	cells,	rendering	them	targets	for	destruction	by	NK	cells.	The	
receptors	 can	 either	 be	 inhibitory,	 such	 as	 killer-cell	 immunoglobulin-like	 receptor	 (KIR)	 in	
humans	and	C-type	lectin-like	Ly49A/C	receptor	in	mice,	or	stimulatory,	such	as	NKp30,	-46,	
and	-80	in	humans;	and	NKG2D	receptors	in	mice.86-91	Natural	killer	cells	play	an	important	role	
in	the	defense	against	viral	infections	and	tumors.	
	
Natural	 killer	 cell	 chemotaxis	 to	 inflammatory	 sites	 in	 mice	 is	 regulated	 by	 sphingosine-1-
phosphate,	CCR2,	CCR5,	CXCR1,	and	CXCR3.92,93	Their	entry	into	lymph	nodes	requires	CD62L.94	
In	humans,	CCR7,	CXCR1,	and	ChemR	mediate	NK	cell	chemotaxis.95	Interactions	with	cells	of	
both	the	innate	and	adaptive	immune	systems	are	important	for	NK	cell	activation.96	Cytokines	
such	as	type	1	IFN-g,	IL-2,	IL-12,	IL-15,	and	IL-18	can	activate	NK	cells	and	are	required	for	full	
cytotoxic	 effects	 to	 occur.97	 On	 the	 other	 hand,	 TGF-β	 and	 Treg	 cells	 can	 regulate	 their	
activity.98,99	
	
Innate	lymphoid	cells	
	
Innate	lymphoid	cells	(ILC)	are	the	most	recently	discovered	group	of	immune	cells,	and	stem	
from	the	common	lymphoid	progenitor.	Whereas	NK	cells	represent	the	innate	version	of	CD8+	
T	 cells,	 ILCs	 are	 the	 corresponding	 equivalent	 of	 CD4+	 T	 cells,	 but	 without	 the	 antigen-
recognizing	receptors	that	adaptive	immune	cells	possess.	The	ILC	family	consists	of	ILC1,	ILC2,	
and	ILC3.	So	far,	studies	have	established	the	importance	of	ILCs	in	regulation	and	surveillance	
of	epithelial	barriers	and	mucosal	surfaces.	In	the	mouse,	ILCs	lack	PRRs,	but	instead	recognize	
pathogens	and	tissue	damage	indirectly	by	sensing	cytokines,	alarmins	and	other	inflammatory	
molecular	secretions,	and	are	able	to	present	antigens	on	MHC	II	complexes	to	CD4+	T	cells.100	
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Innate	 lymphoid	 cell	 1	 recognizes	 IL-12;	 ILC2	 recognizes	 IL-2,	 IL-4,	 IL-7,	 IL-25,	 IL-33,	 thymic	
stromal	lymphopoietin	(TSLP),	tumor	necrosis	factor-like	cytokine	1A	(TL1A),	prostaglandin	E2	
and	leukotriene	D4;	and	ILC3	recognizes	IL-1α	and	-β,	IL-7,	IL-23,	TL1A,	and	prostaglandin	E2.101	
Innate	lymphoid	cells	also	recognize	vitamins	and	metabolites	released	during	tissue	damage.	
Activated	ILC1s	produce	IFN-g	and	TNF-α;	ILC2s	secrete	IL-5,	IL-9,	and	IL-13;	and	ILC3s	produce	
IL-17,	 IL-22,	 GM-CSF,	 and	 IFN-g.101	 Studies	 have	 established	 the	 importance	 of	 ILCs	 in	
inflammatory	bowel	disease,	allergies,	tissue	repair,	and	metabolism.	Data	on	the	role	of	ILCs	
in	transplantation	remains	scant,	however.102 
	
2.5	 Adaptive	immune	response	
 
The	adaptive	immune	response	is	a	delayed-
type	 antigen-specific	 defense	 mechanism	
against	 non-self	 insults	 to	 the	 body.	 The	
cellular	 arm	 comprises	 T	 cells	 and	 the	
humoral	 arm	 B	 cells	 and	 their	 secreted	
antigen-specific	 antibodies.	 All	 cells	 of	 the	
adaptive	 immune	 system	 stem	 from	 a	
lymphoid	 progenitor	 in	 the	 bone	 marrow	
(Figure	4).	
	
T	cells	
	
T	cells	mature	in	the	thymus	and	circulate	between	secondary	lymphoid	tissues	and	other	sites,	
such	as	the	skin	and	mucosal	surfaces,	scouting	for	an	encounter	with	an	antigen	presented	by	
an	APC.	This	circulation	between	the	blood,	lymphatic	system,	and	lymphoid	tissue	increases	
the	chance	of	an	antigen	encounter.	The	combined	negative	and	positive	selection	 involved	
during	 their	 thymic	 education	 ensures	 maintenance	 of	 nonself-recognizing	 T	 cells	 and	
destruction	of	self-recognizing	ones.	They	exit	the	thymus	as	either	CD8+	(MHC	I	dependent)	or	
CD4+	(MHC	II	dependent)	T	cells,	equipped	with	the	T	cell	receptor	(TCR)	and	CD3	receptor.103	
	
Activation	of	T	cells	requires	the	TCR-MHC	receptor-ligand	interaction,	along	with	at	least	two	
other	costimulatory	factors.	One	is	the	B7	family	of	costimulators,	including	the	CD28-CD86/80	
interaction,	and	another	is	the	TNF	receptor	family	of	costimulators,	most	notably	the	CD154-
CD40	receptor-ligand	pair.2	Upon	activation,	naïve	T	cells	may	differentiate	into	a	broad	range	
of	subcategories	in	a	cytokine-	and	context-dependent	manner	presented	in	Figure	5.		
	
After	 cognate	 antigen	 recognition,	 T	 cells	 differentiate	 into	 effector	 cells.	 CD4+	 T	 cells	
differentiate	into	one	of	the	subgroups	presented	in	Figure	5.104	Similarly,	CD8+	cytotoxic	T	cells	
may	further	differentiate	into	either	Tc1,	Tc2,	or	Tc17	cells,	each	with	their	own	specific	effector	
functions	in	allograft	rejection	(Figure	5).	Activated	T	cells	may	enter	a	memory	phase,	where	
Figure	4	–	Lymphoid-derived	cells.	
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they	either	reside	in	lymphoid	tissue	(central)	or	peripheral	tissues	(effector),	rapidly	producing	
cytokines	and	chemokines	upon	recognition	of	their	antigen.2,105	Another	special	subgroup	of	
T	cells	is	the	natural	killer	T	cell	(NKT).	It	develops	in	the	thymus	and	exhibits	a	wide	range	of	
functions	 extending	 from	 extensive	 cytokine	 and	 chemokine	 production	 to	 direct	 cytotoxic	
effects	and	regulation	of	other	immune	cells.106	In	addition	to	the	NK	cell	receptors,	NKT	cells	
also	carry	the	TCR.106,107		
	
B	cells	
	
B	cells	comprise	the	humoral	arm	of	the	adaptive	immune	response	and	are	mainly	present	in	
secondary	 lymphoid	 organs,	 most	 commonly	 in	 lymph	 nodes.	 Their	 function	 is	 highly	
dependent	on	T	cell	activation	and	stimulation,	upon	which	they	differentiate	into	plasma	cells	
and	 initiate	 production	 and	 secretion	 of	 cognate	 antigen-specific	 antibodies.	 Their	 main	
activating	receptor	is	the	B	cell	receptor,	which	recognizes	antigens	directly	or	presented	by	
APCs.	B	cells	are	able	to	produce	antibodies	against	MHC,	minor	histocompatibility	complex	
(miHC),	EC,	and	blood	group	antigens.108	These	antibodies	opsonize	antigen-harboring	cells	and	
facilitate	complement	activation,	opsonization,	and	phagocytosis	by	macrophages	and	DC.	B	
cells	 may	 also	 function	 as	 APCs,	 and	 are	 capable	 of	 presenting	 CD40	 as	 well	 as	 other	
costimulatory	factors	to	T	cells.2,109-111	Activated	B	cells	may	also	enter	a	memory	phase.	These	
Figure	5	–	T	cell	subgroups	and	their	respective	inducer	signals	and	subsequent	
effector	secretions.	IL,	interleukin;	IFN,	interferon;	nTreg,	natural	regulatory	T	cell;	
iTreg,	 inducible	 regulatory	 T	 cell;	 TGF,	 transforming	 growth	 factor;	 TNF,	 tumor	
necrosis	factor.	
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cells	 have	 a	 lower	 threshold	 for	 activation	 during	 interaction	with	 cognate	 antigens	 during	
subsequent	episodes,	and	produce	a	more	rapid	antigen-specific	response.112,113	
	
3. Cardiac	allograft	rejection	
 
The	pathogenesis	of	heart	transplant	rejection	is	a	cumulative	multifactorial	process	in	which	
the	6	phases	of	transplantation	defined	in	the	previous	sections	converge.	Donor	brain	death	
and	TX-IRI	form	the	bulk	of	the	non-immunological	damage	to	the	allograft,	accumulating	local	
DAMPs	and	causing	an	overall	increase	in	allograft	immunogenicity.	Activation	of	the	allograft	
VECs	and	LECs,	allograft	microvascular	dysfunction,	and	release	of	cytokines	and	chemokines	
by	 donor	 passenger	 leukocytes	 and	 ECs	 provide	 the	 necessary	 means	 for	 an	 effective	
immunological	 response	 to	 develop.54,56,57,116-124	 Thus,	 the	 cardiac	 allograft	 is	 primed	 for	
inflammation	prior	 to	 implantation	 into	the	recipient.	What	 follows	after	reperfusion,	 is	 the	
activation	 and	 influx	 of	 innate	 immune	 cells	 into	 the	 allograft,	 memory	 T	 cell	 infiltration,	
allorecognition,	 and	 activation	 and	 proliferation	 of	 a	 de	 novo	 adaptive	 immune	 response.2	
Other	 both	 immunological	 and	 non-immunological	 factors,	 such	 as	 the	 degree	 of	 genetic	
mismatch,	 infections,	 donor	 age,	 and	 duration	 of	 allograft	 ischemia	 may	 accelerate	 this	
pathological	process.125-129		
	
3.1	 Major	histocompatibility	complex	(MHC)	
 
The	MHC	represents	a	group	of	proteins	specialized	in	binding	and	presenting	pathogen-,	self-	
and	nonself-derived	antigens	on	the	cell	surface.	In	humans,	the	MHC	proteins	are	encoded	by	
the	human	leukocyte	antigen	(HLA)	genes.	The	MHC	gene	family	comprises	three	subsets,	of	
which	class	I	and	class	II	are	most	relevant	to	transplantation.	Human	leukocyte	antigen	A,	-B,	
and	–C	encode	MHC	class	I	peptides,	whereas	HLA-DP,	-DM,	-DOA,	-DQ,	and	–DR	encode	MHC	
class	II	peptides.	Major	histocompatibility	complex	1	consists	of	α1-3	and	β2	subunits,	occurs	on	
all	nucleated	cells	and	platelets,	and	presents	both	self-	and	nonself-antigens	recognized	by	NK	
cells	and	CD8+	T	cells;	whereas	MHC	II	consists	of	α1,	α2,	β1,	and	β2	subunits,	usually	occurs	only	
on	APCs,	and	 is	 recognized	by	CD4+	T	cells.114	The	polygenic,	 codominant,	and	polymorphic	
expression	 of	 the	 HLA	 genes	 ensures	 diverse	 antigen	 presentation.	 Nevertheless,	 in	
transplantation,	 this	 diversity	 is	 the	 greatest	 contributor	 to	 tissue	 mismatch,	 as	 recipient	
immune	cells	recognize	allogeneic	donor	mismatched	MHC-molecules	as	foreign	antigens	 in	
the	process	of	allorecognition	(see	later).	In	the	case	of	syngeneic	transplants,	such	as	those	
between	 twins,	 this	allorecognition	does	not	occur	due	 to	 the	MHC-matched	 tissues	of	 the	
donor	and	recipient.	However,	although	MHC	mismatch	is	the	main	decisive	factor	for	allograft	
rejection,	minor	histocompatibility	antigens	are	also	capable	of	activating	the	adaptive	immune	
response,	 as	 witnessed	 in	 transplantation	 between	 MHC-matched	 siblings.115	 Minor	
histocompatibility	antigens	represent	normal	proteins	with	a	variable	degree	of	polymorphism	
in	 the	 population,	 presenting	with	minor	 differences	 in	 peptide	 sequences	 from	 person	 to	
person.		
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3.2	 Innate	immune	activation	and	acute	rejection	
	
The	process	of	acute	rejection	is	depicted	in	Figure	6.	According	to	the	current	paradigm,	the	
innate	response	is	antigen-independent	and	occurs	similarly	regardless	of	the	genetic	variation	
between	the	donor	and	recipient.	In	this	model,	in	the	presence	of	foreign	pathogens,	innate	
cells	are	activated	by	non-self	molecules,	and	in	the	case	of	assumingly	sterile	allogeneic	tissue,	
by	 DAMPs.130,131	 Transplant	 neutrophil	 and	 macrophage	 infiltration	 is	 detected	 at	 30-90	
minutes	and	peaks	at	12h	after	reperfusion.132	This	influx	is	mediated	mainly	by	the	cytokines	
CCL3,	CCL4,	CXCL1,	CXCL2	IL-1R,	IL-6,	and	TNF-α,	generally	peaking	at	9-48h	after	reperfusion	
and	expressed	regardless	of	the	genetic	mismatch	between	donor	and	recipient.132-138	Blocking	
or	knock-out	(KO)	experiments	of	these	cytokines,	chemokines,	or	early	innate	cells	diminish	
the	acute	rejection	following	reperfusion,	underscoring	the	importance	of	this	early	response	
in	allograft	rejection.132-136,138		
	
In	syngeneic	transplants,	the	innate	immune	response	diminishes	after	the	first	24h,	whereas	
in	allogeneic	transplants,	it	persists	and	is	perpetuated	by	the	early	alloantigen-sensitive	graft-
infiltrating	memory	CD8+	T	cells.132	These	CD8+	memory	effector	T	cells	cross-react	with	donor	
antigens,	migrate	within	8-12h	to	the	allograft	in	a	CXCR3-mediated	fashion,	and	stimulate	local	
inflammation	and	cytotoxicity	via	IFN-g	and	CXCL9	expression.139-141	In	addition,	Zecher	D	et	al.	
have	previously	shown	that	innate	monocytes	react	more	aggressively	towards	allogeneic	than	
syngeneic	cells	regardless	of	the	presence	of	adaptive	immune	cells	and	NK	cells,	suggesting	an	
additional	 innate	 non-self-recognition	 pathway.142	 In	 the	 same	 experiment,	 the	 non-self-
recognition	by	recipient	innate	monocytes	was	mediated	mainly	by	genetic	variance	outside	
the	MHC-mismatch	between	donor	and	recipient.142	
	
Natural	 killer	 cells	 have	 also	 recently	 been	 implicated	 as	 important	 mediators	 of	 allograft	
rejection.	 Co-stimulatory	 CD28-blocked	 mice	 are	 able	 to	 reject	 allografts	 in	 a	 CD8+	 T	 cell-
mediated	 fashion.	When	these	 recipient	mice	were	depleted	of	NK	cells,	however,	allograft	
survival	was	significantly	prolonged,	suggesting	that	NK	cells	are	able	to	facilitate	alloantigen-
specific	CD8+	T	cell	activity.143-145	Additionally,	NK	cells	are	capable	of	rejecting	skin	allografts	
independently	 of	 the	 adaptive	 immune	 system	 in	 the	 presence	 of	 exogenous	 IL-15	
stimulation.146	
	
After	 initial	 allograft	 infiltration,	 monocytes	 differentiate	 into	 macrophages.	 Damage-
associated	molecular	patterns	such	as	haptoglobin,	HMGP1,	ROS,	extracellular	ATP,	heat	shock	
proteins,	hyaluronan,	and	sialic	acid	are	sensed	by	the	PRR,	particularly	TLR4,	of	innate	immune	
cells,	 leading	 to	 activation	 of	 NF-κB	 and	 the	 inflammasome.137,147-149	 Subsequently,	 further	
production	and	secretion	of	proinflammatory	cytokines	and	chemokines	ensues,	exacerbating	
the	acute	inflammatory	reaction.	Also,	the	production	of	chemokines	and	growth	factors,	such	
as	 G-CSF,	 mobilize	 and	 attract	 more	 innate	 immune	 cells	 from	 their	 storage	 sites	 to	 the	
transplant.	
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Figure	6	–	1)	Allograft	VEC	and	donor	passenger	leukocyte	activation	and	secretion	of	chemokines	and	acute	phase	cytokines.	
2)	Arrival	and	activation	of	recipient	innate-	and	memory	adaptive	immune	cells.	3)	Migration	of	activated	donor	and	recipient	
APCs	to	secondary	lymphoid	tissues	for	alloantigen	presentation.	4)	Arrival	of	activated	adaptive	effector	immune	cells.	5)	
Adaptive	 immune	cells	exert	 their	effector	 functions	 locally.	Objects	 are	not	 drawn	to	 size.	R,	 recipient;	D,	 donor;	DAMP,	
damage-associated	molecular	pattern;	PRR,	pattern	recognizing	receptor;	VEC/LEC,	vascular/lymphatic	endothelial	cell;	Ag,	
antigen.	For	the	rest	of	the	abbreviations	please	refer	to	the	abbreviations	list	on	page	7.	
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The	allograft	chemokine	profile	transitions	to	one	featuring	mainly	CXCL9,	CXCL10,	and	CCL5	
during	 late	 acute	 rejection,	which	plays	 a	 significant	 role	 in	 the	 recruitment	 of	 alloantigen-
primed	 T	 cells	 to	 the	 allograft.150,151	 Donor	 passenger	 leukocytes	 also	 contribute	 to	 this	
proinflammatory	 process,	 but	 are	 rapidly	 replaced	 by	 recipient	 cells.152	 Also,	 during	 the	
transition	 from	 acute	 rejection	 to	 resolution	 and	 the	 ensuing	 chronic	 inflammation,	 the	
phenotype	of	allograft	infiltrating	macrophages	transitions	from	M1	to	M2	(see	later),	which	
suggests	a	switch	from	an	acute	inflammatory	to	a	chronic	healing	process,	including	aberrant	
fibrosis	and	vascular	intimal	thickening.153		
	
3.3	 Allorecognition	
 
Upon	phagocytosing	the	allogeneic	materials,	APCs,	primarily	DCs,	process	the	antigens	and	
present	 them	 on	 their	 surface	 in	 conjunction	 with	 MHC	 I	 or	 MHC	 II	 molecules.154-158	 The	
lymphatic	vessels	offer	a	convenient	exit	route	for	these	APCs,	and	direct	their	chemotaxis	with	
Figure	7	–	Antigen	presentation	occurs	directly	through	donor	APC	and	
MHC-molecules,	 semi-directly	 through	 recipient	 APC	 and	 donor	 MCH-
molecules,	 or	 indirectly	 through	 recipient	 APC	 and	 MHC-molecules.	
Donor	APCs	may	also	transfer	antigens	to	recipient	APCs	via	exosomes.	
Objects	are	not	drawn	to	size.	APC,	antigen-presenting	cell;	PRR,	pattern	
recognition	receptor;	MHC,	major	histocompatibility	complex;	TCR,	T	cell	
receptor.	
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chemokines	 such	 as	 CCL19,	 CCL21,	 and	 VEGF-C.56,57	 Once	 the	 primed	 donor	 APCs	 reach	
recipient	secondary	lymphoid	tissues,	they	either	directly	present	the	donor	antigen	on	donor	
MHC	molecules	along	with	the	necessary	costimulatory	signals	to	the	recipient	naïve	T	cells	
(direct	antigen	presentation),	transfer	the	antigen	along	with	the	donor	MHC	II	molecule	intact	
to	recipient	DCs	(semi-direct	antigen	presentation),	or	allow	recipient	DCs	to	collect	the	donor	
antigen	 and	 present	 it	 on	 recipient	 MHC	 molecules	 to	 the	 T	 cells	 (indirect	 antigen	
presentation).159	The	 subsequent	addition	of	 costimulatory	 signals,	 such	as	 the	B7	 family	of	
proteins,	allows	activation	of	the	T	cells.160	The	importance	of	these	costimulatory	signals	has	
been	 proven	 by	 the	 inhibition	 of	 acute	 and	 chronic	 rejection	 in	 blocking-	 and	 KO-
experiments.161-163	Allorecognition	has	been	detected	as	early	as	3-8	days	after	transplantation	
in	 mice	 in	 the	 form	 of	 donor-specific	 effector	 T	 cells	 in	 recipient	 secondary	 lymphoid	
tissues.132,139	
	
Donor	DCs	are	 rapidly	depleted	 from	the	cardiac	allograft	and	 replaced	with	corresponding	
recipient	ones.152	The	recipient	DCs	then	proceed	to	collect	donor	antigens	and	present	them	
to	naïve	T	cells	in	secondary	lymphoid	tissues,	but	also	locally	to	allograft-infiltrating	effector	T	
cells	in	an	MHC-dependent	cognate	manner.152	As	such,	it	is	currently	postulated	that	the	initial	
direct	antigen	presentation	by	donor	DCs	to	naïve	recipient	T	cells	plays	an	important	part	in	
initiating	the	process	of	allorecognition	and	adaptive	effector	phase,	whereas	the	subsequent	
semi-direct	 and	 indirect	 pathways	 function	 to	 maintain	 an	 effective	 chronic	 allospecific	
adaptive	immune	response.152	Also,	host	intragraft	APCs	and	graft	VECs	direct,	facilitate	and	
enable	 the	 transmigration	of	allosensitive	memory	and	effector	CD8+	T	cells	 to	 the	graft	by	
presenting	the	cognate	antigen	at	the	vascular	wall.164	
	
On	the	other	hand,	the	low	number	of	donor-derived	APCs,	their	recipient	NK	cell-	and	CD8+	T	
cell-mediated	 cytotoxicity,	 and	 inefficient	 interaction	 with	 recipient	 T	 cells	 challenge	 the	
importance	 of	 the	 direct	 antigen	 presentation	 pathway	 in	 initiating	 a	 sufficient	 alloreactive	
response.165,166	Nevertheless,	Liu	et	al.	have	recently	established	the	importance	of	the	transfer	
of	 exosomes	 from	 a	 few	 donor-derived	 APCs	 to	 a	 several-fold	 higher	 number	 of	 recipient	
conventional	DC	in	allorecognition.166	These	findings	emphasize	the	importance	of	the	semi-
direct	 and	 indirect	 pathways	 in	 both	 initiating	 and	 maintaining	 an	 effective	 allospecific	
response.	
	
3.4	 Adaptive	immune	response	
	
Upon	 activation	 by	 their	 cognate	 antigen,	 inflammatory	 transcription	 factors	 activate	
downstream	 cytokine	 production	 by	 T	 cells.	 The	 extent	 of	 DAMP	 release,	 cytokine	 milieu,	
degree	 of	 MHC-mismatch,	 and	 intensity	 of	 the	 innate	 reaction	 determines	 the	
subdifferentiation	of	the	T	cells.	Bolton	et	al.	demonstrated	the	important	role	of	T	lymphocytes	
in	 allograft	 rejection	using	 adoptive	 transfer	models	of	 primed	alloantigen-reactive	CD4+	or	
CD8+	T	lymphocytes	into	T	cell-depleted	athymic	allograft	recipient	rats.167	So	far,	the	important	
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roles	 of	 Th1,	 Th2,	 and	 Th17	CD4+	 helper	 T	 cell	 subclasses	 have	 been	well-characterized	 and	
established	in	the	setting	of	allograft	rejection.168		
	
The	 Th1	 and	 Th2	 response	 –	 There	 is	 clear	 evidence	 of	 the	 important	 role	 of	 Th1	 cells	 in	
transplant	 rejection.169,170	 Increased	 production	 of	 IL-12	 by	 DAMP-activated	 DC	 and	
macrophages	drives	T-bet	transcription	factor	expression	and	Th1	differentiation	of	CD4+	cells.	
Kreisel	et	al.	observed	that	lung	transplant-infiltrating	neutrophils	promoted	the	Th1	response	
by	stimulating	graft	DCs	to	produce	 IL-12	and	 IFN-g	via	direct	cell-to-cell	contact	and	TNF-α	
secretion.171	Th1	cells	further	activate	macrophages	and	the	Th1	response	by	secreting	IFN-g,	
and	 stimulate	 clonal	 expansion	 of	 activated	 both	 CD4+	 and	 CD8+	 T	 cells	 by	 producing	 IL-2.	
Activated	CD8+	T	cells	produce	more	 IFN-g,	 creating	a	positive	 feedback	 loop	 that	 serves	 to	
amplify	the	Th1	response.	Th1	cells	also	activate	B	cells	to	produce	allospecific	antibodies,	and	
are	capable	of	damaging	graft	cells	directly	by	Fas/FasL-mediated	cytotoxicity.172	On	the	other	
hand,	IFN-g	expression	has	also	been	linked	to	the	regulatory	role	of	Treg	cells	in	transplantation,	
suggesting	a	dual	role	of	IFN-g	in	this	particular	setting.173	
	
Despite	 removing	 the	 Th1	 and	 even	 CD8+	 response	 in	 solid	 organ	 transplant	 recipients,	
however,	allografts	were	still	rejected.174,175	This	pointed	the	way	towards	the	ability	of	Th2	cells	
to	mediate	allograft	rejection.	In	vivo	studies,	however,	have	demonstrated	both	inflammatory	
and	regulating	effects	of	Th2	cells,	which	seem	to	be	mainly	context-	and	timing-dependent.	
Th2	 cells	 produce	 IL-4,	 which,	 on	 one	 hand,	 induces	 IL-12	 production	 by	 DC	 and	 IFN-g	
production	by	NK	and	NKT	cells,	and	on	the	other	hand	promotes	M2	macrophage	polarization	
and	inhibit	the	Th1	response.176-178	
	
The	 Th17	 response	 –	 the	 combination	 of	 cytokines	 IL-6	 and	 TGF-β	 induces	 the	 RORgt	
transcription	factor,	which	drives	the	Th17	phenotype	in	activated	T	cells.	Interleukin	23	serves	
to	maintain	 the	 Th17	 phenotype.	 Studies	 have	 shown	 that	 especially	 IRI-induced	 release	 of	
HMBG-1	activates	innate	immune	cells	that	induce	the	Th17	response,	highlighting	the	role	of	
Th17	T	cells	in	acute	allograft	rejection.120	The	hallmark	of	the	proinflammatory	Th17	response	
is	 IL-17	secretion,	 that	can	mediate	severe	allograft	 rejection	even	 in	 the	absence	of	a	Th1-
response.179	 This	 response	 is	 one	of	 the	major	 driving	 forces	 behind	 acute	 rejection	of	 the	
transplant,	but	has	also	been	shown	to	play	a	role	in	chronic	rejection.120	
	
CD8+	response	–	CD8+	T	cells	differentiate	into	effector	cells	upon	meeting	APCs	carrying	their	
cognate	antigen.180	In	transplantation,	however,	the	generation	of	fully	functional	CD8+	effector	
cells	 usually	 requires	 augmentation	 by	 helper	 T	 cells.181	 In	 this	 scenario,	 CD8+	 T	 cells	 are	
activated	in	the	presence	of	a	CD4+	T	cell	and	APC,	or	when	helper	T	cells	enable	APCs	to	directly	
activate	CD8+	cells.2,181	They	then	migrate	to	the	graft,	enter	the	graft	with	help	from	integrins	
and	cognate	antigen	presentation	by	intragraft	DCs,	recognize	their	cognate	MHC	I-harboring	
donor	cells	and	exert	their	cytotoxic	effects	on	them.164	Their	cytotoxic	effect	is	based	on	the	
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release	of	granzymes,	perforins,	upregulation	of	surface	FasL,	and	secretion	of	TNF-α	and	IFN-
g.2	Both	Tc1	and	Tc2	CD8+	T	cells	are	capable	of	causing	allograft	rejection	and	vasculopathy.182	
	
B	 cell	 response	 –	once	 activated,	 B	 cells	 differentiate	 into	 plasma	 cells	 and	 start	 producing	
allospecific	antibodies.	Antibody-mediated	allograft	damage	occurs	to	a	large	degree	through	
complement	 activation,	which	 is	why	 the	 complement	 component	 C4d	 is	 used	 as	 a	 clinical	
marker	for	antibody-mediated	transplant	rejection.2,108	The	de	novo	produced	alloantibodies	
opsonize	the	graft	cells	and	enhance	the	phagocytosing	activities	of	NK	cells	and	macrophages	
that	harbour	Fc-receptors.	Humoral	rejection	mostly	targets	the	HLA	antigens	on	allograft	VECs,	
leading	to	allograft	vasculitis	characterized	by	VEC	activation,	increased	vascular	permeability,	
microvascular	thrombi,	and	leukocyte	infiltration.183	Hyperacute	rejection	is	an	extreme	form	
of	antibody-	and	complement-mediated	rejection.	 It	 is	caused	by	pre-sensitization,	 involving	
the	 presence	 of	 preformed	 recipient	 alloreactive	 antibodies,	 most	 commonly	 anti-HLA-
antibodies,	 and	may	 occur	 during	 the	 first	minutes	 to	 hours	 after	 reperfusion	 of	 the	 heart	
transplant.183,184	Preoperative	screening	of	donor-reactive	antibodies,	however,	have	 largely	
succeeded	in	preventing	this	detrimental	reaction.	
	
Memory	cell	response	–	blood	transfusions,	prior	infections,	operations,	pregnancies,	and	prior	
transplantations	 may	 induce	 the	 formation	 of	 allograft	 cross-reactive	 memory	 T-	 and	 B	
lymphocytes	in	the	recipient.	These	cells	have	a	much	lower	threshold	for	alloactivation,	and	
may	migrate	to	the	graft,	recognize	their	cognate	antigen,	and	start	producing	their	effector	
cytokines	to	induce	a	secondary	rejection	reaction.185	
	
3.5	 Chronic	rejection	and	allograft	vasculopathy		
	
Chronic	allograft	vasculopathy	(CAV)	is	characterized	by	the	progressive	concentric	narrowing	
of	heart	transplant	blood	vessels,	cardiac	fibrosis,	and,	ultimately,	graft	failure.186	The	complete	
pathogenesis	 has	 not	 yet	 been	 elucidated,	 although	 some	 pieces	 of	 the	 puzzle	 have	 been	
revealed.	
	
The	pathogenesis	of	CAV	involves	both	non-immunological	and	immunological	aspects	(Figure	
8).	The	immunological	aspect	is	supported	by	the	failure	of	syngrafts	to	develop	CAV,	in	contrast	
to	allografts.187	The	pathomechanism	most	likely	involves	a	combination	of	innate	and	adaptive	
immune	 responses	 and	 allograft	 endothelial	 dysfunction	 acting	 in	 concert	 to	 initiate	 an	
aberrant	 allograft	 healing	 process.	 This	 response-to-injury	 mechanism	 involves	 impaired	
vascular	 smooth	 muscle	 cell	 proliferation	 and	 migration	 within	 the	 intima	 of	 the	 allograft	
vessels,	 causing	 progressive	 obstruction	 of	 the	 vessel	 lumen.1,188	 The	 neointimal	 cells	 are	
postulated	to	be	both	donor-	and	recipient-derived.189,190		
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Vascular	growth	factors,	such	as	platelet	derived	growth	factor	(PDGF)	A,	-C,	and	-D	and	VEGF-
A,	-C,	and	–D	are	important	mediators	of	aberrant	angiogenesis	in	chronic	rejection	of	cardiac	
allografts.116,118,119,191-194	 Heart	 transplant	 interstitial	 fibrosis	 involves	 the	 accumulation	 of	
Figure	8	–	Sequences	leading	to	chronic	allograft	rejection	and	vasculopathy.	The	heart	transplant	tissue	damage	during	brain	
death,	 ischemia,	 preservation,	 and	 reperfusion	 increases	 the	 immunogenicity	 of	 the	 allograft	 and	 thus	 provokes	 a	 more	
aggressive	immune	response.	The	pathomechanism	of	CAV	remains	unknown,	but	most	likely	occurs	due	to	a	repeating	cycle	
of	allograft	damage	and	aberrant	tissue	repair.	CAV,	chronic	allograft	vasculopathy.	
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myofibroblasts	in	the	parenchyma.	These	profibrotic	cells	may	be	either	resident,	stem	from	
circulating	 recipient	 progenitor	 cells,	 or	 develop	 as	 a	 result	 of	 epithelial	 to	 mesenchymal	
transition.195	 The	 result	 is	 replacement	 of	 normal	 myocardium	 with	 fibrous	 tissue	 and	 a	
progressive	decrease	in	heart	transplant	functionality.	
	
4. Inflammatory	versus	anti-inflammatory	effects	of	leukocytes	
 
In	 addition	 to	 their	 proinflammatory	 qualities,	 immune	 cells	 have	 a	 considerable	 role	 in	
maintaining	tissue	homeostasis	and	inflammatory	senescence.	During	inflammatory	states,	a	
subcategory	of	regulatory	cells	function	to	limit	the	inflammatory	response,	and	in	some	cases,	
to	 extinguish	 it.	 In	 addition	 to	 distinguished	 phenotypically	 regulatory	 cells,	 some	primarily	
proinflammatory	 leukocytes	express	 regulatory	 functions	 innately.	 These	 immunoregulatory	
qualities	of	immune	cells	have	been	a	topic	of	interest	not	only	in	cancer	biology,	but	also	in	
the	 field	of	 transplant	 immunology	 recently.	 In	 the	case	of	 transplantation,	 the	presence	of	
regulatory	 leukocytes	 is	 usually	 not	 sufficient	 for	 tolerance	 to	develop,	 shifting	 the	balance	
towards	a	proinflammatory	state.	The	spectrum	of	inflammatory	and	regulatory	phenotypes	of	
different	leukocytes	is	presented	in	Figure	9.	
	
Neutrophils	–	neutrophils	are	capable	of	 scavenging	cytokines	and	chemokines	by	secreting	
protectins,	resolvins,	and	lipoxins	that	activate	apoptotic	neutrophils	to	express	CCR5,	which	in	
turn	scavenges	CCL3	and	CCL5.196	They	may	also	express	the	CC-chemokine	receptor	D6	that	
scavenges	all	CC-chemokines,	thetype	2	IL-1	decoy	receptor	that	blocks	IL-1	signalling	through	
the	inflammatory	IL-1R1	receptor,	or	secrete	a	IL-1RA	blocking	ligand.197-199	The	latter	soluble	
molecule	may	be	induced	by	IL-10.199	Neutrophil-derived	ROS	and	Arg1	can	also	modulate	the	
proliferation	and	cytotoxic	 capabilities	of	a	 specific	 subset	of	NK	cells.200,201	Also,	 recently	a	
bipolar	subset	of	tumor-associated	neutrophils	has	been	identified	that	may	exhibit	either	an	
inflammatory	(N1)	or	immunosuppressive	(N2)	phenotype	context-dependently	in	tumors.	The	
N2-polarized	 neutrophils	 are	 maintained	 by	 G-CSF	 and	 TGF-β	 expression,	 whereas	 N1	
polarization	is	stimulated	by	IFN-β.202,203	Alternatively	activated	N2	neutrophils	produce	anti-
inflammatory	Arg1.204	
	
Macrophages	 –	 according	 to	 current	 paradigm,	 macrophages	 polarize	 into	 two	 distinct	
phenotypes	according	to	the	activation	signals	they	receive:	the	classically	activated	(M1)	and	
alternatively	 activated	 (M2)	 macrophage	 (Figure	 9).205,206	 Classically	 activated	 (M1)	
macrophages	are	induced	by	LPS	or	IFN-g	from	Th1	T	cells,	are	proinflammatory,	and	secrete	
ROS	as	well	as	cytokines	CXCL9,	CXCL10,	IL-1,	IL-12p40,	IL-18,	IL-23,	TNF-α,	RELMα,	and	matrix	
metalloproteinases	(Figure	9).205,206	Alternatively	activated	(M2)	macrophages,	however,	have	
immunoregulatory	and	wound-healing	qualities,	are	dependent	on	STAT6	signalling,	and	are	
further	 divided	 into	 M2a,	 M2b,	 and	 M2c	 macrophages.207	 M2a	 macrophages	 are	 mainly	
induced	 by	 Th2	 T	 cell-derived	 IL-4	 or	 IL-13.207	 M2b	 macrophages,	 on	 the	 other	 hand,	 are	
stimulated	by	immune	complexes,	and	M2c	macrophages	by	exposure	to	IL-10	and	IL-21.		
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Figure	9	–	Regulatory	vs.	inflammatory	phenotypes	and	properties	of	leukocytes.	Boxes	above	cells	depict	soluble	molecules	
that	promote	differentiation	of	the	cell,	and	boxes	next	to	the	cells	list	soluble	mediators	typical	for	the	cell	phenotype.	Objects	
are	not	drawn	to	size.	MDSC,	myeloid-derived	suppressor	cell;	TAM,	tumor-associated	macrophage;	Ag,	antigen.	
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M2-polarized	macrophages	secrete	Arg1,	CCL17,	CCL22,	CCL24,	CDH1,	YM1,	and	FIZZ1.205,206	
This	strict	bipolar	characterization	of	macrophage	subsets,	however,	has	recently	been	under	
scrutiny	 for	 oversimplification	 of	 the	 biology.208	 It	 has	 instead	 been	 suggested	 that	
macrophages	exhibit	a	wide	spectrum	of	context-dependent	phenotype	plasticity,	with	M1	and	
M2	polarizations	perhaps	representing	each	extreme.209	
	
Another	recently	described	subset	of	macrophages	are	regulatory	macrophages.	They	express	
large	 quantities	 of	 anti-inflammatory	 IL-10	 and	 iNOS,	 but,	 unlike	 alternatively	 activated	
macrophages,	do	not	express	Arg1	and	are	not	dependent	on	STAT6.210	Interactions	with	Treg	
cells	and	peritoneal	or	pleural	B-1	B	cells	have	been	suggested	as	a	potential	activation	pathway	
for	regulatory	macrophages.211,212	Interleukin-10	production	suppresses	both	the	Th1	and	Th2	
response.207	 Also,	 IFN-g-mediated	 induction	 of	 regulatory	 macrophages	 may	 result	 in	 the	
expression	 of	 programmed	 death	 ligand-1	 and	 FasL,	 which	 induce	 apoptosis	 of	 T	 cells	
harbouring	the	corresponding	receptors.213	
	
Dendritic	cells	–	tolerogenic	DCs	are	a	subset	of	immature	or	maturation-resistant,	alternatively	
activated	DCs.	They	can	acquire	and	present	antigens	to	the	adaptive	immune	system,	but	lack	
the	costimulatory	signals	that	their	inflammatory	counterparts	possess.	Upon	presenting	the	
antigen	to	the	naïve	T	cell,	the	lack	of	costimulatory	signals	(CD80/CD86)	can	lead	to	T	cell	death	
or	anergy.214	Tolerogenic	DCs	have	a	characteristic	expression	pattern	of	low	inflammatory	IL-
12p70	 and	 high	 anti-inflammatory	 IL-10,	 TGF-β,	 IL-27,	 HO-1,	 galectin-1,	 NO,	 DC-SIGN,	 and	
indoleamine-2,3-dixygenase	 production	 (IDO).215,216	 Interleukin-10	 and	 TGF-β	 function	 to	
inhibit	DC	maturation	and	to	maintain	the	tolerogenic	state	of	DCs.	They	also	have	the	ability	
to	 promote	 death	 of	 effector	 inflammatory	 T	 cells	 via	 the	 Fas/FasL	 pathway	 and	 IDO	
production,	 and	 to	 stimulate	 the	 expansion	 of	 Treg	 populations.217-219	 In	 addition	 to	
CD4+CD25hiFoxp3+	Treg	cells,	tolerogenic	DCs	are	capable	of	inducing	activation	and	proliferation	
of	CD8+	Tregs,	regulatory	B	cells,	and	double-negative	T	cells.220-222	The	latter	subtype	of	Treg	cells	
produce	 IFN-g,	 which	 is	 essential	 for	 the	 immunosuppressive	 effects	 of	 tolerogenic	 DCs.220	
Tolerogenic	 DCs	 have	 been	 researched	 as	 a	 possible	 therapeutic	 option	 for	 solid	 organ	
transplantation	in	both	animal	models	and	clinical	trials.216	
	
Myeloid-derived	suppressor	cells	(MDSC)	–	during	physiologic	conditions,	myeloid	precursors	
differentiate	 into	 granulocytes	 or	 monocytes.	 In	 pathologic	 conditions,	 such	 as	 cancer	 or	
certain	 inflammatory	conditions,	however,	this	differentiation	may	be	abrogated,	promoting	
an	immature	form	of	myeloid-derived	cells.	These	cells	have	immunoregulatory	effects	and	are	
referred	to	as	MDSCs.223	They	are	characterized	by	GR-1	and	CD11b	expression	in	mice,	and	
CD11b,	CD33,	CD34,	and	low-to-no	levels	of	MHC	II	in	humans.224	They	can	be	further	divided	
into	 mononuclear	 (CD11b+Ly6G-Ly6Chi)	 and	 polymorphonuclear	 (CD11b+Ly6G+Ly6Clo)	
MDSCs.225	 Myeloid-derived	 suppressor	 cells	 synthesize	 iNOS	 and	 Arg1	 and	 act	 to	 silence	
effector	T	cells,	B	cells,	and	NK	cells.226,227	They	also	promote	Treg	development	by	expressing	
IL-10	and	IFN-g	and	favour	the	M2	polarization	of	macrophages.228,229	Their	suppressor		
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functions,	especially	Arg1	expression,	are	STAT3-mediated,	and	are	stimulated	by	IL-4	and	IL-
13.230,231	In	animal	transplantation	studies,	MDSCs	were	detected	in	both	the	blood	and	kidney	
allograft	of	 recipient	mice	after	 treatment	with	CD28	antibodies,	and	suppressed	effector	T	
cells	iNOS-dependently.232,233	
	
NK	cells	–	although	no	regulatory	NK	cell	populations	have	been	identified	per	se,	NK	cells	are	
able	to	regulate	both	innate	and	adaptive	immune	responses,	which	is	particularly	important	
for	prevention	of	autoimmunity.	They	can	lyse	autologous	immature	myeloid	DCs	via	NKp30-,	
NKp46,	and	DNAM-1-mediated	recognition,	and	activated	macrophages	via	NKG2D-mediated	
recognition.234-236	 Different	 myeloid	 cells,	 however,	 have	 variable	 susceptibility	 to	 NK	 cell-
mediated	 cytotoxicity,	 such	 that	 for	 example	monocyte-derived	macrophages	 are	 relatively	
resistant	 to	 autologous	 NK	 cytotoxicity.236	 Activated	 T	 cells	 are	 also	 susceptible	 to	 NKG2D-
mediated	NK	cell	cytotoxicity.237	Also,	NK	cells	may	suppress	T	cell	proliferation	and	activation	
by	secretion	of	IL-5,	-10,	-13,	TGF-β,	and	p21.238	
	
Mesenchymal	stromal	cells	(MSC)	–	MSCs	are	a	subset	of	multipotent	hematopoietic	cells	 in	
the	bone	marrow.	They	mobilize	from	the	bone	marrow	in	response	to	inflammation,	and	in	
the	case	of	transplantation,	migrate	to	the	allograft	often	early	after	reperfusion.239,240	They	
induce	 Treg	 activity	 via	 expression	 of	 IL-10,	 prostaglandin	 E2,	 TGF-β,	 and	 direct	 contact.241	
Mesenchymal	 stromal	 cells	 also	 play	 a	 role	 in	 maintaining	 immature	 tolerogenic	 DCs	 and	
inhibiting	 the	 production	 of	 graft-specific	 alloantibodies.242,243	 Studies	 have	 established	 the	
tolerogenic	 role	 of	 adoptively	 transferred	 MSCs	 in	 an	 experimental	 allogenic	 heart	
transplantation	model	complemented	with	rapamycin.244	
	
Regulatory	B	cells	–	a	subset	of	 immature	B	cells	with	 immunoregulatory	qualities	has	been	
recognized.	These	B	cells	carry	the	surface	molecules	CD1d,	CD21,	CD24,	IgM,	and	CD19,	and	
promote	Treg	activity.	Their	mechanism	of	function	has	not	yet	been	fully	elucidated,	but	partly	
relies	on	their	high	secretion	of	IL-10.245		
	
Regulatory	 CD4+	 T	 cells	 (Treg)	 –	 these	 cells	 present	 in	 two	 forms:	 natural	 (nTreg)	 and	
induced/adaptive	 (iTreg)	 Treg	 cells.	 Natural	 Treg	 cells	 arise	 from	 the	 thymus	 and	 function	 to	
suppress	 self-directed	 immune	 responses	 in	 the	 periphery.	 Induced	 Treg	 cells,	 on	 the	 other	
hand,	are	CD4+	T	cells	that	differentiate	into	the	regulatory	type	extrathymically.246	Both	types	
are	characterized	by	high	expression	of	transcription	factor	forkhead	box	P3	(FoxP3).	They	can	
inhibit	 effector	 cells	 of	 both	 the	 innate	 and	 adaptive	 immune	 system.	 The	 cytotoxic	 T	
lymphocyte	antigen	4	(CTLA4)	on	the	Treg	surface	binds	to	the	costimulatory	molecules	CD80/86	
on	mature	 APCs,	 decreasing	 their	 costimulatory	 actions	 and	 inducing	 IDO	 expression.247,248	
Also,	the	surface	ATP-catalyzing	CD39	of	Treg	cells	decreases	the	extracellular	ATP	availability,	
leading	to	decreased	APC	activity	and	costimulatory	drive.249	Treg	cells	also	use	their	lymphocyte	
activation	 gene-3	 (LAG-3)	 and	NRP1	 receptors	 to	 bind	 the	MHC	 II	molecule	 and	 surface	 of	
immature	APCs,	respectively,	maintaining	their	immature	state	and	decreasing	their	antigen-
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presenting	capabilities.250,251	For	adaptive	effector	cells,	nTreg	and	iTreg	cells	secrete	IL-10	and	
IL-35,	causing	cell	cycle	arrest	and	diminished	effector	activity,	and	can	also	engage	effector	
cells	directly	via	granzyme-mediated	cytolysis.252-254	Also,	Treg	cells	can	inhibit	IL-2	production	
of	activated	effector	T	cells.255,256	
	
T	 regulatory	 type	 1	 cells	 (Tr1)	 –	 these	 cells	 lack	 the	 FoxP3	 transcription	 factor	 expression	
characteristic	for	Treg	cells.257	They	are	induced	by	IL-6,	-21,	-27,	and	particularly	IL-10	from	Treg	
cells,	regulatory	B	cells,	and	tolerogenic-,	 immature-,	and	plasmacytoid	DCs,	and	function	to	
suppress	APCs	and	effector	T	cells	through	cytokine	expression	(mainly	IL-10);	direct	cell-to-cell	
contact	via	LAG-3,	CTLA4,	and	PD-1;	and	modulation	of	the	cellular	microenvironment	through	
CD39	and	CD73.258-265	They	are	important	for	peripheral	tolerance	and	function	to	regulate	the	
local	microenvironment	of	immune	responses	in	an	antigen-specific	manner.266	
	
Regulatory	 CD8+	 T	 cells	 –	 two	 distinct	 populations	 of	 regulatory	 CD8+	 T	 cells	 have	 been	
identified:	 CD8+CD28-	 T	 cells	 and	 CD8+	 Treg	 cells.	 The	 former	 population	 are	 induced	 by	
alemtuzumab	 therapy	 and	 inhibit	 APC-mediated	 T	 cell	 activity	 via	 cell-to-cell	 contact.267,268	
CD8+Treg	cells,	on	the	other	hand,	are	induced	from	naïve	CD8+	T	cells	by	IL-10	and	produce	IL-
10	to	suppress	effector	T	cell	functions	in	an	antigen-specific	manner.269	Like	Tr1	cells,	they	are	
anergic	when	meeting	their	cognate	antigen.246		
	
Regulatory	CD4-CD8-	T	cells	–	these	double	negative	T	cells	can	kill	effector	T	cells	in	an	antigen-
specific	 manner	 using	 the	 CD95-CD95L	 pathway.	 They	 can	 also	 downregulate	 CD80/86	
expression	on	APCs	and	obtain	their	alloantigens	via	trogocytosis.	Tolerogenic	DCs	induce	IFN-
g	expression	by	double-negative	T	cells,	which	acts	as	a	strong	basis	for	their	immunoregulatory	
functions.246,270,271	
	
5. Gene	therapy	
 
The	 concept	 of	 gene	 therapy	 involves	 introducing	 an	 exogenous	 gene	 into	 target	 cells	 and	
tissues.	 In	clinical	 trials,	 the	purpose	of	 the	 transgene	 is	often	 to	produce	a	 therapeutic-	or	
reporter	protein,	replace	an	aberrant	gene,	account	for	a	lacking	gene	in	genetically	diseased	
patients,	or	to	silence	unwanted	gene	expression.	In	the	case	of	cancer,	oncolytic	gene	therapy	
aims	to	develop	cancer	cell-targeted	viral	vectors	that	only	seek,	replicate	in,	and	ultimately	
destroy	cancer	cells.		
	
There	are	various	ways	to	introduce	new	genetic	material	into	cells,	divided	primarily	into	viral	
and	nonviral	methods.	The	viral	method	uses	a	repertoire	of	different	naturally	occurring	or	
modified	 viruses,	 each	with	 their	 own	 unique	 qualities	 and	 several	 serotypes.	 The	 nonviral	
method	 utilizes	 physical	 and	 chemical	methods	 to	 achieve	 intracellular	 implantation	 of	 the	
genetic	material.272	For	the	purpose	of	this	thesis,	some	of	the	most	common	viral	vectors	will	
be	further	discussed.	
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5.1	 Retrovirus	
	
Retroviruses	 are	 characterized	 by	 their	 ability	 to	 transduce	 dividing	 cells,	 justifying	 their	
frequent	 utilization	 in	 gene	 therapy	 of	 somatic	 and	 germline	 cells,	 most	 commonly	 in	 situ	
treatments.273	Their	lack	of	viral	proteins	renders	them	replication	deficient	and	reduces	their	
immunogenicity.	 Their	 poor	 ability	 to	 transduce	 non-dividing	 cells	 and	 inefficient	 in	 vivo	
transduction,	 however,	 limits	 their	 use	 for	 in	 vivo	 gene	 delivery.273,274	 Also,	 retroviruses	
integrate	 into	 the	 host	 DNA,	 which,	 on	 one	 hand,	 secures	 long-term	 efficient	 transgene	
expression,	but,	on	the	other	hand,	increases	the	risk	of	malignancy.	This	was	the	unfortunate	
case	 in	 the	 revolutionary	 first	 clinical	 gene	 therapy	 trial	 of	 children	 with	 X-linked	 severe	
combined	 immunodeficiency	 syndrome	 (X-SCID),	 in	 which	 four	 of	 the	 11	 treated	 patients	
developed	 leukaemia.275,276	 Nonetheless,	 retroviruses	 prefer	 integration	 at	 promoter	 and	
enhancer	regions,	compared	to	the	seemingly	random	integration	of	 lentiviruses,	 increasing	
the	risk	of	insertional	mutagenesis.277,278	
	
5.2	 Lentivirus	
	
After	 the	aforementioned	X-SCID	 incident	with	 retroviruses,	HIV-derived	 lentiviruses	 gained	
interest	 among	 scientists	 and	 clinicians.	 Although	 carrying	 the	 potential	 for	 insertional	
mutagenesis,	their	mutagenic	risk	seems	lower	than	retroviruses.279,280	Despite	being	a	subclass	
of	 retroviruses,	 lentiviruses	 are	 capable	 of	 transducing	 both	 dividing	 and	 non-dividing	
cells.274,281	This	capability	stems	largely	from	the	integrase	protein,	matrix	protein,	viral	protein	
R,	 and	 polypurine	 tract	 that	 they	 harbour.281-283	 To	 address	 the	 risk	 of	 malignancy,	 non-
integrating	lentiviruses	have	been	designed.	These	integrase-deficient	lentiviruses	have	intact	
tools	 for	 reverse	 transcription,	allowing	 the	vector	DNA	 to	 remain	within	 the	nucleus	as	an	
episome,	and	thus	enabling	sustained	gene	expression	within	post-mitotic	cells.		
	
Clinical	trials	have	been	carried	out	for	the	treatment	of	Parkinson´s	and	Huntington´s	diseases,	
Alzheimer’s,	 lysosomal	 storage	diseases,	 and	 spinal	 injury.284,285	 Lentiviruses	have	also	been	
used	in	gene	immunotherapy	to	induce	leukocyte-specific	transgene	expression	to	target	for	
example	 tumors.286,287	Due	 to	 their	ability	 to	 transduct	both	dividing	and	non-dividing	cells,	
lentiviruses	have	also	been	used	in	experimental	cardiac	gene	therapy	models	to	not	only	map	
cardiac	development,	but	also	for	therapy	of	myocardial	disease.288,289	
	
One	major	drawback	of	lentiviruses,	however,	is	their	relatively	high	immunogenicity	and	anti-
vector	 and	 –transgene	 immune	 responses,	 particularly	 when	 expressed	 in	 APCs.290	 One	
solution	was	to	incorporate	a	target	for	the	hematopoietic	cell-specific	microRNA	mir	142-3p	
in	the	transgene	mRNA,	whereby	the	transgene	was	silenced	only	in	APCs.291	Moreover,	Escors	
et	al.	included	ERK	and	IRF	genes	with	the	lentiviral	transgene,	which	promoted	an	immature	
phenotype	in	DCs,	featuring	CD40	down-regulation,	expression	of	TGF-β,	and	high	expression	
of	IL-10.292	
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5.3	 Adenovirus		
	
Over	100	different	adenoviral	serotypes	have	been	isolated	from	different	species.	The	most	
common	serotypes	used	for	gene	therapy	are	serotypes	2	and,	particularly,	5,	both	of	which	a	
large	proportion	of	adults	have	been	exposed	to	naturally.293	Adenoviruses	can	transduce	both	
dividing	 and	 non-dividing	 cells.293	 Intravenous	 injection	 of	 serotype	 5	 favours	 hepatocyte	
transduction	via	coagulation	factor	X-mediated	heparan	sulfate	proteoglycan	binding.294	Also,	
serotype	 5	 tends	 to	 transduct	 Kupffer	 cells	 via	 scavenger	 receptor-A.294	 Their	 lack	 of	 host	
genome	integration	and	high	pathogenicity	renders	their	gene	expression	levels	transient	and	
their	 clinical	 use	 dangerous,	 respectively.	 In	 the	mouse,	 a	 strong	 innate	 immune	 response	
directed	at	the	capsid	proteins	initiates	shortly	after	intravenous	injection	and	peaks	at	6	hours	
after	 injection.295	 Also,	 their	 high	 immunogenicity	 limits	 their	 use	 to	mainly	 liver,	 lung,	 and	
localized	cancer	therapies.296,297	Neutralizing	antibodies	are	mainly	directed	towards	the	three	
major	 capsid	 proteins:	 the	 penton	 base,	 fiber,	 and,	 particularly,	 the	 hexon.298,299	 Also,	
adenovirus-sensitive	CD4+	T	cells	have	been	isolated	from	individuals	of	nearly	all	age	groups.300	
Modified	 replication-deficient	 adenoviruses	 have	 been	 developed,	 however,	 that	 provide	 a	
safer	 option	 for	 clinical	 use,	 although	 larger	 titers	 have	 been	 reported	 to	 cause	 unwanted	
hepatic	and	inflammatory	side-effects	in	clinical	trials.301	Replication-competent	adenoviruses,	
on	the	other	hand,	have	been	used	in	oncolytic	therapies.302		
	
5.4	 Adeno-associated	virus	(AAV)	
	
Adeno-associated	viruses	are	members	of	the	Parvoviridae	family	and	are	structurally	similar	
to	adenoviruses,	but	lack	their	pathogenicity.	They	harbour	a	single-stranded	4.7kb	large	DNA	
genome,	 consisting	 of	 two	 large	 open	 reading	 frames	 (ORF)	 flanked	 by	 inverted	 terminal	
repeats	(ITR).303,304	The	left	ORF	encodes	four	replication	proteins,	whereas	the	right	one	three	
viral	 structural	 proteins	 VP1-3.303-305	 The	 ITRs	 encode	 the	 elements	 required	 for	 genome	
replication	 and	 packaging.303	 Current	 recombinant	 AAVs	 (rAAV)	 have	 been	 constructed	 by	
deleting	the	replication	proteins,	effectively	removing	their	genome	integration	and	replicative	
capability.306,307	As	such,	the	rAAV-carried	transgene	remains	as	an	extrachromosomal	element	
in	the	target	cell	nucleus.306,307	
	
Several	AAV	serotypes	have	been	identified,	each	differing	mainly	at	the	level	of	capsid	amino	
acid	sequence	and	attachment	receptors,	granting	them	different	tissue	tropisms	and	in	vivo	
transduction	 kinetics.3,304	Most	 experiments	 have	 been	 focused	 on	AAV	 serotypes	 1-9.	 The	
surface	receptors	for	AAV2	have	been	elucidated	to	some	degree,	including	the	heparan	sulfate	
proteoglycan,	αvβ5	and	αvβ1	integrins,	fibroblast	growth	factor	receptor	1,	hepatocyte	growth	
factor	receptor,	and	laminin	receptor	(Figure	10).308-312	Receptors	of	the	remaining	serotypes,	
however,	are	yet	to	be	fully	elucidated.	Nevertheless,	the	laminin	receptor	has	been	identified	
on	 serotypes	 3,	 8,	 and	 9	 as	 well,	 along	 with	 the	 terminal	 N-linked	 galactose	 receptor	 on	
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serotype	9	(Figure	10).312,313	Also,	heparan	sulfate	proteoglycan	has	been	identified	on	AAV6,	
whereas	sialic	acid	binding	has	been	demonstrated	for	serotypes	4	and	5.314,315	
	
The	 life-cycle	and	 transduction	kinetics	of	AAVs	 include	cellular	binding,	 -entry,	 intracellular	
trafficking,	 nuclear	 entry,	 viral	 uncoating,	 and	 second-strand	 synthesis.	 Inefficient	 rAAV	
trafficking	 and	 second-strand	 synthesis	 have	 been	 identified	 as	major	 rate-limiting	 steps	 in	
rAAV	gene	expression.316,317	Although	the	precise	transduction	mechanisms	of	AAVs	has	not	
been	 elucidated	 yet,	 the	 current	 theory	 proposes	 several	 entry	 mechanisms	 ranging	 from	
micropinocytosis	and	clathrin-coated	pits	and	vesicles	to	lipid	raft-based	mechanisms.318-320	In	
addition	 to	 viral	 attachment	 receptors,	 the	 cellular	 AAV	 receptor	 mediates	 the	 entry	 of	
rAAVs.321	 Figure	11	depicts	 the	 clathrin-mediated	entry	 and	 cellular	 trafficking	of	 rAAV2.	 In	
short,	after	receptor	binding,	dynamin-mediated	clathrin-coated	pitting	occurs	and	pinches	off,	
forming	a	clathrin-coated	vesicle	holding	the	rAAV2	virus.322	The	intracellular	trafficking	of	the	
vesicle	 involves	 Rac1-	 and	 phosphatidylinositol	 3-kinase-mediated	 microtubular	 transfer	
towards	the	nucleus.318	Next,	the	intravesicular	pH	is	lowered	via	endosomal	proton	pumps,	
promoting	the	externalization	of	phospholipase	A2	and	nuclear	localization	sequence-carrying	
N-terminus	of	 the	 viral	 protein	1.323,324	 The	activated	phospholipase	A2	acts	 in	 concert	with	
cathepsins	B	and	L	to	allow	the	virus	to	escape	the	vesicle	and	disassemble	the	viral	capsule.325	
Finally,	according	to	current	theories,	after	exiting	the	endosome,	the	viral	particle	binds	to	the	
nuclear	importer	protein	importin-β	and	enters	the	nucleus	through	a	nuclear	pore	complex.326	
Figure	10	–	Structure	of	adeno-associated	virus	serotypes	2,	8,	and	9.	Objects	are	not	drawn	to	size.	AAV,	adeno-associated	
virus;	 FGFR-1,	 fibroblast	 growth	 factor	 receptor	 1;	 HGFR,	 hepatocyte	 growth	 factor	 receptor;	 HSP,	 heparan	 sulfate	
proteoglycan;	LamR,	laminin	receptor;	TNG,	terminal	N-linked	galactose.			
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So	far,	AAV	serotypes	8	and	9	have	been	established	as	the	most	efficient	vectors	in	transducing	
cardiac	and	skeletal	muscle	in	experimental	animal	models.327-331	In	contrast,	despite	the	83%	
and	82%	capsid	homology	of	AAV2	with	AAV8	and	AAV9,	respectively,	AAV2	prefers	the	liver	
and	only	weakly	transduces	cardiac	tissue	after	systemic	administration	into	mice.304,330,331	
	
The	low	immunogenicity	of	AAV	is	reflected	by	the	near	zero	innate	immune	response	that	it	
evokes.332	 A	 humoral	 response,	 on	 the	 other	 hand,	 is	 more	 likely,	 as	 evidenced	 by	 a	 96%	
incidence	of	AAV-specific	antibodies	in	subjects	of	a	clinical	AAV	study.333,334	These	neutralizing	
antibodies	have	been	shown	to	limit	pulmonary	and	hepatic,	but	not	muscle,	brain,	or	retina	
transduction.335,336	 Anti-AAV	 cellular	 immunity	 appears	 to	 be	 route-dependent,	 as	
intraperitoneal,	intravenous,	and	subcutaneous,	but	not	intramuscular	administration	of	AAV	
provoked	an	immune	response.337	
	
Clinical	 trials	 with	 AAV	 have	 been	 carried	 out	 to	 treat	 for	 example	 Parkinson’s	 disease,	
haemophilia,	rheumatoid	arthritis,	and	cystic	fibrosis.	Although	not	all	studies	were	successes,	
they	 provided	 evidence	 for	 the	 safety	 of	 AAVs.338-341	 One	 patient	 treated	 for	 rheumatoid	
Figure	11	–	AAV2	attachment,	endocytosis,	intracellular	trafficking,	and	nuclear	entry.	Objects	are	not	drawn	to	size.	VP,	viral	
protein;	PLA,	phospholipase	A2;	NLST,	nuclear	localization	sequence.	
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arthritis	died	of	Histoplasmosis	sepsis	within	4	days	of	AAV	injection,	but	it	was	later	concluded	
that	the	main	contributing	factor	was	the	use	of	the	immunosuppressant	adalimumab.341	Also,	
injection	of	AAV	vectors	into	the	hepatic	artery	of	patients	treated	for	haemophilia	induced	a	
rise	in	serum	transaminase	levels,	indicating	hepatitis.342,343	
	
Several	 experimental	 animal	models	of	 cardiac	 transplantation	have	been	 carried	out	using	
both	recombinant	adenovirus	and	AAV	vectors.	Therapies	including	HO-1,	heat	shock	proteins,	
CTLA4-Ig,	 and	 CD40-Ig,	 along	 with	 IL-18-,	 RANTES-,	 and	 CCL2-antagonists	 have	 shown	
improvements	 in	 cardiac	 allograft	 survival.344-351	 Clinical	 heart	 transplant	 studies	 with	 AAV	
vectors	are	pending,	however.	
 
6. Vascular	endothelial	growth	factors	
	
The	VEGF	family	comprises	the	glycoproteins	VEGF-A,	-B,	-C,	-	D,	-E,	and	placental	growth	factor	
(PlGF),	with	their	corresponding	receptors	VEGFR-1,	-2,	-3,	NRP1,	and	-2	(Figure	12).5	They	were	
first	 discovered	 as	 soluble	 cancer-related	mediators	 of	 vascular	 permeability.352	 Since	 then,	
their	spectrum	of	biological	functions	has	been	extended	to	vasculogenesis,	inflammation,	and	
metabolic	regulation.5	
	
	
Figure	12	 –	 Vascular	 endothelial	 growth	 factors	 and	 their	 corresponding	 receptors.	Objects	 are	not	 drawn	 to	 size.	 VEGF,	
vascular	endothelial	growth	factor;	VEGFR,	vascular	endothelial	growth	factor	receptor;	PlGF,	placental	growth	factor;	NRP,	
neuropilin	receptor.	
	 40	
6.1	 VEGF-A	
	
Vascular	endothelial	growth	factor	A	exists	mainly	in	four	different	isoforms	(VEGF121,	-165,	-
189,	and	-206)	that	form	after	differential	splicing	of	the	VEGF	gene.353	Deletion	of	the	VEGF-A	
gene	 in	 mice	 is	 lethal	 and	 results	 in	 cardiovascular	 abnormalities.354	 Vascular	 endothelial	
growth	factor	A	has	potent	pro-angiogenic	and	vasodilatory	effects	and	binds	to	VEGFR-1,	-2,	
NRP1,	 and	 -2.355	 Its	 angiogenic,	 mitogenic,	 and	 permeability	 effects	 are	 mainly	 mediated	
through	VEGFR-2,	causing	EC	proliferation,	sprouting,	and	tube	formation.356-358	In	the	setting	
of	 heart	 transplantation,	 VEGF-A	 induces	 expression	 of	 adhesion	 proteins	 and	
chemoattractants	from	VECs,	and	plays	a	significant	role	in	both	acute	and	chronic	rejection	of	
heart	 transplants.116,118,359	 Overexpression	 of	 VEGF-A	 in	 the	 heart	 transplant	 increases	 the	
influx	and	activation	level	of	macrophages	and	promotes	both	acute	and	chronic	rejection	of	
the	allograft.116,118,359	Anti-VEGF-A	therapy,	on	the	other	hand,	diminishes	acute	rejection	of	
heart	transplants	and	the	development	of	CAV	in	rodent	models.116,118,359	
	
6.2	 VEGF-B	
	
Vascular	endothelial	growth	 factor	B	 is	expressed	 in	 the	majority	of	 tissues,	particularly	 the	
heart.360,361	Alternative	splicing	of	the	VEGF-B	gene	yields	two	isoforms:	VEGF-B167	and	VEGF-
B186.	 Isoform-B167	 contains	 a	 heparin-binding	 domain	 that	 causes	 swift	 local	 adhesion	 to	
extracellular	heparan	sufalte	proteoglycans	upon	secretion.362	Isoform-B186,	on	the	other	hand,	
lacks	the	heparin-binding	domain,	making	it	readily	diffusible	in	tissues.	Vascular	endothelial	
growth	factor	B	binds	to	VEGFR-1	and	NRP1,	and	in	contrast	to	the	rest	of	the	VEGF-family,	has	
no	evident	angiogenic	or	lymphangiogenic	properties.363-367	Studies	on	the	effects	of	VEGF-B	
have	 been	 ambiguous.368	 It	 seems	 to	 be	 inert	 during	 normal	 physiological	 conditions,	 but	
appears	to	regulate	the	survival	of	VECs	and	CMCs	through	regulation	of	anti-apoptotic	signals	
in	overexpression	experiments.369,370	In	vitro,	VEGF-B	mediates	the	survival	of	ECs,	pericytes,	
and	VSMCs.371	Other	studies	have	demonstrated	the	metabolic	effects	of	VEGF-B,	particularly	
the	 trafficking	 of	 free	 fatty	 acids	 by	 VECs	 and	 the	 induction	 of	 fatty-acid	 oxidation	 on	 a	
transcriptional	 level.372-374	 Others	 have	 found	 a	 protective	 role	 of	 VEGF-B	 in	 ischemic	
cardiomyopathy	 through	 coronary	 vascular	 expansion	 and	epicardial	 arterialization.370,375-377	
The	role	of	VEGF-B	in	heart	transplantation	has	not	been	studied,	however.	
	
6.3	 VEGF-C	
	
Vascular	 endothelial	 growth	 factor	 C	 is	 produced	 as	 a	 precursor	 protein,	 but	 undergoes	
proteolytic	cleavage	to	achieve	its	biologically	active	form.378	It	binds	to	VEGFR-2	and	-3,	and	is	
produced	in	the	lung,	heart,	liver,	and	kidney	in	adults.378,379	Dendritic	cells,	macrophages,	and	
CD4+	 T	 cells	 are	 a	 rich	 source	of	VEGF-C.56,57,380-382	 It	 has	been	established	as	 an	 important	
mediator	of	lymphangiogenesis	and	leukocyte	chemotaxis,	particularly	through	its	interactions	
with	VEGFR-3.56,57,194	The	indispensable	role	of	VEGF-C	for	the	development	of	the	lymphatic	
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system	is	evidenced	by	the	 lymphedema	and	early	death	of	VEGF-C	KO	mice,	as	well	as	the	
excessive	 lymphangiogenesis	 that	 results	after	VEGF-C	overexpression.367,383	 It	 is	 involved	 in	
several	 inflammatory	 conditions,	 including	 bacterial	 infections,	 organ	 transplantation,	 and	
rheumathoid	arthritis,	and	has	direct	effects	on	lymphatic	vessels	and	inflammatory	cells	by	for	
example	 upregulation	 of	 the	 chemokine	 CCL21	 and	 increased	migration	 and	maturation	 of	
VEGFR-3+	DCs.56,57,83,382,384	In	heart	transplantation,	blocking	of	VEGFR-3	and	VEGF-C	reduces	
the	exit	of	DCs	from	the	allograft,	and	thus	diminishes	allorecognition	and	alleviates	cardiac	
allograft	rejection.56,57	
	
6.4	 VEGF-D	
	
Vascular	 endothelial	 growth	 factor	 D	 undergoes	 proteolytic	 modification	 after	 mRNA	
translation	to	yield	its	biologically	active	form.	It	binds	to	receptors	VEGFR-2	and	-3	and,	like	
VEGF-C,	is	involved	in	angiogenesis	and	lymphangiogenesis.385	Unlike	VEGF-C,	however,	VEGF-
D	is	not	required	for	the	development	of	the	lymphatic	circulation.386	The	angiogenic	effects	of	
VEGF-D	have	also	been	established.387	
	
6.5	 VEGF-E	
	
Vascular	endothelial	growth	factor	E	has	a	strong	affinity	for	VEGFR-1	and	is	a	potent	angiogenic	
factor.388,389	Three	different	isoforms	of	VEGF-E	have	been	isolated,	of	which	VEGF-ENZ-7	is	the	
most	potent	angiogenic	one.388,389	
	
6.6	 PlGF	
	
Placental	growth	factor	was	first	isolated	from	the	placenta	and	is	also	expressed	in	the	heart	
and	lungs.390	It	has	four	distinct	isoforms	and	binds	to	VEGFR-1	and	NRP-1.	Knock-out	of	PlGF	
does	not	seem	to	induce	a	specific	phenotype	in	mice,	but	instead	causes	poor	recovery	from	
myocardial	infarction	and	impaired	angiogenesis	during	hypoxic	insults.391	
 
7. Hypoxia-inducible	factors	
	
Oxygen	 (O2)	 is	one	of	 the	 fundamental	 requirements	 for	human	 life.	On	a	 cellular	 level,	O2	
enables	ATP	production	via	oxidative	phosphorylation	by	serving	as	the	final	electron	acceptor	
in	 the	 mitochondrial	 electron	 transport	 chain.	 Cells,	 however,	 have	 several	 adaptive	
mechanisms	 to	accommodate	 low	oxygen	states,	 such	as	 those	presented	by	 ischemia,	 low	
oxygen	tension,	inflammation,	and	cancer.	One	of	the	main	adaptive	responses	is	the	activation	
of	hypoxia-inducible	factor	(HIF).	
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Hypoxia-inducible	 factor	 is	 a	 transcriptional	 factor	 consisting	 of	 an	 oxygen-labile	 α-subunit	
(either	 HIF-1α	 or	 -2α	 isoform)	 and	 a	 constitutive	 regulatory	 β-subunit	 (HIF-β).392	 During	
normoxia,	O2-sensing	collagen	4-prolyl	hydroxylases	(PHD)	hydroxylate	HIF-α,	marking	it	for		
ubiquitylation	by	the	von	Hippel-Lindau	tumor	suppressor	protein	(pVHL).393-396	In	experimental	
pVHL-KO	animals,	HIF-levels	are	profoundly	increased,	confirming	a	dominant	regulatory	role	
of	pVHL	in	HIF	homeostasis.397	Also,	factor	inhibiting	HIF	(FIH)	is	a	protein	that	hydroxylates	HIF-
1α	and	-2α	in	the	presence	of	oxygen,	inhibiting	interactions	between	HIF	and	its	C-terminal	
transactivation	domain	(CTAD)	and	transcriptional	coactivators.398	Thus,	during	normoxia,	HIF	
levels	are	maintained	low	by	continuous	destabilization	and	degradation	(Figure	13).		
	
When	O2-levels	are	compromised,	however,	the	catalytic	activity	of	PHDs	is	lost,	allowing	HIF-
α	 to	 escape	 hydroxylation	 and	 to	 dimerize	 with	 HIF-β.399,400	 Similarly,	 ROS,	 NO,	 and	
intermediates	of	the	tricarboxylic	acid	cycle	have	been	shown	to	inhibit	the	activity	of	PHDs,	
with	 ROS	 also	 suppressing	 FIH,	 resulting	 in	 HIF-α	 stabilization	 (Figure	 13).401-403	 The	
mitochondrial	 deacetylase	 sirtuin-3,	 on	 the	 other	 hand,	 blocks	 the	 formation	 of	 ROS	 by	
Figure	 14	 –	 During	 hypoxia,	 HIF-α	 dimerizes	 with	 HIF-β	 and	 proceeds	 to	 form	 a	 transcriptional	 complex	with	 PKM2	 and	
P300/CBP.	PKM2,	pyruvate	kinase	isoform	M2;	CBP,	creb-binding	protein;	HIF,	hypoxia-inducible	factor.		
Figure	13	 –	 During	normoxia,	 PHDs	 hydroxylate	 HIF	 and	mark	 it	 for	 ubiquitylation	by	VHL.	
Hypoxia,	NO,	products	of	the	citric	acid	cycle,	and	ROS,	on	the	other	hand,	inhibit	the	actions	
of	PHDs,	stabilizing	HIF.	NO,	nitric	oxide;	SIRT3,	sirtuin-3;	ROS,	reactive	oxygen	species;	PHD,	
4-prolyl	hydroxylase;	VHL,	Von	Hippel	Lindau	protein;	HIF,	hypoxia-inducible	factor;	FIH,	factor	
inhibiting	F;	CBP,	Creb-binding	protein.	
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activating	superoxide	dismutase	and	several	tricarboxylic	acid	cycle	enzymes;	and	modulation	
of	 specific	 electron	 transport	 chain	 components,	 thus	 promoting	 the	 activity	 of	 PHDs	 and	
destabilization	of	HIF-α.404,405	
	
7.1	 HIF	activity	and	effects	
	
Upon	dimerization	with	HIF-β	during	hypoxic	conditions,	HIF	proceeds	to	form	a	transcriptional	
complex	together	with	its	coactivators	p300/Creb-binding	protein	(CBP)	and	an	M2	isoform	of	
pyruvate	 kinase	 (PKM2).399,406	 This	 complex	 proceeds	 to	 regulate	 the	 gene	 expression	 of	
downstream	targets	via	binding	to	hypoxia-response	elements	(HRE)	of	HIF-responsive	genes	
(Figure	14).400	The	downstream	adaptive	effects	of	HIF	include:	
	
Metabolism	 – To	 allow	 cells	 to	 adapt	 to	 hypoxia,	 HIFs	 promote	 anaerobic	 glycolysis	 by	
transcriptional	regulation	of	key	metabolic	factors.	First,	the	expression	of	glucose	transporters	
GLUT1	and	GLUT3,	along	with	glycolytic	enzymes	hexokinases	1	and	2	and	phosphoglycerate	
kinase	 1	 are	 increased.407-409	 Next,	 the	 expression	 of	 lactate	 dehydrogenase	 A	 (LDHA)	 is	
stimulated,	enhancing	the	regeneration	of	NAD+	for	use	 in	glycolysis.410	This,	along	with	the	
induction	of	pyruvate	dehydrogenase	kinase-1	and	-3	(PDK1),	shunts	pyruvate	away	from	the	
mitochondria,	 reducing	 oxidative	 phosphorylation	 and	 cellular	 oxygen	 consumption.411,412	
Furthermore,	studies	have	demonstrated	that	VHL	KO	of	renal	carcinoma	cells	induces	MXI-1,	
which	causes	suppression	of	PGC-1α,	a	critical	mediator	of	mitochondrial	biogenesis.413	Also,	
HIF-1α	 induces	 BNIP3,	 which	 reduces	 the	 interaction	 of	 Bcl-2/xL	 with	 Beclin-1,	 leading	 to	
selective	mitochondrial	autophagy.414		
	
Inflammation	(Figure	15)	–	inflammatory	sites	tend	to	be	ischemic	due	to	vascular	dysfunction,	
edema	 and	 increased	 local	 oxygen-consumption,	 activating	 HIF	 in	 both	 resident	 cells	 and	
infiltrating	leukocytes.415	As	opposed	to	parenchymal	cells,	HIF	may	be	stabilized	in	an	oxygen-
independent	manner	in	immune	cells.	Among	innate	leukocytes,	bacteria	and	PRR	ligation	can	
induce	HIF-1α	 oxygen-independently.416,417	 Also,	 TNF-α	 and	 ROS	may	 stabilize	 HIF-1α	 in	 an	
oxygen-independent	 fashion.418,419	 In	 fact,	myeloid	 cell-specific	 deletion	 of	 HIF-1α	 causes	 a	
profound	decrease	in	the	anti-bacterial	capabilities	of	neutrophils	and	macrophages,	further	
suggesting	 an	 important	 role	 of	 HIF	 for	 successful	 inflammatory	 responses.420	 In	 general,	
activation	of	HIF,	particularly	HIF-1α,	in	inflammatory	cells	induces	a	metabolic	reprogramming	
to	increase	the	production	of	ATP,	which	enables	active	aggregation,	invasion,	and	motility	of	
leukocytes,	 especially	 macrophages.420	 In	 macrophages	 and	 DCs,	 proinflammatory	 stimuli	
stabilize	HIF-1α,	 leading	to	enhanced	glycolysis	and	reduced	oxidative	phosphorylation	in	an	
iNOS	 and	 NO-dependent	 manner,	 much	 like	 the	 Warburg	 effect	 in	 tumor	 cells.421	 These	
metabolic	changes	ensure	sufficient	energy	production	for	leukocytes	to	carry	out	their	effector	
functions	 in	hypoxic	 inflammatory	 regions.	 Loss	of	VHL	 in	myeloid	 cells	 does	not	 affect	 the	
development	of	neutrophils	and	macrophages,	whereas	in	thymocytes,	 it	drastically	reduces	
thymic	cellularity;	a	change	that	is	reversible	by	blocking	HIF-1α.420,422	
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In	neutrophils,	HIF	activation	prolongs	their	lifespan	by	inhibition	of	apoptotic	pathways	via	NF-
κB,	 increases	 the	 production	 of	 antimicrobial	 granule	 contents	 (cathelicidin,	 cathepsin	 G,	
elastase),	and	enhances	epithelial	binding	via	induction	of	β2	integrin	expression.416,423,424		
	
In	 macrophages,	 NF-κB	 and	 TNF-α expression	 stabilize	 HIF-1α,	 whereas	 IL-4	 stabilizes	 HIF-
2α.418,425,426	 Hypoxia-inducible	 factor-1α	 mediates	 the	 differentiation	 of	 monocytes	 to	
macrophages,	enhances	microbial	phagocytosis,	and	stimulates	the	expression	of	TNF-α,	iNOS,	
and,	 consequently,	 NO.416	 Hypoxia-inducible	 factor-2α	 also	 stimulates	 the	 production	 of	
cytokines	TNF-α,	IFN-g,	IL-1β,	and	IL-12,	but	does	not	affect	NO	expression	in	macrophages.427	
Overall,	hypoxia	enhances	the	expression	of	a	plethora	of	inflammatory	receptors,	cytokines	
and	 angiogenic	 factors	 by	 macrophages,	 including	 IL-1α,	 IL-1β,	 IL-6,	 IL-8,	 IL-12,	 VEGF,	
angiopoietins,	and	CXCR4,	as	well	the	surface	expression	of	TLRs	2,	4,	6,	and	9.415-417,428-430	On	
the	other	hand,	studies	have	highlighted	an	 important	 role	of	HIF-2α	 in	mediating	 the	anti-
inflammatory	and	pro-tumor	effects	of	tumor-associated	macrophages	(TAM).427	Also,	the	M2	
polarization	 of	 macrophages	 seems	 to	 be	 HIF-2α-dependent	 and	 arginase-driven	 and	 is	
characterized	 by	 moderate	 glycolytic-	 but	 high	 oxidative	 activity,	 particularly	 fatty	 acid	
oxidation.426,431	 In	 contrast,	 HIF-1α	 seems	 to	mediate	 the	M1	polarization	 of	macrophages,	
characterized	by	robust	glycolysis	and	basal	oxidative	phosphorylation.431	Also,	the	role	of	HIF-
Figure	15	–	Hypoxia-inducible	factor	is	stabilized	oxygen-independently	in	leukocytes	and	exerts	highly	context-	and	cell	type-
dependent	effects	in	inflammatory	cells.	HIF,	hypoxia-inducible	factor;	PRR,	pattern	recognition	receptor;	ROS,	reactive	oxygen	
species;	TCR,	T	cell	receptor;	VEGF,	vascular	endothelial	growth	factor;	Ang,	angiopoietin;	TAM,	tumor	associated	macrophage;	
MDSC,	myeloid-derived	suppressor	cell.	
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1α	in	MDSC-development	has	been	established.	In	a	hypoxic	tumor	microenvironment,	MDSCs	
acquire	 profound	 immunosuppressive	 abilities	 via	 HIF-1α-regulated	 iNOS	 and	 Arg1	
expression.432	 In	 fact,	 in	 cancer	 tissue,	 HIF-1α	 expression	 is	 associated	 with	 a	 poor	 clinical	
outcome.	 In	 this	 setting,	 it	 also	 plays	 an	 important	 role	 in	 the	 migratory	 and	 angiogenic	
capabilities	of	TAMs,	which	exhibit	protumor	functions.433,434			
	
Hypoxia	enhances	 the	proinflammatory	actions	of	DCs	 via	HIF-1α-mediated	upregulation	of	
triggering	 receptor	 expressed	 on	 myeloid	 cells	 (TREM-1),	 leading	 to	 DC	 maturation	 and	
enhanced	 antigen	 presentation.435	 These	 activated	 cells	 are	 characterized	 by	 increased	
maturation	marker	CD80	and	CD86	expression,	enhanced	expression	of	chemokine	receptors	
CXCR4	and	CCR7,	as	well	as	increased	secretion	of	the	Th1	and	Th17-priming	soluble	mediators	
TNF-α,	IL-1β,	IL-12,	CXCL8,	CCL5,	CCL17,	and	osteopontin.435	On	the	other	hand,	other	studies	
have	 described	 decreased	 DC	 maturation	 and	 antigen	 presenting	 capabilities	 in	 a	 hypoxic	
environment.436	 In	 a	 murine	 model	 of	 colitis,	 HIF-1α	 promoted	 DCs	 to	 produce	 anti-
inflammatory	IL-10	and	to	induce	Treg	cells.437		
	
In	T	cells,	especially	Th17	cells,	ligation	of	the	TCR	stabilizes	HIF-1α	via	the	phosphoinositol-3-
kinase/mTOR	pathway	and	STAT3	expression.438-440	Moreover,	CD8+	effector	cells	upregulate	
both	 HIF-1α	 and	 -2α	 in	 an	mTOR-dependent	manner	 after	 TCR	 ligation.441-443	 Interleukin-2	
induces	 HIF-1α	 stabilization,	 whereas	 IL-4	 induces	 HIF-2α	 stabilization	 in	 CD8+	 T	 cells.426,443	
Hypoxia-inducible	 factor-2α	 plays	 a	 pivotal	 role	 in	 the	 ability	 of	 CD8+	 T	 cells	 to	mount	 and	
maintain	 an	 effective	 anti-microbial	 and	 oncolytic	 response.443	 Also,	 HIF	 promotes	 Th17	
differentiation	by	enhancing	glycolysis	and	transactivating	RORgt.444	This	is	evidenced	by	the	
finding	 that	HIF-1α-/-	 T	 cells	 fail	 to	 inhabit	Th17	characteristics,	even	after	 culturing	 in	Th17-
promoting	conditions.444	Furthermore,	HIF-1α	inhibits	the	development	of	Treg	cells	by	direct	
marking	of	Foxp3	 for	ubiquitin-mediated	degradation,	but,	on	 the	other	hand,	 seems	 to	be	
required	for	effective	Treg	effector	functions	during	certain	conditions.444	Moreover,	in	a	murine	
model	 of	 colitis,	 HIF-1α	 was	 indispensable	 for	 Treg	 differentiation.445	 Similarly,	 HIF-1α	 may	
downregulate	 Th1	 functions	 via	 IL-10	 expression,	 as	 evidenced	 by	 a	 decrease	 in	 their	 IFN-γ	
production.446 
	
All	in	all,	both	HIF-1α	and	-2α	play	intricate	roles	in	shaping	the	immune	response	and	immune	
cell	 phenotype.	 The	 overall	 effect,	 however,	 seems	 to	 be	 highly	 context-	 and	 cell	 type-
dependent.		
	
Angiogenesis	–	hypoxic	tissue	strives	to	maintain	oxygen	supply	by	inducing	angiogenesis.	One	
prime	 example	 of	 this	 is	 cancer,	 which	 uses	 angiogenesis	 and	 lymphangiogenesis	 to	 both	
maintain	 the	 supply	of	oxygen	and	nutrients,	and	 to	establish	metastases.447	As	an	oxygen-
sensitive	transcription	factor,	HIF	plays	an	 important	role	 in	angiogenesis.448	The	profoundly	
impaired	angiogenesis	and	death	of	HIF-/-	mice	underscores	 the	 importance	of	HIF	 for	both	
developmental	angiogenesis	and	adaptive	vasculogenesis.449	During	hypoxia,	HIF	stabilization	
	 46	
enhances	the	expression	of	a	wide	variety	of	proangiogenic	genes	from	different	cells,	including	
VEGF-A,	 PlGF,	 Ang1	 and	 -2,	 PDGF-B,	 and	 their	 corresponding	 receptors.450-454	 Also,	 HIF	
stimulates	 the	 expression	of	 a	 plethora	of	matrix	 remodelling	 agents	 that	 create	 a	 suitable	
environment	 for	 VEC	 proliferation,	 migration,	 and	 tube	 arrangement,	 including	 matrix	
metalloproteinases,	 plasminogen	 activator	 receptors	 and	 inhibitors,	 and	 procollagen	 prolyl	
hydroxylase.448	Macrophages	are	also	a	rich	source	of	VEGF,	which	is	stimulated	by	HIF-1α,	but	
not	 HIF-2α.455,456	 In	 contrast,	 HIF-2α	 induces	 the	 expression	 of	 soluble	 VEGFR-1	 from	
macrophages,	which	proceeds	to	scavenge	and	neutralize	the	angiogenic	effects	of	VEGF.457	
	
7.2	 HIF	in	organ	transplantation	
	
Studies	on	HIF	in	solid	organ	transplantation	are	limited.	Hypoxia-inducible	factor-1α	has	been	
detected	 in	biopsies	 from	human	kidney	allografts.458	 Inhibiting	PHDs	 in	 rat	kidney	allograft	
donors	activated	HIF	and	prevented	graft	injury	and	prolonged	allograft	survival.459	In	contrast,	
Keränen	 et	 al.	 demonstrated	 that	 recipient,	 but	 not	 donor,	 treatment	with	 a	 PHD-inhibitor	
attenuated	allograft	acute	rejection	and	improved	long-term	survival.460	Furthermore,	cardiac	
allograft	 ischemia	 and	 acute	 and	 chronic	 rejection	 increases	 intracardiac	 HIF	 activity.461,462	
Schneider	 et	 al.	 demonstrated	 ischemia-resistance	 in	 PHD-/-	 hepatic	 allografts	 in	 mice.463	
Regarding	 lung	 transplantation,	 Jiang	 X	 et	 al.	 observed	 that	 adenovirus-mediated	
overexpression	of	HIF-1α	in	mouse	tracheal	transplants	maintained	transplant	microvascular	
perfusion,	epithelial	integrity,	and	attenuated	chronic	rejection.464	Also,	Ropponen	et	al.	have	
recently	demonstrated	that	a	constantly	active	HIF-pathway	in	myeloid	cells	ameliorates	the	
development	of	obliterative	airway	disease	in	an	experimental	mouse	lung	allograft	model.465	
	
The	role	of	HIFs	in	heart	transplantation	has	not	been	fully	elucidated	yet,	and	is	warranted	to	
find	 alternative	 therapeutic	 targets	 for	 prevention	 of	 TX-IRI	 and	 transplant	 rejection.	
Furthermore,	the	accumulated	evidence	of	the	important	role	of	HIF	in	mediating	inflammation	
has	so	far	not	been	investigated	in	the	setting	of	heart	transplantation.	
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OBJECTIVES	
 
I. Determine	the	safest	and	most	efficient	AAV	vector	for	use	in	gene	therapy	of	the	heart	
transplant	out	of	the	three	serotypes	2,	8,	and	9.		
		
II. Investigate	the	role	of	VEGF-B	in	heart	TX-IRI	using	transgene	and	gene	therapy	tools.	
	
III. Determine	 the	 role	 of	 HIF-1α	 and	 -2α	 in	 myeloid-derived	 cell	 functions	 in	 heart	
transplantation	using	transgene	and	gene	therapy	tools.	
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METHODS	
	
Permission	 for	 animal	 experimentation	 was	 obtained	 from	 the	 State	 Provincial	 Office	 of	
Southern	Finland.	The	animals	received	care	in	compliance	with	the	“Guide	for	the	Care	and	
Use	of	Laboratory	Animals”	prepared	by	the	National	Academy	of	Sciences	and	published	by	
the	 National	 Academies	 Press	 (ISBN	 0-309-15400-6,	 revised	 2011).	 All	 gene	 therapy	
experiments	 were	 performed	 with	 permission	 from	 the	 Finnish	 Board	 of	 Gene	 technology	
(001/M/2000).	
	
Rat	and	mouse	heterotopic	heart	transplantation	
	
All	 procedures	 were	 performed	 with	 the	 animals	 under	 general	 anesthesia	 with	 inhalable	
Isoflurane.	All	animals	received	buprenorphine	(Temgesic)	as	perioperative	analgesia.	
	
Heart	procurement:	 First,	 the	donor	heart	was	perfused	with	 ice-cold	heparin-PBS	 solution.	
Next,	 the	caval	and	pulmonary	veins	were	 ligated	en	bloc	by	posterior	 ligature	and	excised.	
Finally,	the	aorta	and	pulmonary	artery	were	excised	and	the	heart	removed	from	the	thoracic	
cavity	 for	 ex	 vivo	 preservation	 in	 ice-cold	 +4°C	 heparinized	 PBS	 during	 preparation	 of	 the	
recipient.	
	
Preparation	 of	 the	 recipient:	 Laparotomy	 was	 performed	 along	 the	 linea	 alba	 to	 minimize	
intraoperative	bleeding.	The	abdominal	descending	aorta	and	inferior	vena	cava	were	prepared	
by	 dissecting	 the	 surrounding	 visceral	 fat	 and	 connective	 tissue.	 Both	 vessels	 were	 then	
clamped	cranially	and	caudally.	
	
Implantation:	The	donor	heart	aorta	and	pulmonary	artery	were	end-to-side	anastomosed	to	
the	recipient	descending	aorta	and	inferior	vena	cava,	respectively,	using	continuous	sutures.	
The	 clamps	 were	 opened	 and	 the	 recipient	 abdominal	 wall	 was	 closed	 in	 two	 layers	 with	
continuous	sutures.	
	
Table	4	–	Heart	transplantation	models	
Model	 Species	 Donor	breed	 Recipient	breed	 Warm	ischemia	(hours)	
Cold	ischemia	
(hours)	
Syngeneic	
Rat	 Dark	Agouti	 Dark	Agouti	 1	
No	IRI:	0	
IRI:	2	or	4	
Mouse	 Balb/C	 Balb/C	 1	
Allogeneic	 Rat	 Dark	Agouti	 Wistar	Furth	 1	
Mouse	 Balb/C	 C57/Bl	 1	
IRI,	ischemia-reperfusion	injury.	
	
Samples:	The	animals	were	sacrificed	and	samples	were	taken	at	6	hours	for	IRI,	5-10	days	for	
acute	rejection,	or	≥	2	months	post-transplant	for	chronic	rejection	experiments	(Table	4).	The	
heart	 transplant	 was	 divided	 into	 three	 transverse	 sections:	 the	 apical	 part	 was	 stored	 in	
RNAlater	for	RNA	extraction	and	RT-PCR,	the	middle	part	was	stored	in	Tissue-Tek	and	snap-
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frozen	in	liquid	nitrogen	and	isopentane	for	use	as	cryostat	sections	and	immunohistochemical	
staining,	and	the	basal	part	was	stored	in	paraformaldehyde	for	histological	staining.		
	
Experimental	models	
	
Study	I	–	AAV	
	
	
	
	
	
	
	
	
	
	
	
	
	
 
Intravenous	 experiment	 (Figure	 16):	 We	 injected	 200µl	 of	 AAV9	 (6.98x108	 vg/µl,	 n	 =	 3)	
systemically	into	DA	rats	weighing	50g	via	the	superficial	femoral	vein	through	a	small	inguinal	
incision	and	transplanted	their	hearts	into	fully	MHC-
matched	DA	rats	after	6	weeks.		
	
Intracoronary	experiment	(Figure	16):	The	donor	heart	
aorta	 and	 pulmonary	 artery	 were	 clamped	 after	
harvest	 and	 the	 coronary	 tree	 slowly	 perfused	 with	
200µl	of	cold	vector	solution	using	a	30G	needle.	The	
viral	 titers	 for	AAV2,	AAV8,	and	AAV9	were	2.68x108	
vg/µl	in	the	syngeneic	experiment	(n	=	6	/	group),	and	
1.09x109	vg/µl	for	AAV2	(n	=	4)	and	7.82x108	vg/µl	for	
AAV9	(n	=	6)	in	the	allogeneic	experiment.	
	
Recombinant	 vector	 production,	 cell-lines	 and	
plasmids:	 First,	 the	 firefly	 luciferase	 (Luc)	 gene	 was	
cloned	into	the	psub-CMV-WPRE	of	AAV	serotypes	2,	
8	and	9	(Figure	17).	Next,	we	cotransfected	293T	cells	
with	one	of	each	new		
	
Figure	16	–	Experimental	model	in	study	I.	IV,	intravenous;	IC,	intracoronary;	h,	hour;	AAV,	adeno-associated	virus.	
Figure	17	–	Constructed	rAAV	plasmid.	AAV,	adeno-
associated	 virus;	 ITR,	 inverted	 terminal	 repeat;	
CMV,	cytomegalovirus,	WPRE,	woodchuck	hepatitis	
virus	 post-transcriptional	 response	 element;	 pA,	
poly-Adeno;	 Amp,	 ampicillin-resistance	 gene;	 ori,	
origin	of	replication.	
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recombinant	 rAAV	vector	plasmid,	 the	AAV	packaging	plasmid	pAAV/Ad-rep	 (ACG),	 and	 the	
adenovirus	helper	plasmid	pBS-E2A-VA-E4	(Figure	18).	After	48	hours,	we	released	the	rAAVs	
by	 three	 freeze-thaw	 cycles	 in	 liquid	nitrogen.	 rAAV2,	 -8,	 and-9	were	purified	by	 iodixanol-
gradient	ultra-centrifugation.	Due	to	the	presence	of	heparan-sulphate	receptors	on	rAAV2,	we	
applied	heparin-sepharose	high-performance	liquid	chromatography	in	its	purification.		
	
Immunosuppression:	 Syngeneic	 transplant	 recipients	 received	 no	 immunosuppression.	 To	
inhibit	 acute	 allograft	 rejection	 and	 to	 allow	moderate	 chronic	 inflammation,	 recipients	 of	
allografts	 were	 post-operatively	 immunosuppressed	 with	 subcutaneous	 cyclosporine	 A	
(Novartis),	with	a	suboptimal	dose	of	2mg/kg/day	the	first	7	days	and	1mg/kg/day	thereafter.	
	
Study	II	–	VEGF-B	
	
The	effect	of	chronic	myocardial	VEGF-B	overexpression	on	heart	transplant	IRI	was	determined	
using	 transgenic	 rat	 strains,	whereas	 the	effects	of	 short-term	VEGF-B	overexpression	were	
investigated	 using	 local	 Adenoviral	 delivery	 of	 VEGF-B	 to	 allografts	 (Figure	 19).	 In	 both	
experiments,	 cold	 preservation	 and	 warm	 ischemia	 times	 were	 2	 hours	 and	 1	 hour,	
respectively.	We	 sacrificed	 the	 recipients	 at	 6	 hours	 (n	 =	 6	 /	 group)	 after	 reperfusion	 and	
collected	samples	for	ex	vivo	analyses.	
	
	
Figure	18	–	293T	cells	were	cotransfected	with	a	recombinant	adeno-associated	virus	(AAV)	plasmid,	AAV	packaging	plasmid	
pAAV/Ad-rep,	and	the	adenovirus	helper	plasmid	pBS-E2A-VA-E4.	After	48h,	 the	rAAVs	were	released	by	three	 freeze-thaw	
cycles	 in	 liquid	 nitrogen.	 AAV,	 adeno-associated	 virus;	 ITR,	 inverted	 terminal	 repeats;	 CMV,	 cytomegalovirus;	 WPRE,	
Woodchuck	hepatitis	virus	post-transcriptional	regulatory	element.	
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Effect	of	 ischemia	and	 reperfusion	on	heart	VEGF-B	mRNA	expression:	We	 subjected	hearts	
from	wild-type	DA	 rats	 to	 2h	ex	 vivo	 cold	 ischemia	with	 or	without	 an	 additional	 1h	warm	
ischemia	 and	measured	 the	 cardiac	mRNA	 expression	 levels	 of	 VEGF-B	 with	 qRT-PCR.	 The	
corresponding	measurements	were	made	at	6h	after	reperfusion	on	a	separate	set	of	hearts	
transplanted	into	major	MHC-mismatched	WF	rats	with	or	without	2h	ex	vivo	cold	ischemia.		
	
Effect	of	 chronic	VEGF-B	overexpression	on	heart	 transplant	 IRI	 (Figure	19):	We	performed	
intra-abdominal	heterotopic	heart	 transplantations	 from	specific	pathogen-free	male	Wistar	
(HsdBrl	 Han:	 WIST)	 to	 minor	 MHC-mismatched	 Wistar	 Furth	 (WF,	 RT1u)	 rats.	 Allograft	
myocardial	perfusion	was	determined	with	serial	laser	Doppler	measurements	at	1	min,	5	min	
and	6	hours	post-operatively.	
	
Effect	of	short-term	VEGF-B	overexpression	on	heart	transplant	IRI	(Figure	19):	DA	donor	rats	
were	 injected	 intravenously	 via	 the	 penile	 vein	with	 either	 150µl	 each	 of	 AAV9-hVEGF-B167	
(5.55x109	vg/µl)	and	–hVEGF-B186	(9.98x109	vg/µl)	or	AAV9-HSA	(human	serum	albumin,	control	
group,	1.85x109	vg/µl)	(n	=	6	/	group)	5	days	prior	to	transplanting	their	heart	into	major	MHC-
mismatched	Wistar	Furth	rats.		
	
Immunosuppression:	none.	
	
Study	III	–	HIF	
	
Generation	of	transgenic	mice	strains:	Mice	with	myeloid-derived-cell-specific	deletion	of	VHL	
or	HIF-1α	were	created	by	crossing	C57Bl/6	mice	carrying	a	floxed	VHL	(loxP)	or	HIF-1α	allele,	
respectively,	with	C57Bl/6	mice	 carrying	 the	myeloid-lineage-specific	 lysozyme	M	promoter	
(LysMCre)	 allele,	 deleting	 the	 floxed	 gene	 specifically	 in	 the	 myeloid-lineage.	 The	 result	 is	
homozygous	deficiency	of	HIF-1α	(constant	HIF-1α	inactivation)	or	VHL	(constant	activation	of	
HIF-1α	 and/or	HIF-2α)	 in	myeloid-derived	 cells,	 referred	 to	 as	mHIF-1α-/-	 and	mVHL-/-	mice,	
Figure	19	–	Experimental	model	in	study	II.	IV,	intravenous;	h,	hour;	AAV,	adeno-associated	virus.	
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respectively.	Wild	type	littermates	(LM)	with	homozygously	floxed	either	HIF	or	VHL,	but	lacking	
the	Cre	recombinase	served	as	control	recipients.	
	
Experimental	model:	First,	the	gene	expression	profile	of	the	transgenic	myeloid-derived	cells	
was	 investigated	 in	 vitro.	 Next,	 the	 transgenic	 effect	 was	 researched	 in	 vivo	 by	 using	 the	
transgenic	mice	as	recipients	for	fully	MHC-mismatched	heart	allografts	in	IRI,	acute	rejection,	
and	survival	models.	Finally,	the	effect	of	myeloid-derived	cell-specific	HIF	activation	(VHL	KO)	
or	 inactivation	 (HIF	 KO)	 on	 splenocyte	 functions	 were	 investigated	 in	 vitro	 in	 an	 antigen-
independent	polyclonal	T	cell	proliferation	assay.	
	
In	vitro	experiments:	Resident	peritoneal	myeloid-derived	cells	were	isolated	from	both	mVHL-
/-	and	mHIF-/-	mice,	using	corresponding	cells	from	littermate	mice	as	controls.	After	sacrifice	
via	 cervical	 dislocation,	 the	 peritoneal	 cavity	 was	 infused	 with	 ice-cold	 PBS	 and	 gently	
massaged.	 Next,	 the	 peritoneal	 lavage	 was	 collected	 through	 a	 mid-line	 laparotomy,	
centrifuged	 for	 10	minutes,	 washed	 with	 PBS,	 rid	 of	 erythrocytes,	 and	 the	 final	 cell	 pellet	
collected	 into	 RPMI	 comprising	 10%	 heat-inactivated	 fetal	 bovine	 serum,	 penicillin	 100	
units/ml,	 and	 streptomycin	 100	 μg/ml).	 The	 cells	 were	 plated	 for	 2-4h,	 non-adherent	 cells	
washed	off	with	PBS,	and	adherent	cells	collected	for	mRNA	isolation	and	qPCR	analysis.	
	
In	vivo	experiments	(Figure	20):	Heart	allografts	were	subjected	to	2h	ex	vivo	cold	preservation	
only	in	the	IRI	model	and	removed	at	6h	after	reperfusion.	In	the	acute	rejection	model	the	
heart	allografts	were	removed	at	5	days	after	reperfusion.	In	the	survival	model,	heart	allografts	
were	 palpated	 transabdominally	 daily	 and	 animals	 sacrificed	 and	 samples	 taken	 when	 no	
palpable	beat	was	felt.	
	
T	cell	proliferation	assay:	Unfractionated	splenocytes	were	isolated	from	the	mVHL-/-transgenic	
and	littermate	mice	and	rid	of	erythrocytes	and	large	cell	debris.	2x105	cells	were	cultured	on	
a	96-well	plate	and	stimulated	with	CD3/CD28	T	cell	Expander	(Dynabeads®,	Life	Technologies	
Ltd,	UK)	at	a	1:1	ratio	for	3	days.	Next,	the	cells	were	pulsed	with	3H-thymidine	(3.7	×	104	Bq	
per	well;	GE	Healthcare,	Buckinghamshire,	England),	harvested	after	6h,	and	analyzed	with	a	
Microbeta	 liquid	 scintillation	 counter	 (Wallac,	 Turku,	 Finland)	 using	 OptiScint	 HiSafe	
scintillation	 fluid	 (PerkinElmer,	 Waltham,	 MA).	 Background	 from	 non-stimulated	 wells	 was	
removed.	 Finally,	 the	 experiment	 was	 repeated	 by	 mixing	 littermate	 splenocytes	 with	
Figure	20	–	Experimental	model	in	study	III.	VHL,	Von	Hippel	Lindau	protein,	HIF,	hypoxia-inducible	factor;	KO,	knock-out;	
h,	hour.	
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syngeneic	mVHL-/-	peritoneal	myeloid-derived	cells	at	ratios	of	1:1,	1:2,	and	1:4	(2x105	cells	/	
well),	using	littermate	myeloid-derived	cells	as	controls.	
	
Immunosuppression:	none.	
	
General	methods	
	
Measurement	of	cardiac	troponin	T:	The	rat	serum	levels	of	cardiac	troponin	T	were	analyzed	
with	 the	 fifth-generation	 troponin	 T	 test	 (Troponin	 T,	 STAT,	 Roche	 Diagnostics,	 Basel,	
Switzerland).	Cardiac	troponin	T	was	measured	with	electrochemiluminescence	immunoassay	
(ECLIA)	on	the	Elecsys	2010	immunoassay	analyser	(Roche	Diagnostics).	
	
RNA	and	DNA	isolation:	Total	RNA	and	DNA	were	isolated	from	apical	tissue	samples	of	heart	
transplants	using	the	RNeasy	and	DNeasy	kit	(Qiagen,	Hilden,	Germany),	respectively.	A	High-
RNA-to-cDNA	kit	(Applied	Biosystems,	Foster	City,	CA)	was	used	to	reverse-transcribe	RNA.	
	
Quantitative	real-time	RT-PCR:	The	RotorGene-6000	(Corbett	Research,	Doncaster,	Australia)	
was	used	for	Quantitative	real-time	reverse-transcription	polymerase	chain	reaction	(qRT-PCR),	
using	2x	DyNAmo	Flash	SYBR	Green	Master	mix	(Finnzymes,	Espoo,	Finland).	We	calculated	the	
number	of	mRNA	copies	of	each	gene	of	interest	from	corresponding	standard	curves	using	the	
RotorGene	software	(Corbett	Research).		
	
Immunohistochemistry	
	
Table	5	–	Antibodies	and	their	concentrations	used	in	immunohistochemical	staining	of	cardiac	samples. 
	
	
Species	 Antibody	 Concentration	 Manufacturer	code	
Rat	
CD4	 5	µg/mL	 554835	(BD	Biosciences	Pharmingen)	
CD8	 5	µg/mL	 554854	(BD	Biosciences	Pharmingen)	
MPO	 20	µg/mL	 AB9535	(Abcam)	
OX-62	 10	µg/mL	 MCA1029G	(Serotec)	
ED-1	 5	µg/mL	 22451D	(BD	Pharmingen)	
RECA-1	 50	µg/mL	 MCA97	(AbD	Serotec)	
α-SMA	 1:5000	 A2547	(Sigma-Aldrich)	
VEGF-B	 0.2	µg/mL	 AF751	(R&D	Systems)	
Dystrophin	 3.3	µg/ml	 NCL-DYS2	(Leika	Microsystems)	
NKG2D/CD314	 1	µg/mL	 bs-0938R	(Bioss)	
Oil-Red-O	 5	µg/mL	 Sigma	Aldrich	
Mouse	
MPO	 20	µg/mL	 AB9535	(Abcam)	
CD4a	 5	µg/mL	 553043	(BD	Biosciences	Pharmingen)	
CD8a	 5	µg/mL	 553027	(BD	Biosciences	Pharmingen)	
CD11b	 5	µg/mL	 553308	(BD	Biosciences	Pharmingen)	
CD11c	 5	µg/mL	 557394	(BD	Biosciences)	
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Cryostat	 sections	were	 stained	 using	 the	 peroxidase	 ABC	method	 (Vectastain	 Elite	 ABC	 Kit,	
Vector	 Laboratories,	 Inc.,	 Burlingame,	 CA)	 and	 the	 reaction	 revealed	 by	 3-amino-9-
ethylcarbazole	 (AEC,	 Vector	 Laboratories).	 Counterstaining	 was	 performed	 using	 Mayer’s	
hemalum.	Immunohistochemical	staining	antibodies	are	presented	in	Table	5.	
	
Statistical	analyses	
	
Survival	 data	 is	 presented	 in	 Kaplan-Meier	 plots.	 P-values	 for	 the	 survival	 analyses	 were	
obtained	with	the	log-rank	test,	and	hazard	ratios	(HR)	with	confidence	intervals	(CI)	with	the	
Cox	 regression	 test.	 Linear	data	was	analyzed	with	 the	parametric	 Student’s	 t-test	 for	 two-
group	comparisons	and	One-way	ANOVA	for	comparison	of	multiple	groups.	Non-linear	data	
was	 analyzed	with	 the	 non-parametric	Mann-Whitney	 test	 for	 two-group	 comparisons	 and	
Kruskal-Wallis	 test	 for	 comparison	 of	 multiple	 groups.	 For	 all	 analyses,	 two-tailed	 p-values	
<0.05	were	considered	significant.	All	data	analyses	were	carried	out	using	IBM	SPSS	Statistics	
version	23.0	(SPSS,	Inc.,	Chicago,	Illinois).	
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RESULTS	
		
1. Adeno-associated	virus	
	
Rationale	 and	 objective:	 AAV	 serotypes	 2,	 8,	 and	 9	 are	 established	 as	 non-pathogenic	 and	
cardiotropic	viral	vectors,	but	none	of	them	have	been	investigated	for	use	as	a	long-term	gene	
therapy	vector	for	heart	transplants.	We	investigated	the	long-term	kinetics	and	safety	of	AAV	
vectors	2,	8,	and	9	in	rat	heart	transplantation	and	studied	the	effect	of	route	of	administration	
on	heart	transplant	transduction	rates.	
	
Intracoronary	delivery	of	AAV9	results	in	rapid	and	strong	transgene	expression	in	vivo	
	
Syngraft	recipient	in	vivo	bioluminescence	imaging	revealed	an	early	AAV9-mediated	luciferase	
expression	after	the	first	postoperative	week,	localized	to	the	cranium,	thorax,	and	extremities,	
gradually	 shifting	 towards	 the	abdominal	 region	 from	 the	2nd	postoperative	week	onwards.	
(Figure	21).	At	 its	peak,	the	luciferase	signal	 in	the	AAV9	group	was	8-fold	and	4-fold	higher	
than	the	corresponding	values	in	the	AAV2	and	AAV8	groups	(p<0.05	versus	each	group;	Figure	
21),	respectively.	The	luciferase	signal	from	recipients	of	AAV2-Luc-perfused	heart	transplants	
peaked	 at	 1	 month	 after	 transplantation	 (Figure	 21).	 The	 signal	 was	 weakest	 from	 these	
animals,	but	was	most	localized	to	the	region	of	the	transplant	(Figure	21).	
	
	
Intracoronary	delivery	of	AAV2	results	in	highest	heart	transplant	transduction	efficiency	and	
transgene	activity	
	
Ex	vivo	analyses	showed	that	intracoronary	AAV2-Luc	perfusion	of	syngeneic	heart	transplants	
resulted	in	the	highest	intragraft	vector	copy	numbers,	luciferase	mRNA	levels,	and	luciferase	
protein	activity	at	6	months	after	transplantation	(p<0.05	versus	AAV8	and	AAV9;	Figure	22).	
Intracoronary	delivery	of	AAV8	and	AAV9,	on	the	other	hand,	resulted	in	vector	leakage	into	
Figure	21	–	Long-term	comparison	of	transgene	kinetics	and	localization	of	AAV2,	AAV8,	and	AAV9	in	a	syngeneic	rat	heart	
transplantation	model.	*p<0.05	versus	AAV2	and	AAV8	for	all	measurement	points.	AAV,	adeno-associated	virus;	sec,	seconds;	
h,	hours;	IVIS,	in	vivo	imaging	system.	
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the	 recipient	 abdominal	 cavity,	 and	 thus	 low	 intragraft	 vector	 numbers	 and	 transgene	
quantities	(Figure	22).	
	
	
	
	
	
	
	
	
	
	
This	also	held	true	in	the	allogeneic	model,	in	which	AAV2	resulted	in	highest	intragraft	vector	
copies	at	one	month	after	 transplantation,	with	a	 trend	towards	higher	 intragraft	 luciferase	
protein	 activity	 as	 well	 (Figure	 23).	 Two	 hours	 of	 cold	 ischemia	 reduced	 the	 numbers	 of	
intragraft	 vector	 copies	 in	 both	 the	 AAV2	 and	 AAV9	 group,	 although	mRNA	 and	 luciferase	
protein	levels	remained	similar	to	grafts	without	additional	cold	ischemia	(Figure	23).	
	
	
	
Figure	22	–	Long-term	comparison	of	transgene	kinetics	and	localization	of	AAV2,	AAV8,	and	AAV9	in	a	syngeneic	rat	heart	
transplantation	model.	*p<0.05	versus	AAV2	and	AAV8	for	all	measurement	points.	AAV,	adeno-associated	virus;	sec,	seconds;	
Luc,	luciferase;	RLU,	real	light	unit.	
Figure	23	–	Long-term	comparison	of	transgene	kinetics	and	localization	of	AAV2,	AAV8,	and	AAV9	in	an	allogeneic	rat	heart	
transplantation	model.	*p<0.05	versus	AAV2	and	AAV8	for	all	measurement	points.	AAV,	adeno-associated	virus;	sec,	seconds;	
h,	hour;	Luc,	luciferase.	
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Intracoronary	delivery	of	AAV9-Luc	promotes	inflammation	in	
syngrafts	and	allografts	
	
To	assess	the	safety	of	the	viral	vectors,	we	examined	the	heart	
transplants	for	inflammatory	cell	influx,	extent	of	fibrosis,	and	
development	of	CAV.		
	
In	 syngrafts,	 the	 number	 of	 intragraft	 ED-1+	 macrophages,	
MPO+	 neutrophils,	OX-62+	DCs,	 and	CD4+	 T	 cells	was	 similar	
between	 the	 serotype	groups	 compared	 to	 control	 samples.	
The	number	of	CD8+	cytotoxic	T	cells,	however,	was	increased	
in	 AAV9-Luc-perfused	 syngrafts	 at	 6	 months	 after	
transplantation.	 In	 allografts,	 the	 number	 of	 CD11b+	
macrophages	were	increased	in	AAV9-Luc	perfused	hearts	at	4	
weeks	after	transplantation.	The	extent	of	fibrosis	and	CAV	was	
unchanged	 in	 AAV-perfused	 hearts	 compared	 to	 control	
samples	among	both	syngrafts	and	allografts.		
	
Donor	 intravenous	 delivery	 of	 AAV9	 results	 in	 local	 heart	
transplant	transgene	expression	
	
To	 determine	 the	 effect	 of	 route	 of	 administration	 on	 the	
localization	 of	 AAV9-Luc,	 we	 compared	 donor	 intravenous	
injection	to	ex	vivo	allograft	intracoronary	injection.	We	found	
that	donor	intravenous	injection	resulted	in	a	more	transplant-
localized	signal	than	allograft	intracoronary	injection	at	4	weeks	
after	 injection	(Figure	24),	making	it	a	more	feasible	route	of	
administration	for	future	studies.	
	 	
Figure	24	–	We	injected	AAV9-Luc	either	
intravenously	into	heart	donors	prior	to	
transplantation	 after	 6	 weeks	 (top	
panel),	 or	 into	 the	 coronary	 circulation	
ex	 vivo	 before	 implantation	 into	 the	
recipient	 (lower	 panel)	 and	 examined	
the	 luciferase	 signal	 with	 non-invasive	
bioluminescent	 imaging	 for	 4-8	 weeks.	
AAV;	 adeno-associated	 virus;	 IV,	
intravenous.	
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2. Vascular	endothelial	growth	factor	B	
	
Rationale	 and	 objective:	 VEGF-A,	 -C,	 and	 –D	 have	 implications	 for	 angiogenesis,	
lymphangiogenesis,	and	inflammation	in	cardiac	allografts.	The	role	of	VEGF-B,	however,	has	
not	been	investigated	in	the	setting	of	heart	transplantation.	Recent	studies	have	shed	light	on	
the	protective	effects	of	VEGF-B	in	ischemic	cardiomyopathy	and	metabolic	homeostasis,	which	
warrants	the	study	of	VEGF-B	in	heart	transplant	IRI.377,466	
	
Allograft	VEGF-B	mRNA	expression	decreases	after	heterotopic	heart	transplantation	
	
The	abnormal	hemodynamics	of	heterotopically	transplanted	rat	heart	transplants	lead	to	left	
ventricular	unload	and	remodelling.	To	determine	the	potential	role	of	VEGF-B	in	this	process,	
we	 performed	 rat	 allogeneic	 heart	 transplantations	 to	 immunosuppressed	 recipients	 and	
analyzed	correlations	between	CMC	size	and	VEGF-B	mRNA	expression	at	6	hours,	3-,	56-,	and	
100	days	after	transplantation.	
	
Cardiac	allograft	VEGF-B	mRNA	expression	decreased	significantly	 towards	 later	 time-points	
after	transplantation	(Figure	25A-B,	p<0.001),	and	correlated	with	the	decrease	 in	CMC	size	
during	that	time	period	(Figure	25C).	
	
Ischemia	and	reperfusion	induce	VEGF-B	expression	in	heart	transplants	
	
Hearts	 preserved	 in	 cold	 solution	 for	 2	 hours	 witnessed	 a	 significant	 increase	 in	 qRT-PCR-
measured	VEGF-B	mRNA	expression,	which	remained	high	at	6	hours	after	transplantation	into	
recipients	(Figure	26).	 
Figure	 25	 –	 (A)	 Cardiomyocyte	 surface	 area,	 (B)	 transplant	 relative	 VEGF-B	 mRNA	 expression,	 and	 (C)	 scatter	 plot	 of	
cardiomyocyte	area	vs.	transplant	VEGF-B	mRNA	expression	after	allogenic	rat	heart	transplantation.	***p<0.001	versus	native	
hearts	for	all	measurement	points.	h,	hour;	d,	day;	VEGF-B,	vascular	endothelial	growth	factor	B;	CMC,	cardiomyocte.	
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Chronic	 transgenic	 CMC-specific	 human	 VEGF-B-overexpressing	 rat	 heart	 transplants	 are	
hypertrophic	and	suffer	from	post-operative	tissue	perfusion	defects	
	
Vascular	endothelial	growth	factor	B	may	play	a	role	in	transendothelial	fatty	acid	transport	and	
CMC	fatty	acid	metabolism.373,374	To	determine	the	metabolic	effects	of	VEGF-B	in	the	heart,	
we	analyzed	cardiac	dimensions,	CMC	size,	and	intracellular	lipid	deposits	of	human	VEGF-B-
overexpressing	hearts	(Figure	27).	
	
Figure	26	–	(A)	Native	hearts	from	DA	
rats	 were	 exposed	 to	 ex	 vivo	 2-hour	
cold	 preservation	with	 or	 without	 1-
hour	warm	 ischemia	 (n	 =	 5	 /	 group).	
Native	hearts	without	ischemia	served	
as	controls.	(B)	DA	donor	hearts	were	
subjected	 to	 ex	 vivo	 2-hour	 cold	
preservation	 and	 transplanted	 into	
WF	 recipients.	 Transplants	 were	
removed	 and	 analyzed	 for	 VEGF-B	
mRNA	 expression	 at	 6	 hours	 after	
reperfusion.	 Heart	 transplants	
without	2-hour	preservation	served	as	
controls.	 Results	 are	 normalized	 to	
18S	 rRNA.	 *p<0.05.	VEGF-B,	 vascular	
endothelial	growth	factor	B;	h,	hour.	
Figure	27	–	Cardiomyocyte-specific	transgenic	human	VEGF-B	(hVEGF-B)-overexpressing	hearts	were	subjected	to	2-hour	cold	
and	 1-hour	warm	 preservation	 and	 transplanted	 into	 recipient	 rats	 in	 a	 minor	 MHC-mismatch	model	 (n	 =	 6/group).	 (A)	
Quantitative	 RT-PCR	 measurements	 of	 heart	 transplant	 hVEGF-B	 mRNA	 expression	 levels	 normalized	 to	 18S	 rRNA,	
amplification	of	hVEGF-B	transgene	cDNA,	and	immunofluorescent	staining	of	hVEGF-B	protein	in	heart	transplants.	(C)	Right	
wall	(RV),	left	wall	(LV),	and	septum	(S)	in	histologic	sections.	Scale	bar	=	1	mm.	(D)	Average	CMC	area	from	dystrophin-stained	
heart	sections.	Scale	bars	in	B,	C,	and	D	=	5	µm.	Data	are	presented	as	box	plots	and	analyzed	using	the	Mann-Whitney	U	test.	
*p<0.05,	 ***p<0.001	 RT-PCR,	 reverse	 transcriptase	 polymerase	 chain	 reaction;	 CMC,	 cardiomyocyte;	 VEGF-B,	 vascular	
endothelial	growth	factor	B;	Tg,	transgenic;	WF,	Wistar	Furth.	
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The	cardiac	dimensions	and	amount	of	ORO+	lipid	deposits	were	similar	between	the	control	
and	VEGF-B	group,	whereas	the	average	CMC	area	was	increased	in	the	VEGF-B	overexpressing	
hearts	(Figure	27).		
	
The	extent	of	fibrosis	and	capillary	density	was	similar	between	the	control	and	VEGF-B	group.	
Vascular	endothelial	growth	factor-B-overexpressing	heart	transplants,	however,	suffered	from	
diminished	post-operative	tissue	perfusion	as	measured	by	Doppler	ultrasound	up	to	6	hours	
after	reperfusion	(p<0.05;	Figure	28).	Similarly,	the	amount	of	cardiac-specific	TnT	release	was	
higher	in	VEGF-B-overexpressing	heart	transplants	when	compared	to	controls	(p<0.01;	Figure	
28)	without	any	significant	differences	in	intragraft	inflammatory	cell	numbers.		
	
	
Short-term	 AAV-mediated	 cardiac	 allograft-specific	 hVEGF-B	 overexpression	 causes	
macrophage	influx	but	fails	to	induce	morphologic	changes	in	the	heart	transplant	
	
Wild-type	 cardiac	 allograft	 donor	 DA	 rats	 received	 an	 intravenous	 dose	 of	 AAV9-hVEGF-B	
(isotypes	167	and	186)	5	days	prior	to	heart	procurement	and	implantation	into	major	MHC-
mismatched	WF	rats.	
	
Quantitative	 RT-PCR	 measurements	 of	 allograft	 hVEGF-B	 mRNA	 and	 immunofluorescence	
staining	of	hVEGF-B	protein	confirmed	effective	AAV9-mediated	cardiac	allograft	transduction	
(p<0.001;	Figure	29).	No	difference	in	cardiac	allograft	mass	or	serum	TnT	concentration	was	
observed	between	the	groups	(Figure	29B-C).	The	inflammatory	cell	influx	(Figure	29D),	RECA+	
capillary	density,	and	average	CMC	surface	area	were	similar	between	the	groups.	We	observed	
a	1.5-fold	higher	number	of	intragraft	ED-1+	macrophages	in	the	VEGF-B	group,	with	a	1.6-fold	
increase	 in	 proinflammatory	 cytokine	 IL-12p35	 mRNA	 expression	 at	 6h	 after	 reperfusion	
(p<0.05;	Figure	29D-E). 	
	
Figure	28	–	(A)	Doppler-measured	heart	transplant	tissue	perfusion	rates	at	set	postoperative	time	points	(B)	Recipient	serum	
cardiac	troponin	T	concentration	was	measured	6	hours	after	reperfusion.	*p<0.05,	**p<0.01.	WT,	wild	type;	Tg,	transgenic.	
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Figure	 29	 –	 (A)	 Real-time	 RT-PCR	 of	 the	 hVEGF-B	 transgene	 in	 cardiac	 allografts	 and	
immunofluorescence	staining	of	the	human	VEGF-B	protein	in	cardiac	allograft	paraffin-
embedded	cross	sections.	White	arrows	indicate	hVEGF-B+	cells.	Scale	bar	=	5	µm.	(B)	Heart	
transplants	were	weighed	before	implantation	into	WF	recipient	rats.	(C)	Recipient	serum	
cardiac	TnT	concentration	6	hours	after	HTx.	(D)	Cardiac	allograft	inflammatory	cell	influx	
at	6	hours	after	reperfusion.	(E)	mRNA	expression	levels	of	IL-12p35	from	cardiac	allograft	
samples	 taken	6	hours	 after	 reperfusion.	 Results	were	normalized	 to	GAPDH.	 *p<0.05,	
***p<0.001.	AAV,	adeno-associated	virus;	g,	grams.	
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3. Hypoxia-inducible	factor	
	
Rationale	and	objective:	Hypoxia-inducible	factor	is	a	major	transcriptional	switch	in	hypoxic	
conditions,	 regulating	 a	 wide	 spectrum	 of	 cellular	 functions	 ranging	 from	 metabolism	 to	
survival.	Interestingly,	HIF	has	been	implicated	as	an	important	mediator	of	the	immunological	
functions	of	myeloid-derived	cells,	which	form	an	integral	part	of	TX-IRI	and	both	acute	and	
chronic	rejection	of	heart	transplants.	We	investigated	the	role	of	HIF	in	the	inflammatory	and	
regulatory	functions	of	heart	transplant	recipient	myeloid-derived	cells.		
	
HIF-1α	 and	 -2α	 stabilization	 in	 myeloid-derived	 cells	 induces	 an	 immunosuppressive	
phenotype	in	vitro	
	
We	collected	 and	 analyzed	 the	 gene	 expression	profile	 of	 naïve	myeloid-derived	 cells	 from	
mVHL-/-	and	mHIF-1α-/-	C57/Bl	mice	and	compared	them	to	corresponding	cells	from	control	
littermate	mice.	
	
Myeloid-derived	 cells	 from	 mVHL-/-	 mice	 had	 an	 increased	 expression	 of	 HIF-1α	 and	 anti-
inflammatory	 HO-1,	 IDO,	 and	 Arg1	 (p<0.01);	 and	 decreased	 DC	 maturation	 marker	 CD83	
expression	(p<0.001).	They	also	showed	increased	expression	of	pro-inflammatory	VEGF-A,	IL-
1β,	and	IP-10	(CXCL10)	(p<0.05).	Also,	myeloid-derived	cells	from	mVHL-/-	mice	showed	a	strong	
trend	towards	increased	MDSC-specific	S100A9	mRNA	expression.	Myeloid-derived	cells	from	
mHIF-1α-/-	mice	showed	a	trend	towards	higher	expression	of	pro-inflammatory	cytokines	IP-
10	(CXCL10),	RANTES	(CCL5),	and	CD83.	
	
Stabilization	of	HIF-1α	and	-2α	in	recipient	myeloid-derived	cells	alleviates	IRI		
	
We	performed	heterotopic	allogeneic	heart	transplantations	from	wild-type	mice	to	mVHL-/-	
(n	=	8)	and	mHIF-1α-/-	(n	=	6)	transgenic	mice,	subjecting	the	transplants	to	2	hours	of	ex	vivo	
cold	preservation.	Littermate	recipients	served	as	controls	(n	=	15).	
Figure	30	–	(A)	Serum	release	of	cardiac	 troponin-T	(cTnT)	 in	cardiac	allograft	recipients	6	hours	after	reperfusion.	(B)	The	
number	of	allograft	infiltrating	inflammatory	cells	6	hours	after	reperfusion.	*p<0.05.	cTnT,	cardiac	troponin	T.	
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Serum	cTnT	was	significantly	lower	in	mVHL-/-	recipients	when	compared	to	littermate	controls	
at	6	hours	after	transplantation	(p<0.05;	Figure	30).	The	number	of	intragraft	infiltrating	MPO+	
neutrophils	 was	 significantly	 increased	 in	 mVHL-/-	 recipients	 at	 6	 hours	 after	 reperfusion	
(p<0.05;	Figure	30),	but	the	number	of	CD11b+	macrophages,	CD11c+	DCs,	and	CD4+/CD8+	T	
cells	remained	unchanged	(Figure	30).		
	
In	mVHL-/-	recipients	the	expression	of	heart	transplant	anti-inflammatory	IL-10	was	1.5-fold	
higher	and	Arg1	2.1-fold	higher	at	6	hours	after	reperfusion	compared	to	littermate	controls,	
although	no	statistical	significance	was	observed	(Table	6).	Conversely,	the	mRNA	levels	of	pro-
inflammatory	VEGF-A	and	TNF-α	were	significantly	decreased	in	the	in	mVHL-/-	group	(p<0.01	
and	<0.05	respectively;	Table	6).	
	
Table	6	–	Relative	gene	expression	profile	of	cardiac	allografts	6	hours	after	transplantation	into	mVHL-/-	recipient	mice	
compared	to	littermate	controls.	
	
Gene	 Relative	mRNA	expression	 ±	SEM	 p-value	
Arg1	 2.1	 0.7	 0.506	
IL-33	 1.8	 0.9	 0.190	
STAT6	 1.6	 0.4	 0.169	
IL-10	 1.5	 0.2	 0.115	
CXCR2	 1.4	 0.4	 0.506	
GM-CSF	 1.4	 0.7	 0.875	
IL-2	 1.4	 0.3	 0.294	
G-CSF	 1.3	 0.7	 0.392	
HO-1	 1.2	 0.2	 0.392	
S100A9	 1.2	 0.2	 0.428	
MIP-2α	(CXCL2)	 1.0	 0.5	 0.825	
IL-12p35	 1.0	 0.1	 0.970	
RANTES	(CCL5)	 1.0	 0.3	 0.910	
STAT3	 0.9	 0.1	 0.792	
IL-6	 0.9	 0.3	 0.975	
iNOS	 0.9	 0.1	 0.294	
HIF-2α	 0.9	 0.0	 0.031	
IDO1	 0.8	 0.1	 0.384	
HIF-1α	 0.8	 0.1	 0.208	
MCP-1	(CCL2)	 0.8	 0.3	 0.428	
CD83	 0.8	 0.1	 0.975	
FOXp3	 0.7	 0.1	 0.925	
MIP-1α	(CCL3)	 0.6	 0.2	 0.270	
IP-10	(CXCL10)	 0.6	 0.1	 0.681	
IL-1β	 0.6	 0.1	 0.265	
CD80	 0.5	 0.1	 0.057	
GROα	(CXCL1)	 0.5	 0.2	 0.728	
TNF-α	 0.4	 0.0	 0.034	
VEGF-A	 0.2	 0.0	 0.008	
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In	contrast,	in	mHIF-1α-/-	cardiac	allograft	recipients,	the	degree	of	myocardial	injury	and	the	
intragraft	numbers	of	inflammatory	cells	remained	unchanged	compared	to	littermate	controls	
(Figure	30).	However,	cardiac	allografts	transplanted	into	mHIF-/-	recipients	showed	increased	
mRNA	expression	of	pro-inflammatory	iNOS,	VEGF-A,	and	RANTES	(CCL5),	with	decreased	anti-
inflammatory	HO-1	and	Arg1	mRNA	levels	at	6	hours	after	reperfusion	(p<0.05;	Table	7).	
	
Table	7	–	Relative	gene	expression	profile	of	cardiac	allografts	6	hours	after	transplantation	into	mHIF-1α-/-	recipient	mice	
compared	to	littermate	controls.	
	
Stabilization	of	HIF-1α	and	-2α	in	recipient	myeloid-derived	cells	alleviates	acute	rejection	of	
heart	allografts	
	
We	performed	heterotopic	allogeneic	heart	transplantations	from	wild-type	mice	to	mVHL-/-	(n	
=	5)	or	mHIF-1α-/-	(n	=	9)	transgenic	mice.	Littermate	recipients	served	as	controls	(n	=	6).	The	
recipients	 did	 not	 receive	 any	 immunosuppression,	 allowing	 the	 development	 of	 acute	
rejection	before	removal	at	5	days	after	transplantation.	
Gene	 Relative	mRNA	expression	 ±	SEM	 p-value	
MIP-1α	(CCL3)	 2.3	 1.8	 0.494	
IL-2	 2.3	 1.2	 0.445	
RANTES	(CCL5)	 2.2	 0.4	 0.024	
STAT6	 2.2	 1.3	 0.612	
VEGF-A	 1.9	 0.2	 0.023	
IL-1β	 1.9	 0.9	 0.622	
MCP-1	(CCL2)	 1.5	 0.6	 0.335	
iNOS	 1.4	 0.2	 0.029	
IL-33	 1.4	 0.9	 0.866	
G-CSF	 1.4	 0.8	 0.933	
TNF-α	 1.4	 0.3	 0.154	
CD80	 1.4	 0.7	 0.616	
IL-10	 1.3	 0.5	 0.892	
GM-CSF	 1.2	 0.7	 0.933	
CD83	 1.1	 0.6	 0.437	
S100A9	 1.1	 0.4	 0.933	
CXCR2	 1.1	 0.5	 0.933	
HIF-2α	 1.1	 0.1	 0.213	
IL-12p35	 1.1	 0.2	 0.820	
HIF-1α	 1.0	 0.1	 0.892	
STAT3	 0.9	 0.1	 0.385	
MIP-2α	(CXCL2)	 0.8	 0.4	 0.933	
IP-10	(CXCL10)	 0.8	 0.3	 0.616	
FOXp3	 0.8	 0.1	 0.820	
IDO1	 0.8	 0.1	 0.250	
IL-6	 0.5	 0.2	 0.205	
Arg1	 0.4	 0.1	 0.045	
HO-1	 0.4	 0.0	 0.018	
GROα	(CXCL1)	 0.3	 0.1	 0.612	
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The	number	of	allograft-infiltrating	CD11b+	macrophages,	CD11c+	DC,	and	CD4+	and	CD8+	T	
cells,	 but	 not	MPO+	 neutrophils,	 was	 reduced	 in	mVHL-/-	 recipients	 compared	 to	 allografts	
transplanted	 into	 littermate	 recipients	 (p<0.05;	 Figure	 31).	 These	 allografts	 also	 showed	 a	
significantly	reduced	mRNA	expression	of	TNF-α,	 IFN-γ,	 IP-10	(CXCL10),	RANTES	(CCL5),	 IL-4,	
GM-CSF,	 FOXp3,	 IDO,	CD86,	 iNOS,	and	HO-1	compared	 to	allografts	 in	 littermate	 recipients	
(p<0.05;	Table	8).		
	
	
Table	8	–	Relative	gene	expression	profile	of	cardiac	allografts	5	days	after	transplantation	into	VHL-/-	recipient	mice	
compared	to	littermate	controls.	
Gene	 Relative	mRNA	expression	 ±	SEM	 p-value	
HIF-2α	 1.71	 0.20	 0.053	
STAT3	 1.23	 0.35	 0.443	
TGF-β	 1.05	 0.34	 0.878	
S1009A	 1.03	 0.73	 0.960	
VEGF-A	 0.87	 0.35	 0.712	
CD80	 0.73	 0.24	 0.369	
THBS5	 0.68	 0.19	 0.215	
HIF-1α	 0.63	 0.12	 0.321	
CD83 0.59	 0.16	 0.167	
IL-1β	 0.57	 0.41	 0.358	
IL-17	 0.54	 0.53	 0.768	
Arg1	 0.39	 0.19	 0.135	
IL-6	 0.37	 0.15	 0.086	
IL-10	 0.32	 0.13	 0.142	
CD86	 0.28	 0.07	 0.012	
FOXP3	 0.17	 0.06	 0.014	
TNF-α	 0.17	 0.06	 0.000	
iNOS	 0.16	 0.08	 0.015	
IL-4	 0.13	 0.13	 0.026	
GM-CSF	 0.12	 0.03	 0.042	
RANTES	(CCL5)	 0.11	 0.03	 0.001	
IFN-γ	 0.04	 0.01	 0.017	
IP-10	(CXCL10)	 0.04	 0.02	 0.001	
IDO	 0.02	 0.01	 0.001	
HO-1	 0.02	 0.01	 0.001	
Figure	31	–	Number	of	cardiac	allograft	infiltrating	inflammatory	cells	5	days	after	transplantation	into	fully	MHC-incompatible	
littermate,	VHL-/-,	or	HIF-1α-/-	C57/Bl	mice.	
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Myeloid-derived	cell	HIF-1α	expression	is	dispensable	for	their	inflammatory	properties	
	
Heart	 allografts	 transplanted	 into	mHIF-1α-/-	 recipients	 experienced	 a	 similar	 acute	 cellular	
immune	response	as	allografts	transplanted	into	littermate	mice	(Figure	31).	These	hearts	also	
showed	an	 increased	expression	of	pro-inflammatory	 IL-17	compared	 to	 littermate	controls	
(p<0.05),	suggesting	an	exacerbated	inflammatory	state.	The	expression	of	other	pro-and	anti-
inflammatory	factors	was	similar	to	littermate	controls.		
	
Cardiac	allograft	survival	is	prolonged	in	mVHL-/-	recipients	
	
To	 investigate	the	 long-term	 implications	of	 the	diminished	acute	rejection	we	performed	a	
survival	model.	Heart	allografts	were	transplanted	into	non-immunosuppressed	major	MHC-
mismatched	 littermate,	 mVHL-/-,	 or	 mHIF-1α-/-	 C57/Bl	 mice	 and	 followed-up	 with	 daily	
abdominal	palpation.	The	end-point	was	lack	of	palpable	heart	allograft	activity.	
	
The	 median	 survival	 of	 allografts	 transplanted	 into	 mVHL-/-	 recipients	 was	 significantly	
prolonged	to	20±4	days	(p<0.05;	Figure	32),	with	a	significantly	higher	cardiac	allograft	Arg1	
expression	compared	to	 littermate	controls	at	 the	moment	of	 failure	 (p<0.05;	Table	9).	The	
corresponding	 survival	 was	 10±1	 days	 for	 littermate	 controls	 and	 9±1	 days	 for	 mHIF-1α-/-	
recipients	(Figure	32).	
	
	
Figure	32	–	Allograft	survival	as	measured	by	daily	abdominal	palpation	of	contractile	activity	of	the	transplant.	∗p<0.05.	
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Table	9	–	Relative	gene	expression	profile	of	cardiac	allografts	transplanted	into	mVHL-/-	recipients	after	failure	in	the	survival	
model	compared	to	Littermate	controls.	
	
Myeloid-derived	cell	HIF-1α	and	-2α	transduction	induces	variable	gene	expression	profiles	in	
vitro	
	
To	dissect	HIF-1α	and	HIF-2α-mediated	differences	in	gene	expression	profiles	of	macrophages,	
rat	macrophages	were	transduced	with	adenoviral	vectors	encoding	stabilized	forms	of	HIF-1α	
or	HIF-2α.	
	
High	levels	of	pro-inflammatory	CCR7,	CD86,	and	GM-CSF	were	detected	in	HIF-1α-transduced	
macrophages	 compared	 to	 control	 GFP-transduced	 macrophages	 (p<0.05).	 The	 mRNA	
expression	of	MDSC-associated	STAT3	transcription	factor	was	increased	in	HIF-1α-transduced	
macrophages,	along	with	a	decrease	in	pro-inflammatory	IL-1β.	Arginase-1	mRNA,	on	the	other	
hand,	was	significantly	 increased	in	HIF-2α-transduced	macrophages	(p<0.05).	No	significant	
difference	was	observed	in	HO-1	or	IDO	mRNA	expression	between	the	groups.	
	 	
Gene	 Relative	mRNA	expression	 ±	SEM	 p-value	
Arg1	 2.2	 0.6	 0.012	
IL-10	 1.8	 0.8	 0.194	
MIP-1α	(CCL3)	 1.4	 0.6	 0.279	
RANTES	(CCL5)	 2.3	 1.7	 0.279	
HO-1	 1.7	 0.4	 0.133	
IFN-γ	 1.7	 0.7	 0.376	
IL-6	 1.5	 0.6	 0.279	
IL-33	 1.6	 1.1	 0.376	
iNOS	 2.5	 1.0	 0.085	
VEGF-A	 1.6	 0.6	 0.279	
IP-10	(CXCL10)	 2.1	 1.0	 0.133	
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DISCUSSION	
 
1. Adeno-associated	virus	
	
Heart	 transplant	 gene	 therapy	 could	 provide	 a	 safe	 method	 for	 applying	 local	 therapeutic	
effects	to	the	allograft	without	the	dangerous	systemic	side-effects	of	the	current	multi-drug	
immunosuppressive	 regimens.	 It	 would	 require	 a	 nonpathogenic	 gene	 vector,	 capable	 of	
allograft-specific	long-term	transgene	expression	after	ex	vivo	 intracoronary	perfusion	of	the	
heart	transplant.	In	this	study,	we	demonstrated	that	AAV2	was	superior	to	AAV8	and	AAV9	in	
transducing	heart	transplants	after	ex	vivo	intracoronary	delivery,	whereas	AAV9	was	superior	
after	intravenous	delivery.	For	the	sake	of	clinical	relevance,	we	only	performed	longitudinal	in	
vivo	luminescence	measurements	and	safety	assessments	of	recipients	of	intracoronary	AAV-
perfused	heart	transplants.		
	
Heart	transplant	localization	
 
AAV	 serotypes	 6,	 8,	 and	 9	 have	 been	 established	 as	 the	most	 cardiotropic	 serotypes	 after	
intravenous	 injection	 into	rats.328,330,331,467	Our	 IV	experiment	disclosed	similar	 findings,	with	
AAV9-injected	rats	showing	highest	viral	DNA	and	transgene	mRNA	levels	in	the	heart	tissue,	
and	AAV2-injected	rats	the	lowest	at	1	month	after	injection.	This	heart-specific	AAV9	luciferase	
expression	was	maintained	after	transplantation	into	a	wild-type	recipient	rat.	Intracoronary	
delivery	of	the	vectors,	however,	produced	opposite	results,	with	AAV2	resulting	in	the	highest	
intragraft	viral	DNA	and	transgene	mRNA	and	protein	expression,	and	AAV9	the	 lowest	at	6	
months	after	syngeneic	and	1	month	after	allogeneic	transplantation.	This	discrepancy	is	most	
likely	 related	 to	 vector-	 and	 tissue-related	 factors	 governing	 the	 transduction	 properties	 of	
AAVs.		
	
Adeno-associated	virus	serotype	2	preferentially	enters	tissues	via	fenestrated	epithelium	and,	
contrary	 to	 AAV8	 and	 AAV9,	 is	 equipped	 with	 the	 extracellular	 heparan	 sulfate	 receptor,	
facilitating	 its	attachment	to	the	extracellular	matrix	and	granting	 it	a	short	blood-clearance	
time.308,468-470	Moreover,	 the	 slow	blood-clearance	of	AAV9	after	 systemic	delivery	 suggests	
that	it	requires	a	prolonged	time	to	cross	the	endothelial	layer	for	cardiac	transduction.469	In	
vivo	IVIS	imaging	of	laparotomized	recipient	rats	of	AAV9-perfused	heart	transplants	confirmed	
the	 escape	 of	 AAV9	 into	 the	 abdominal	 cavity	 of	 the	 recipients.	 Therefore,	 the	 lower	
adhesiveness	and	slow	transendothelial	access	of	AAV8	and	AAV9	may	explain	their	abdominal	
escape	 after	 intracoronary	 delivery	 into	 heart	 transplants	 and	 higher	 cardiac	 transductivity	
after	IV	administration.	
	
Clinical	translation:	neither	donor	nor	recipient	IV	delivery	of	viral	vectors	is	suitable	for	gene	
therapy	in	clinical	Htx.	This	is	due	to	the	long	clearance	time	of	many	vectors,	prolonged	warm	
ischemia	time	after	donor	brain	death,	and	nonspecific	tissue	transduction	in	both	donors	and	
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recipients.	 The	 latter	 effect	may	 also	 cause	 problems	 for	 harvesting	 and	 transplantation	 of	
other	organs,	due	to	the	versatile	context-	and	tissue-dependent	effects	of	therapeutic	genes.	
Ex	vivo	heart	transplant	perfusion,	however,	would	be	clinically	feasible,	and	could	minimize	
the	 systemic	 transduction	 of	 the	 donor	 and	 recipient.	 This	 is	 especially	 true	 now,	with	 the	
increasing	use	of	ex	vivo	perfusion	devices.471	
	
Efficiency	
	
Ignoring	 localization,	 we	 observed	 efficient	 transgene	 expression	 at	 4	 weeks	 after	
transplantation	 with	 all	 AAV	 serotypes	 in	 both	 the	 syngeneic	 and	 allogeneic	 models.	 The	
expression	 remained	 stable	 throughout	 the	 follow-up	 time	until	 6	months	 in	 the	 syngeneic	
model,	and	1	month	in	the	allogeneic	model.	In	the	syngeneic	model,	the	AAV9	kinetics	were	
profoundly	higher	than	AAV2	and	AAV8	at	all	late	measurement	points.		
	
Clinical	 translation:	 these	 vector	 kinetics	 could	 be	 suitable	 for	 clinical	 treatment	 of	 chronic	
allograft	 rejection	 or	 diagnosis	 of	 acute	 rejection	 episodes	 using	 reporter	 genes.	 Potential	
therapeutic	 proteins	 could	 include	 both	 anti-inflammatory	 and	 anti-proliferative	
factors.117,351,472	Although	AAV2	and	AAV9	show	some	transgene	activity	on	the	second	post-
operative	 day,	 these	 low	early	 transgene	 kinetics	would	most	 likely	 not	 be	 suitable	 for	 the	
treatment	 of	 IRI	 and	 early	 acute	 allograft	 rejection,	 and	 recipients	 would	 require	 optimal	
traditional	immunosuppression	for	the	first	post-operative	weeks	or	months.		
	
Safety	profile	
	
Heart	 transplant	 intracoronary	 delivery	 of	 AAV8	 and	 AAV9	 induced	 a	 CD8+	 T	 cell	 response	
measured	at	6	months	after	transplantation	of	syngeneic	hearts.	This	could	partly	explain	the	
low	 transplant-specific	 transduction	 efficiency	 of	 AAV8	 and	 AAV9.	 A	 vector-directed	
inflammation	 and	 immunogenicity-mediated	 decrease	 in	 transduction	 efficiency,	 however,	
would	 be	 expected	 to	 occur	 homogenously	 in	 the	 recipient,	 and	 not	 only	 in	 the	 heart	
transplant.	 The	 recipients	 of	 AAV-perfused	 allografts,	 on	 the	 other	 hand,	 were	
immunosuppressed	with	daily	doses	of	cyclosporine.	This	may	have	blunted	the	T	cell	response	
observed	in	syngeneic	grafts.	Adeno-associated	virus	serotype	9-perfused	allografts,	however,	
experienced	 an	 ED-1+	 macrophage	 response	 4	 weeks	 following	 transplantation.	 Heart	
transplant	 AAV2-perfusion	 induced	 no	 inflammatory	 responses	 in	 either	 the	 syngeneic	 or	
allogeneic	model.		
	
We	observed	only	minor	hepatic	transduction	with	all	AAV	serotypes	in	both	the	syngeneic	and	
allogeneic	model.	The	quantities	were	nearly	non-existent	in	the	syngeneic	model,	whereas	in	
the	allogeneic	model,	we	found	significant	amounts	of	AAV9	vector	particles	in	liver	samples.	
This	difference	is	most	likely	due	to	the	later	end-point	for	the	syngeneic	experiment,	enabling	
the	highly	regenerative	hepatic	tissue	to	remove	transduced	cells.473	Nevertheless,	none	of	the	
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animals	presented	with	clinical	signs	of	hepatic	damage	or	other	side-effects	during	the	follow-
up	time.	During	tissue	sampling,	no	macroscopic	signs	of	hepatic	damage	or	ascites	were	noted.	
Thus,	hepatic	transduction	seems	not	to	pose	a	threat	to	recipients	in	our	future	experimental	
models.	Also,	we	observed	no	 increased	 incidence	of	CAV	or	cardiac	 fibrosis	 in	AAV-treated	
hearts	in	syngrafts	or	allografts.	
	
Clinical	translation:	Adeno-associated	virus	vectors	may	cause	both	host	humoral	and	cellular	
immune	reactions	in	the	form	of	viral	capsid	protein-specific	neutralizing	antibodies	and	CD8+	
cytotoxic	T	cells,	 respectively.333,334,343,474-476	This	study	established	that	especially	AAV8	and	
AAV9	 have	 higher	 immunogenicity	 than	 AAV2	 in	 the	 rat,	 which	must	 be	 considered	 when	
choosing	a	vector	for	clinical	trials.	A	large	proportion	of	the	population	are	infected	with	latent	
AAV	and	the	majority	possess	viral	capsid	protein-targeted	neutralizing	antibodies.333,477	This	is	
a	 major	 barrier	 limiting	 recipient	 transgene	 expression	 in	 clinical	 trials,	 and	 should	 be	
considered	when	applying	gene	therapy	to	clinical	heart	transplantation.	Some	studies	have	
utilized	 immunosuppressants	 to	 extend	AAV-mediated	 transgene	 expression,	 although	with	
varying	results.478,479	This	could	be	a	feasible	strategy	among	transplant	recipients,	which	could	
be	maintained	on	a	suboptimal	minimal	immunosuppressive	regimen.	
	
Conclusions	and	clinical	implications	
	
Our	 results	 highlight	 the	 importance	 of	 route	 of	 administration	 on	 heart	 transplant	 vector	
transduction	 efficiency.	 Ex	 vivo	 vector	 perfusion	 of	 heart	 transplants	 is	more	 feasible	 than	
donor	IV	treatment,	which	suggests	AAV2	as	a	potential	gene	therapy	vector	for	clinical	heart	
transplantation.	Also,	the	lower	immunogenicity	of	AAV2	supports	its	use	in	clinical	trials.	For	
bench-side	experimental	animal	studies,	however,	donor	IV	administration	of	the	viral	vector	
is	 technically	 simpler	 and	 more	 straight-forward.	 For	 this	 purpose,	 AAV9	 would	 be	 more	
suitable,	as	it	resulted	in	efficient	heart	transduction	rates	after	systemic	IV	administration	into	
the	donor,	and	remained	highly	expressed	in	the	heart	after	transplantation	into	the	recipient.					
	
2. Vascular	endothelial	growth	factor	B	
	
This	study	sheds	new	light	on	the	role	and	effects	of	VEGF-B	in	rat	heart	transplantation.	We	
established	that	VEGF-B	gene	expression	was	significantly	increased	in	native	hearts	subjected	
to	2	hours	ex	vivo	cold	ischemia	and	remained	high	at	least	up	to	6	hours	after	transplantation	
into	recipient	rats.	This	reaction,	however,	is	most	likely	not	protective	in	the	setting	of	heart	
transplantation,	as	neither	long-term	nor	short-term	heart	transplant-specific	overexpression	
of	VEGF-B	limited	TX-IRI.	
	
Vascular	 endothelial	 growth	 factor	 B	 overexpression	 induces	 cardiac	 hypertrophy.375,376	
Moreover,	 it	 reduces	 ischemic	 CMC	 injury	 in	 a	myocardial	 infarction	model	 and	 decreases	
apoptosis	via	BH3	inhibition	both	in	vitro	and	in	vivo.365,369,375,376,480	Our	experiments,	however,	
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indicated	 no	 such	 protective	 effects	 of	 VEGF-B	 overexpression	 on	 TX-IRI,	 the	 early	 innate	
inflammatory	response,	or	CMC	apoptosis.	On	the	other	hand,	we	observed	CMC	hypertrophy	
and	increased	expression	of	the	extracellular	ATPase	CD39	in	long-term	VEGF-B-overexpressing	
heart	transplants	at	6h	after	reperfusion,	without	changes	in	the	cardiac	lipid	storage.	These	
findings	 suggest	 an	 altered	 metabolic	 environment	 in	 the	 VEGF-B-overexpressing	 hearts,	
possibly	due	to	an	increase	in	CMC	aerobic	oxidative	metabolism	induced	by	VEGF-B.481	The	
increased	expression	of	the	electron	transport	chain	component	cytochrome	C	oxidase	in	long-
term	VEGF-B	overexpressing	heart	transplants	supported	this	idea.	Also,	we	found	that	heart	
transplant	 VEGF-B	 expression	 decreased	 with	 diminished	 cardiac	 allograft	 workload.482	
Together,	these	findings	suggest	that	VEGF-B	may	be	an	important	factor	in	the	maintenance	
of	CMC	metabolic	homeostasis	and	adaptation	to	increased	workload.		
	
Short-term	 AAV-mediated	 heart	 transplant	 VEGF-B	 overexpression	 failed	 to	 reproduce	 the	
cardiac	metabolic	and	morphologic	effects	of	long-term	transgenic	VEGF-B	overexpression	and	
did	not	affect	the	post-transplant	recipient	cardiac-specific	TnT	(cTnT)	release.	This	implies	that	
the	 increased	cTnT	release	after	 transplantation	of	 long-term	overexpressing	VEGF-B	hearts	
was	mostly	due	to	the	hypertrophied	CMCs,	and	to	a	lesser	degree	due	to	the	high	basal	cardiac	
metabolic	rate	and	resulting	lower	ischemic	tolerance.	
	
Vascular	endothelial	growth	factor-B	gene	deletion	diminishes	blood	vessel	survival	in	an	in	vivo	
oxygen-induced	 vessel	 regression	 model	 of	 mouse	 corneal	 pockets.368,371	 In	 myocardial	
infarction	 models,	 VEGF-B	 treatment	 expands	 the	 coronary	 vasculature	 and	 epicardial	
arterialization.370,375,376	Vascular	endothelial	growth	factor	B	also	functions	as	a	survival	factor	
for	 VECs,	 pericytes,	 and	 SMCs	 in	 vitro.368,371	 In	 contrast,	 we	 observed	 impaired	myocardial	
perfusion	of	long-term	VEGF-B-overexpressing	hearts	after	transplantation	into	recipients.	The	
capillary	 density	 was	 similar	 to	 control	 hearts,	 suggesting	 CMC	 hypertrophy	 as	 a	 probable	
cause.	
	
Heart	 transplant	 AAV-mediated	VEGF-B	 overexpression	 caused	 an	 increased	 influx	 of	 ED-1+	
macrophages	 and	 IL-12p35	 expression,	 suggesting	 a	 proinflammatory	 environment.	 No	
previous	studies	have	shown	a	direct	effect	of	VEGF-B	on	macrophages.	Instead,	VEGF-B	can	
scavenge	VEGFR-1	to	increase	the	proinflammatory	effects	of	VEGFR-2	ligation	by	VEGF-A.377	
	
Conclusions	and	clinical	implications	
	
This	 study	 provides	 preliminary	 insight	 into	 the	 role	 of	 VEGF-B	 in	 heart	 transplant	 IRI.	 The	
findings	are	scarce,	but	may	suggest	a	role	for	VEGF-B	in	the	maintenance	of	CMC	oxidative	
metabolism.	Although	the	effects	of	heart	transplant	VEGF-B	overexpression	were	negative	in	
terms	 of	 post-operative	myocardial	 damage	 and	 inflammation	 in	 this	 study,	 the	 long-term	
implications	 of	 VEGF-B	 in	 heart	 transplants	 remains	 unknown	 and	 warrants	 further	
investigation.	 In	 the	 current	 study,	 however,	 donor	 rats	 were	 healthy	 and	 the	 response	
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variables	 were	 limited	 to	 myocardial	 damage	 and	 inflammation,	 ignoring	 the	 potential	
beneficial	 effects	 VEGF-B	 could	 have	 on	 myocardial	 energy	 expenditure	 and	 contractile	
efficiency	 in	 extended	 criteria	 heart	 transplants.	 Nevertheless,	 it	 would	 be	 particularly	
interesting	to	investigate	the	role	of	VEGF-B	in	older	donor	hearts	that	suffer	from	aberrant	
metabolism	and	poorer	prognosis.	In	this	setting,	our	findings	of	VEGF-B-induced	high	cardiac	
basal	metabolic	rate	and	CMC	hypertrophy	could	be	of	clinical	benefit	to	the	recipient.	
	
3. Hypoxia-inducible	factor	
	
Previous	research	has	established	the	cell-	and	context-dependent	role	of	HIF-1α	and	HIF-2α	in	
inflammatory	cell	functions. This	study	investigates	the	role	of	HIF-1α	and	HIF-2α	in	myeloid-
derived	cells	in	the	setting	of	heart	transplantation.	We	establish	that	HIF-1α	and	HIF-2α	induce	
a	regulatory	phenotype	in	myeloid-derived	cells	that	alleviate	allograft	IRI	and	acute	rejection,	
and	prolongs	allograft	survival.	The	results	also	challenge	the	importance	of	HIF-1α	in	the	pro-
inflammatory	functions	of	myeloid-derived	cells.	
	
In	mVHL-/-	recipients,	the	allograft	cytokine	milieu	experienced	an	anti-inflammatory	shift	early	
after	transplantation,	with	 increased	regulatory	 IL-10	and	Arg1	and	decreased	 inflammatory	
TNF-α	 and	 VEGF-A	 expression	 at	 6h	 post-reperfusion.	 Arginase-1,	 IL-10	 and	 iNOS	 are	
characteristic	for	the	immunosuppressive	qualities	of	MDSC,	M2	macrophages,	and	regulatory	
macrophages	 and	 neutrophils.432,483	 As	 such,	 due	 to	 the	 whole-tissue	 nature	 of	 the	mRNA	
measurements,	 the	 source	 of	 these	 regulatory	 factors	 remains	 uncertain.	We	 observed	 no	
significant	changes	in	the	intragraft	transcription	factor	STAT3	levels,	however,	which	is	linked	
to	the	immunoregulatory	properties	of	MDSCs.484,485	
	
At	5	days	after	transplantation,	cardiac	allografts	in	non-immunosuppressed	mVHL-/-	recipients	
experienced	 a	 profoundly	 diminished	 adaptive	 immune	 response	 and	 acute	 rejection,	 as	
measured	by	the	decreased	influx	of	innate	immune	cells	and	T	cells,	and	reduced	expression	
of	Th1,	Th2,	and	Th17	effector	cytokines	TNF-α,	IFN-g,	IL-4,	and	IL-17.	In	vitro	experiments	further	
revealed	 that	 VHL-/-	 myeloid-derived	 cells	 were	 capable	 of	 dose-dependently	 reducing	
CD3/CD28-stimulated	antigen-nonspecific	splenocyte	proliferation.	Collectively,	these	results	
imply	 that	 the	 early	 allograft-infiltrating	 VHL-/-	 myeloid-derived	 cells	 may	 actively	 suppress	
activated	 adaptive	 immune	 cells,	 possibly	 through	 direct	 cell	 contact	 or	 ROS,	 or	 anti-
inflammatory	 Arg1,	 IL-10,	 and	 iNOS	 expression.	 These	 results,	 however,	 do	 not	 clarify	 the	
influence	of	VHL-/-	myeloid	cells	on	allorecognition.	Nevertheless,	although	cardiac	allografts	
transplanted	 into	VHL-/-	 recipients	had	significantly	prolonged	survival,	 they	were	eventually	
rejected.	 This	 implies	 that	 allorecognition	 does	 occur	 in	 these	 recipients,	 possibly	 through	
memory	T	and	B	cells	and	small	numbers	of	APCs.2	Also,	the	almost	complete	lack	of	intragraft	
myeloid-derived	 cells	 seen	 5	 days	 after	 transplantation	 most	 likely	 decreased	 the	 local	
regulatory	effect	achieved	early	after	reperfusion	and	was	insufficient	to	dampen	the	ensuing	
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adaptive	immune	response,	despite	increased	local	Arg1	expression.	The	proposed	mechanism	
behind	our	observations	are	depicted	in	Figure	33.	
	
Figure	 33	 –	 Proposed	 progression	 of	 the	 alloimmune	 reaction	 in	 mVHL-/-	 cardiac	 allograft	 recipient	 mice:	 1)	 recipient	
immunoregulatory	 myeloid-derived	 cells	 infiltrate	 the	 allograft	 as	 a	 response	 to	 allograft-released	 acute	 inflammatory	
chemokines	and	cytokines	and	dampen	the	innate	immune	response	through	immunoregulatory	Arg1	and	IL-10	expression.	2)	
The	lack	of	chemokines	results	in	decreased	graft-infiltrating	regulatory	cells.	3)	Delayed	allorecognition	occurs	and	allografts	
are	eventually	rejected.	h,	hour;	VHL,	Von-Hippel	Lindau	protein;	IRI,	ischemia-reperfusion	injury;	R,	recipient;	D,	donor;	DN,	
donor	 neutrophil;	 DM,	 donor	 macrophage;	 RN,	 recipient	 neutrophil;	 RM,	 recipient	 macrophage;	 MDSC,	 myeloid-derived	
suppressor	cell;	TAM,	tumor-associated	macrophage;	DC,	dendritic	cell.	Objects	are	not	drawn	to	size.		
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Hypoxia-inducible	factor	1α	has	previously	been	implicated	as	an	important	mediator	of	the	
inflammatory	 actions	 of	 leukocytes,	 including	 neutrophil	 and	 macrophage	 activation,	
migration,	and	cytokine	production.416,420,423,424	It	has	also	been	implicated	as	a	major	factor	in	
M1	macrophage	polarization.426,431	On	the	other	hand,	myeloid-cell-specific	HIF-1α	deficiency	
slows	tumor	progression,	 indicating	an	enhanced	anti-tumor	response.486	We	observed	that	
mHIF-1α	-/-	recipient	myeloid-derived	cells	retained	their	ability	to	migrate	to	and	infiltrate	the	
allografts,	 and	 to	 induce	 a	 proinflammatory	milieu	 in	 the	 allograft	 at	 6h	 after	 reperfusion,	
characterized	by	increased	RANTES	and	VEGF-A	expression	and	decreased	anti-inflammatory	
HO-1	expression.	Also,	 at	5	days	after	 transplantation,	 the	allografts	 transplanted	 into	non-
immunosuppressed	 mHIF-1α	 -/-	 recipients	 underwent	 significant	 acute	 rejection,	 with	 a	
pronounced	Th17-response.	The	significance	of	this	response,	however,	was	challenged	by	the	
similar	survival	between	the	mHIF-1α	-/-	and	LM	control	group.	These	results	underscore	the	
context-dependent	role	of	HIF-1α	in	inflammatory	cells,	and	suggest	an	alternative	activation	
route	for	myeloid-derived	cells	in	the	setting	of	transplantation.	
	
HIF-1α	versus	HIF-2α	
	
Loss	of	VHL	enabled	the	accumulation	of	both	HIF-1α	and	HIF-2α.	Therefore,	it	remains	unclear	
which	 isoform	to	attribute	the	regulatory	effects	to.	Our	attempt	to	 investigate	this	 issue	 in	
vitro	produced	inconclusive	results.	On	one	hand,	myeloid-derived	cell	transduction	with	HIF-
1α	 induced	 the	MDSC	 and	M2	macrophage-specific	 transcription	 factor	 STAT3,	 and	 on	 the	
other	hand,	HIF-2α	transduction	promoted	the	expression	of	Arg1,	which	is	also	characteristic	
of	 both	 MDSC	 and	 M2	 macrophages.	 Again,	 these	 results	 highlight	 the	 context-	 and	 cell-
dependent	roles	of	HIF	in	inflammatory	cells	and	warrants	further	studies	to	uncover	the	true	
potential	of	HIF	in	transplant	rejection.	
	
Conclusions	and	clinical	implications	
	
In	 summary,	 activation	 of	 the	HIF	 pathway	 (mVHL-/-)	 in	 heart	 transplant	 recipient	myeloid-
derived	 cells	 induced	 a	 regulatory	 phenotype	 that	 reduced	 ischemia-reperfusion	 and	 acute	
rejection,	and	prolonged	allograft	survival.	In	contrast	to	prior	belief,	myeloid-derived	cell	HIF-
1	expression	was	not	required	for	an	effective	inflammatory	response.	Thus,	our	results	suggest	
that	 genetic	 or	 pharmacological	 HIF	 activation	 in	 myeloid-derived	 cells	 may	 offer	 a	 novel	
therapeutic	 strategy	 to	 modulate	 recipient	 alloimmune	 responses	 after	 solid	 organ	
transplantation.	 Maintaining	 inflammatory	 regulation,	 however,	 would	 most	 likely	 require	
successive	adoptive	transfers,	as	allografts	transplanted	into	mVHL-/-	recipients	were	eventually	
rejected.	
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Future	directions	in	heart	transplantation	
	
The	 future	 of	 heart	 transplantation	 lies	 in	 reducing	 the	 number	 of	 transplant	 recipients,	
increasing	the	donors,	and	maximizing	transplant	survival	and	patient	quality	of	life.	Advances	
in	genomics	and	proteomics	are	paving	the	way	for	personalized	transplantation.	The	discovery	
of	 new	 therapeutic	 targets	 and	markers	 for	 rejection	would	 enable	 targeted	 therapies	 and	
reduce	 the	 need	 for	 invasive	 endomyocardial	 biopsies	 for	 diagnosing	 transplant	 rejection,	
respectively.	Nonetheless,	biological	therapies	are	increasingly	common	in	the	clinic.487	Gene-
therapy	 can	 prolong	 or	 potentially	 prevent	 the	 alloimmune	 response	 by	 costimulatory	
blockade,	or	by	inducing	regulatory	leukocytes	in	the	recipient.488,489	Gene-editing	techniques,	
most	 notably	 CRISPR-Cas9	 has	 enabled	 the	 production	 of	 genetically	 engineered	 pigs.	 By	
removing	unwanted	infectious	genes	and	reducing	tissue	allogenicity,	xenotransplantation	is	
brought	closer	to	reality.490-492	Clinical	trials	with	Treg	cells	are	striving	to	reduce	the	dependence	
of	 organ	 recipients	 on	 traditional	 immunosuppressive	 drugs.493	 Similar	 strides	 are	made	 in	
bringing	regulatory	DC	to	clinical	transplantation.494	Although	in	its	infancy,	advances	in	tissue	
engineering	have	enabled	researchers	to	3D-print	organs	using	recipient	cells,	paving	the	way	
for	an	endless	supply	of	organs	in	the	future.495		
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CONCLUSIONS	
 
1. Ex	vivo	intracoronary	AAV2	transduces	heart	transplants	more	efficiently	than	AAV8	and	
AAV9.	 The	 route	 of	 viral	 vector	 administration	 affects	 heart	 transplant	 transduction	
efficiency	significantly,	with	donor	 intravenous	administration	of	AAV9	achieving	higher	
cardiac	transduction	rates	than	ex	vivo	heart	transplant	AAV9	coronary	perfusion.	
	
2. Heart	transplant	VEGF-B	expression	is	stimulated	by	ischemia	and	leads	to	heart	transplant	
CMC	hypertrophy	and	 increased	susceptibility	 to	 ischemia-reperfusion	 injury	after	 long-
term	 transplant-specific	 overexpression,	 without	 any	 effect	 on	 capillary	 or	 arteriole	
density.	
	
3. Recipient	myeloid-derived	 cell-specific	HIF	 stabilization	diminishes	 ischemia-reperfusion	
injury	and	acute	rejection,	and	prolongs	allograft	survival	due	the	regulatory	phenotype	of	
the	VHL-/-	inflammatory	cells.	Loss	of	HIF-1α	in	recipient	myeloid-derived	cells,	on	the	other	
hand,	does	not	affect	the	inflammatory	reactions	in	the	heart	transplant.		
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YHTEENVETO	(FINNISH	SUMMARY)	
 
Sydämensiirto	 on	 usein	 viimeinen	 vaikean	 sydäntaudin	 hoitomuoto.	 Alan	 kehityksistä	
huolimatta	 sydänsiirteen	 akuutti	 ja	 krooninen	 hyljintä	 ovat	 edelleen	 merkittäviä	
sydämensiirron	 pitkäaikaistuloksia	 heikentäviä	 tekijöitä.	 Hyljintään	 johtava	 patofysiologinen	
tapahtumaketju	saa	alkunsa	siirteen	luovuttajan	aivokuolemasta,	etenee	sydänsiirteen	ex	vivo-
kylmäsäilytyksen	 ja	 reperfuusion	 aikana,	 ja	 kulminoituu	 siirteeseen	 kohdistuvaan	
vastaanottajan	 immuunijärjestelmän	 aktivaatioon	 sekä	 siirteen	 vaskulopatiaan.	 Tässä	
väitöskirjatutkimuksessa	 arvioidaan	 Adeno-associated	 viruksen	 (AAV)	 tehoa	 ja	 turvallisuutta	
sydänsiirteen	 geeniterapiavektorina,	 selvitetään	 verisuonikasvutekijä	 vascular	 endothelial	
growth	 factor	 B:n	 (VEGF-B)	 osuutta	 sydänsiirteen	 iskemia-reperfuusiovauriossa	 (IRI),	 sekä	
hypoksiassa	 aktivoituvan	 transkriptiotekijä	 hypoxia-inducible	 factor:in	 (HIF)	 vaikutuksia	
vastaanottajan	 sydänsiirrettä	 vahingoittavien	 myeloidilinjan	 tulehdussolujen	
proinflammatorisissa	mekanismeissa.	
	
AAV-serotyyppien	2,	8	ja	9	pitkäaikaiskinetiikkaa	ja	turvallisuutta	arvioitiin	perfusoimalla	rotan	
sydänsiirteen	 sepelvaltimopuusto	 kullakin	 serotyypillä	 ja	 vertailemalla	 reportterigeenin	
ilmentymistä	ja	sydänsiirteen	tulehdusvastetta	keskenään.	VEGF-B:n	roolia	sydänsiirteen	IRI:ssa	
tutkittiin	 yli-ilmentämällä	 kasvutekijää	 sydänsiirteessä	 sekä	 transgeenisesti,	 että	 AAV-
virusvektoreiden	 välityksellä.	 HIF:n	 osuutta	 sydänsiirteen	 hyljintäreaktion	 synnyssä	 tutkittiin	
käyttämällä	myeloidilinjan	soluihin	keskitettyä	HIF-1α	ja	-2α	yli-	tai	ali-ilmentäviä	transgeenisiä	
hiiriä	sydänsiirteen	vastaanottajina.	
	
AAV2	oli	tehokkain	virusvektori	sydänsiirteessä	sepelvaltimoon	injisoitaessa,	kun	taas	AAV9	oli	
tehokkain	 sydänsiirteen	 luovuttajalle	 suonensisäisesti	 annettuna.	 AAV9	 aiheutti	 lievän	
tulehduksellisen	 vasteen	 sydänsiirteissä.	 Pitkäaikainen,	 mutta	 ei	 lyhytaikainen	 VEGF-B	 yli-
ilmentäminen	 sydänsiirteessä	 aiheutti	 sydänlihassolujen	 hypertrofian	 ja	 korkeamman	
metabolisen	tarpeen,	altistaen	siten	sydänsiirrettä	IRI:n	haittavaikutuksille.	HIF-1α	sekä	HIF-2α	
aktivaatio	 sydänsiirteen	 vastaanottajan	 myeloidilinjan	 soluissa	 aiheutti	 näissä	
immunoregulatorisen	 fenotyypin,	 joka	 vähensi	 merkittävästi	 sydänsiirteen	 IRI:ä	 ja	 akuuttia	
hyljintäreaktiota,	ja	pidensi	merkittävästi	sydänsiirteen	selviytymistä.	
	
Tulokset	korostavat	virusvektorien	antoreittien	tärkeyttä	sydänsiirteen	geeniterapiassa.	VEGF-
B	säätelee	sydämen	metaboliaa	ja	voi	mahdollisesti	vaikuttaa	sydänsiirteen	iskemiatoleranssiin.	
HIF-1α	 ja	 HIF-2α	 ovat	 tärkeitä	 myeloidilinjan	 valkosolujen	 tulehduksellisten	 toimintojen	
säätelijöitä,	joita	voisi	hyödyntää	allogeenisen	sydänsiirteen	hyljinnän	ehkäisemisessä.	
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SAMMANFATTNING	(SWEDISH	SUMMARY)	
	
Hjärttransplantation	är	ofta	den	sista	behandlingsalternativet	för	terminal	hjärtsjukdom.	Trots	
framsteg	 inom	 transplantationsmedicin	 belastar	 hjärttransplantatets	 avstötningsreaktion	
patienternas	 långtidsöverlevnad.	 Den	 händelsekaskad	 som	 leder	 till	 hjärttransplantatets	
avstötning	påbörjas	av	donatorns	hjärndöd,	progredierar	genom	ex	vivo	transport	av	organet,	
förvärras	 av	 reperfusion	 och	 kulminerar	 i	 hjärttransplantatets	 kroniska	 vaskulopati.	 I	 denna	
avhandling	 utvärderas	 Adeno-associated	 virus	 (AAV)	 effektivitet	 och	 säkerhet	 som	
hjärttransplantatets	genterapivektor.	Dessutom	undersöks	vaskulära	tillväxtfaktoren	vascular	
endothelial	growth	factor	B	(VEGF-B)	roll	i	hjärttransplantatets	ischemi-reperfusion	skada	(IRI)	
och	 transkriptionsfaktorn	 hypoxia-inducible	 factor	 (HIF)	 roll	 i	 inflammatoriska	 funktioner	 av	
myeloidlinjens	celler	i	hjärttransplantatets	avstötningsreaktion.	
	
I	 försökskonstellationen	 användes	 råttan	och	musen	 som	modell	 för	 hjärttransplantationer.	
Hjärttransplantatets	 koronarkärl	 perfuserades	 med	 AAV	 serotyperna	 2,	 8	 eller	 9.	
Långtidskinetiken	samt	säkerheten	jämfördes	genom	att	mäta	reportergenets	expression	och	
hjärttransplantatets	 inflammatoriska	 infiltrat.	 För	 att	 undersöka	 VEGF-B	 roll	 i	
hjärttransplantatets	 IRI	 användes	 transgena	 råttor	 och	 AAV	 virusvektorer	 för	 att	 nå	
överexpression	av	VEGF-B	i	hjärttransplantatet.	Vid	undersökning	av	HIF	använde	vi	transgena	
möss	med	myeloid-specifik	antingen	överexpression	eller	knock-out	av	HIF.	
	
Enligt	resultaten	var	AAV2	den	mest	effektiva	vektorn	efter	perfusion	av	hjärttransplantatets	
koronarkärl,	 medan	 AAV9	 var	 mest	 effektiv	 efter	 intravenös	 administrering	 till	 donatorn.	
Serotyp	9	orsakade	en	lindring	inflammation	i	hjärttransplantatet.	Kronisk,	men	inte	kortvarig	
överexpression	 av	 VEGF-B	 i	 råttans	 hjärttransplantat	 orsakade	 kardiomyocyt	 hypertrofi	 och	
högre	 metaboliska	 krav,	 och	 förvärrade	 således	 IRI.	 HIF	 orsakade	 en	 immunoregulatorisk	
fenotyp	i	myeloidlinjens	celler,	som	minskade	märkvärdigt	på	hjärttransplantatets	IRI	och	både	
akut	och	kronisk	avstötning.	
	
Sammanfattnignsvis	verkar	AAV2	vara	effektivast	efter	intrakoronär	och	AAV9	efter	intravenös	
administrering	 i	 råttans	 experimentella	 modell	 för	 hjärttransplantation.	 Således	 betonar	
resultaten	administreringsvägen	av	AAV	virusvektorerna	i	genterapi	av	hjärttransplantat.	VEGF-
B	 verkar	 reglera	 hjärtans	 energikrav	 och	 kan	 således	 spela	 en	 viktig	 roll	 i	 hjärtans	
ischemitolerans.	 Transkriptionsfaktorerna	 HIF-1α	 och	 -2α	 reglerar	 den	 anti-inflammatoriska	
fenotypen	 av	 myeloidlinjens	 celler	 och	 kan	 således	 potentiellt	 utnyttjas	 i	 vården	 av	
hjärttransplantatets	avstötningsreaktion.	
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